DE69130563T2 - Screening-verfahren für genbanken (recombinant libraries) - Google Patents

Screening-verfahren für genbanken (recombinant libraries)

Info

Publication number: DE69130563T2
Authority: DE; Germany
Prior art keywords: protein; encoding; interest; genbanks; nucleotide sequences
Prior art date: 1990-05-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Revoked

Application number

DE69130563T

Other languages

English (en)

Other versions

DE69130563D1 (de

Inventor

William Dower

Steven Cwirla

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Alere San Diego Inc

Original Assignee

Biosite Diagnostics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-05-01

Filing date

1991-05-01

Publication date

1999-06-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24060691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69130563(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-05-01 Application filed by Biosite Diagnostics Inc filed Critical Biosite Diagnostics Inc

1999-01-14 Application granted granted Critical

1999-01-14 Publication of DE69130563D1 publication Critical patent/DE69130563D1/de

1999-06-24 Publication of DE69130563T2 publication Critical patent/DE69130563T2/de

2011-05-02 Anticipated expiration legal-status Critical

Status Revoked legal-status Critical Current

Links

238000000034 method Methods 0.000 title abstract 2
238000012216 screening Methods 0.000 title 1
108090000623 proteins and genes Proteins 0.000 abstract 6
102000004169 proteins and genes Human genes 0.000 abstract 6
101710132601 Capsid protein Proteins 0.000 abstract 2
101710094648 Coat protein Proteins 0.000 abstract 2
108020004414 DNA Proteins 0.000 abstract 2
102100021181 Golgi phosphoprotein 3 Human genes 0.000 abstract 2
101710125418 Major capsid protein Proteins 0.000 abstract 2
108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
101710141454 Nucleoprotein Proteins 0.000 abstract 2
101710083689 Probable capsid protein Proteins 0.000 abstract 2
238000001261 affinity purification Methods 0.000 abstract 1
239000013602 bacteriophage vector Substances 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
210000004408 hybridoma Anatomy 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
239000002245 particle Substances 0.000 abstract 1
241001515965 unidentified phage Species 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

DE69130563T 1990-05-01 1991-05-01 Screening-verfahren für genbanken (recombinant libraries) Revoked DE69130563T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/517,659 US5427908A (en)	1990-05-01	1990-05-01	Recombinant library screening methods
PCT/US1991/002989 WO1991017271A1 (en)	1990-05-01	1991-05-01	Recombinant library screening methods

Publications (2)

Publication Number	Publication Date
DE69130563D1 DE69130563D1 (de)	1999-01-14
DE69130563T2 true DE69130563T2 (de)	1999-06-24

Family

ID=24060691

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DE69130563T Revoked DE69130563T2 (de)	1990-05-01	1991-05-01	Screening-verfahren für genbanken (recombinant libraries)
DE69133437T Revoked DE69133437T2 (de)	1990-05-01	1991-05-01	Siebtestverfahren für Genbanken (recombinant libraries)
DE98200770T Pending DE98200770T1 (de)	1990-05-01	1991-05-01	Siebtestverfahren für Genbanken (recombinant libraries)

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DE69133437T Revoked DE69133437T2 (de)	1990-05-01	1991-05-01	Siebtestverfahren für Genbanken (recombinant libraries)
DE98200770T Pending DE98200770T1 (de)	1990-05-01	1991-05-01	Siebtestverfahren für Genbanken (recombinant libraries)

Country Status (10)

Country	Link
US (2)	US5427908A (de)
EP (3)	EP1555328A3 (de)
JP (1)	JP3344584B2 (de)
AT (2)	ATE174067T1 (de)
AU (1)	AU7793991A (de)
DE (3)	DE69130563T2 (de)
DK (2)	DK0527839T3 (de)
ES (2)	ES2124224T3 (de)
GR (1)	GR3029421T3 (de)
WO (1)	WO1991017271A1 (de)

Families Citing this family (2038)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5547839A (en) *	1989-06-07	1996-08-20	Affymax Technologies N.V.	Sequencing of surface immobilized polymers utilizing microflourescence detection
US7413537B2 (en)	1989-09-01	2008-08-19	Dyax Corp.	Directed evolution of disulfide-bonded micro-proteins
US5498538A (en) *	1990-02-15	1996-03-12	The University Of North Carolina At Chapel Hill	Totally synthetic affinity reagents
US5747334A (en) *	1990-02-15	1998-05-05	The University Of North Carolina At Chapel Hill	Random peptide library
US5427908A (en) *	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
EP0600866B1 (de) *	1990-06-01	1997-12-03	Chiron Corporation	Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
US5723286A (en)	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
US6172197B1 (en) *	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
GB9015198D0 (en) *	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US7063943B1 (en)	1990-07-10	2006-06-20	Cambridge Antibody Technology	Methods for producing members of specific binding pairs
US6916605B1 (en) *	1990-07-10	2005-07-12	Medical Research Council	Methods for producing members of specific binding pairs
GB9206318D0 (en) *	1992-03-24	1992-05-06	Cambridge Antibody Tech	Binding substances
US6258530B1 (en)	1990-09-28	2001-07-10	Ixsys, Inc.	Surface expression libraries of randomized peptides
US5770434A (en) *	1990-09-28	1998-06-23	Ixsys Incorporated	Soluble peptides having constrained, secondary conformation in solution and method of making same
US6893845B1 (en)	1990-09-28	2005-05-17	Applied Molecular Evolution, Inc.	Surface expression libraries of heteromeric receptors
US5871974A (en) *	1990-09-28	1999-02-16	Ixsys Inc.	Surface expression libraries of heteromeric receptors
US5698426A (en) *	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
CA2095633C (en) *	1990-12-03	2003-02-04	Lisa J. Garrard	Enrichment method for variant proteins with altered binding properties
EP0834576B1 (de) *	1990-12-06	2002-01-16	Affymetrix, Inc. (a Delaware Corporation)	Detektion von Nukleinsäuresequenzen
WO1992011272A1 (en) *	1990-12-20	1992-07-09	Ixsys, Inc.	Optimization of binding proteins
CA2105300C (en)	1991-03-01	2008-12-23	Robert C. Ladner	Process for the development of binding mini-proteins
WO1992015702A1 (en) *	1991-03-07	1992-09-17	Andrew Raymon Morton Bradbury	The biological selection of useful molecules
US5955341A (en) *	1991-04-10	1999-09-21	The Scripps Research Institute	Heterodimeric receptor libraries using phagemids
DK1471142T3 (da) *	1991-04-10	2009-03-09	Scripps Research Inst	Heterodimere receptor-biblioteker under anvendelse af fagemider
US6492160B1 (en)	1991-05-15	2002-12-10	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5858657A (en) *	1992-05-15	1999-01-12	Medical Research Council	Methods for producing members of specific binding pairs
US5962255A (en) *	1992-03-24	1999-10-05	Cambridge Antibody Technology Limited	Methods for producing recombinant vectors
DE69230142T2 (de)	1991-05-15	2000-03-09	Cambridge Antibody Tech	Verfahren zur herstellung von spezifischen bindungspaargliedern
US6225447B1 (en)	1991-05-15	2001-05-01	Cambridge Antibody Technology Ltd.	Methods for producing members of specific binding pairs
DE4122599C2 (de) *	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid zum Screenen von Antikörpern
AU669489B2 (en) *	1991-09-18	1996-06-13	Affymax Technologies N.V.	Method of synthesizing diverse collections of oligomers
PT1696031E (pt) *	1991-12-02	2010-06-25	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) *	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
WO1994000470A1 (en) *	1992-06-30	1994-01-06	The Wistar Institute Of Anatomy And Biology	DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES
DE69331278T2 (de) *	1992-09-04	2002-07-18	Scripps Research Inst	Phagemiden die einen oberflächenrezeptor und ein heterologes oberflächenprotein co-exprimieren
DE4243770A1 (de) *	1992-12-23	1994-06-30	Behringwerke Ag	Verfahren zur Herstellung von rekombinanten und synthetischen Peptiden und deren Verwendung
AU6235294A (en)	1993-02-02	1994-08-29	Scripps Research Institute, The	Methods for producing polypeptide binding sites
WO1995010296A1 (en) *	1993-10-12	1995-04-20	Glycomed Incorporated	A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5922545A (en) *	1993-10-29	1999-07-13	Affymax Technologies N.V.	In vitro peptide and antibody display libraries
DK0744958T3 (da)	1994-01-31	2003-10-20	Univ Boston	Polyklonale antistofbiblioteker
US20060078561A1 (en) *	1994-01-31	2006-04-13	The Trustees Of Boston University	Polyclonal antibody libraries
US6335160B1 (en) *	1995-02-17	2002-01-01	Maxygen, Inc.	Methods and compositions for polypeptide engineering
US5525735A (en) *	1994-06-22	1996-06-11	Affymax Technologies Nv	Methods for synthesizing diverse collections of pyrrolidine compounds
US5525734A (en) *	1994-06-22	1996-06-11	Affymax Technologies N.V.	Methods for synthesizing diverse collections of pyrrolidine compounds
US6576236B1 (en)	1994-07-01	2003-06-10	Dana Farber Cancer Institute	Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US6010861A (en) *	1994-08-03	2000-01-04	Dgi Biotechnologies, Llc	Target specific screens and their use for discovering small organic molecular pharmacophores
US7597886B2 (en) *	1994-11-07	2009-10-06	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US7820798B2 (en) *	1994-11-07	2010-10-26	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US5766914A (en) *	1995-01-26	1998-06-16	Michigan State University	Method of producing and purifying enzymes
US7429646B1 (en)	1995-06-05	2008-09-30	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like 2
US5834184A (en) *	1995-05-17	1998-11-10	Harada; Kazuo	In vivo selection of RNA-binding peptides
DK1143006T3 (da) *	1995-08-18	2008-07-14	Morphosys Ip Gmbh	Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US6828422B1 (en)	1995-08-18	2004-12-07	Morphosys Ag	Protein/(poly)peptide libraries
US7368111B2 (en)	1995-10-06	2008-05-06	Cambridge Antibody Technology Limited	Human antibodies specific for TGFβ2
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
US6300063B1 (en)	1995-11-29	2001-10-09	Affymetrix, Inc.	Polymorphism detection
US6953663B1 (en) *	1995-11-29	2005-10-11	Affymetrix, Inc.	Polymorphism detection
US6537776B1 (en)	1999-06-14	2003-03-25	Diversa Corporation	Synthetic ligation reassembly in directed evolution
US7888466B2 (en)	1996-01-11	2011-02-15	Human Genome Sciences, Inc.	Human G-protein chemokine receptor HSATU68
AU2527397A (en) *	1996-03-13	1997-10-01	Protein Design Labs, Inc.	Fas ligand fusion proteins and their uses
US5866341A (en) *	1996-04-03	1999-02-02	Chugai Pharmaceutical Co., Ltd.	Compositions and methods for screening drug libraries
US6699658B1 (en)	1996-05-31	2004-03-02	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
US6696251B1 (en)	1996-05-31	2004-02-24	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
US6300065B1 (en)	1996-05-31	2001-10-09	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
DE69723531T3 (de)	1996-10-01	2012-09-06	Geron Corp.	Katalytische Untereinheit der menschlichen Telomerase
US6139817A (en) *	1996-10-15	2000-10-31	Smithkline Beecham Corporation	Method for determining gene essentiality in a pathogen
IL119587A (en) *	1996-11-07	2000-12-06	Univ Ramot	Method of preparing and for obtaining bimolecular interactions
US5922537A (en) *	1996-11-08	1999-07-13	N.o slashed.AB Immunoassay, Inc.	Nanoparticles biosensor
US5942422A (en) *	1996-11-14	1999-08-24	The Trustees Of Columbia University In The City Of New York	Method for generating a directed, recombinant fusion nucleic acid
US6555310B1 (en)	1997-04-04	2003-04-29	Biosite Diagnostics, Inc.	Polyclonal libraries
US6057098A (en) *	1997-04-04	2000-05-02	Biosite Diagnostics, Inc.	Polyvalent display libraries
EP0985033A4 (de) *	1997-04-04	2005-07-13	Biosite Inc	Polyvalente und polyklonale bibliotheken
US6365347B1 (en)	1997-04-11	2002-04-02	The Regents Of The University Of California	Method for identifying disruptors of biological pathways using genetic selection
PT975755E (pt)	1997-04-16	2007-06-26	Millennium Pharm Inc	Proteínas crsp (proteínas segregadas ricas em cisteínas), moléculas de ácido nucleico que as codificam e suas utilizações
EP1005569A2 (de)	1997-08-01	2000-06-07	MorphoSys AG	Verfahren und phage für die identifizierung von multimere polypeptidkomplexkodierende nukleinsäuresequenzen
WO1999015897A1 (en) *	1997-09-19	1999-04-01	Chiron Corporation	Subtractive protein screening for gene identification
US6607878B2 (en)	1997-10-06	2003-08-19	Stratagene	Collections of uniquely tagged molecules
GB9722131D0 (en) *	1997-10-20	1997-12-17	Medical Res Council	Method
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6893877B2 (en)	1998-01-12	2005-05-17	Massachusetts Institute Of Technology	Methods for screening substances in a microwell array
US6759243B2 (en)	1998-01-20	2004-07-06	Board Of Trustees Of The University Of Illinois	High affinity TCR proteins and methods
US6335185B1 (en)	1998-02-03	2002-01-01	University Technologies International Inc.	Bacteriophage vectors generated by bacteriophage/plasmid recombination
US6841347B1 (en)	1998-02-05	2005-01-11	The General Hospital Corporation	In vivo construction of DNA libraries
WO1999040208A1 (en) *	1998-02-05	1999-08-12	The General Hospital Corporation	In vivo construction of dna libraries
EP1066369B1 (de) *	1998-03-18	2006-07-19	Quark Biotech, Inc.	Selektion/subtraktionsansatz zur genidentifizierung
CA2323776C (en)	1998-03-19	2010-04-27	Human Genome Sciences, Inc.	Cytokine receptor common gamma chain like
US7163682B2 (en)	1998-04-13	2007-01-16	The Forsyth Institute	Glucan binding protein and glucosyltransferase immunogens
US7056517B2 (en)	1998-04-13	2006-06-06	The Forsyth Institute	Glucosyltransferase immunogens
EP2311490A3 (de)	1998-07-13	2011-05-04	Board of Regents, The University of Texas System	Verwendung von Antikörper gegen Aminophospholipide zur Krebsbehandlung
US6323325B1 (en)	1998-07-23	2001-11-27	The United States Of America As Represented By The Department Of Health And Human Services	Agents that bind to and inhibit human cytochrome P450 2A6
US6335428B1 (en) *	1998-07-23	2002-01-01	The United States Of America As Represented By The Department Of Health And Human Services	Agents that bind to and inhibit human cytochrome P450 1A2
IL140918A0 (en)	1998-07-27	2002-02-10	Genentech Inc	Improved transformation efficiency in phage display through modification of a coat protein
US6190908B1 (en)	1998-08-12	2001-02-20	The Scripps Research Institute	Modulation of polypeptide display on modified filamentous phage
CA2345392A1 (en) *	1998-09-24	2000-03-30	Duke University	Method of measuring protein-protein interactions in living cells
US6420110B1 (en)	1998-10-19	2002-07-16	Gpc Biotech, Inc.	Methods and reagents for isolating biologically active peptides
GB9826247D0 (en) *	1998-11-30	1999-01-20	Nycomed Pharma As	Method
CA2363779A1 (en)	1999-02-26	2000-08-31	Human Genome Sciences, Inc.	Human endokine alpha and methods of use
EP1179000A4 (de)	1999-02-26	2005-10-12	Millennium Pharm Inc	Ausscheidungsproteine und ihre verwendung
US6642353B1 (en)	1999-03-17	2003-11-04	Chugai Seiyaku Kabushiki Kaisha	Peptide ligands for the erythropoietin receptor
DE19915057A1 (de)	1999-04-01	2000-10-19	Forschungszentrum Borstel	Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
US6492497B1 (en)	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
DE69940364D1 (de)	1999-05-18	2009-03-19	Dyax Corp	Fab Fragmentbibliotheken und Verfahren für deren Verwendung
US20020102613A1 (en)	1999-05-18	2002-08-01	Hoogenboom Hendricus Renerus Jacobus Mattheus	Novel Fab fragment libraries and methods for their use
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
US7291714B1 (en) *	1999-06-30	2007-11-06	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
US20040001826A1 (en) *	1999-06-30	2004-01-01	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
EP1144607B1 (de) *	1999-07-20	2008-12-17	MorphoSys AG	Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
EP2360254A1 (de)	1999-08-23	2011-08-24	Dana-Farber Cancer Institute, Inc.	Screeningverfahren zur Isolierung von Anti-pd1 Antikörper und deren Verwendungen
US6794132B2 (en)	1999-10-02	2004-09-21	Biosite, Inc.	Human antibodies
US7135287B1 (en)	1999-10-02	2006-11-14	Biosite, Inc.	Human antibodies
US20070111259A1 (en) *	1999-10-02	2007-05-17	Medarex, Inc.	Human antibodies
AU783776B2 (en)	1999-10-12	2005-12-01	Chemocentryx, Inc.	Chemokine receptor
US6569674B1 (en)	1999-12-15	2003-05-27	Amersham Biosciences Ab	Method and apparatus for performing biological reactions on a substrate surface
US6589778B1 (en)	1999-12-15	2003-07-08	Amersham Biosciences Ab	Method and apparatus for performing biological reactions on a substrate surface
US6642046B1 (en) *	1999-12-09	2003-11-04	Motorola, Inc.	Method and apparatus for performing biological reactions on a substrate surface
US20060073509A1 (en) *	1999-11-18	2006-04-06	Michael Kilpatrick	Method for detecting and quantitating multiple subcellular components
EP3225632B1 (de)	1999-11-30	2020-05-06	Mayo Foundation for Medical Education and Research	An b7-h1, ein neuartiges immunregulierendes molekül bindende antikörper
US6680209B1 (en) *	1999-12-06	2004-01-20	Biosite, Incorporated	Human antibodies as diagnostic reagents
JP2003516755A (ja) *	1999-12-15	2003-05-20	ジェネンテック・インコーポレーテッド	ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
DE60034817T2 (de)	1999-12-30	2008-01-31	President And Fellows Of Harvard College, Cambridge	Verfahren zur modulierung der aktivität von th2-zellen durch modulierung der aktivität von xbp-1
KR20120011898A (ko)	2000-02-10	2012-02-08	아보트 러보러터리즈	사람 인터류킨-１８에 결합하는 항체 및 이를 제조하고 사용하는 방법
CA2400644C (en) *	2000-02-18	2009-07-14	Board Of Trustees Of The Leland Stanford Junior University	Apparatus and methods for parallel processing of micro-volume liquid reactions
US20020151040A1 (en)	2000-02-18	2002-10-17	Matthew O' Keefe	Apparatus and methods for parallel processing of microvolume liquid reactions
BR0110610A (pt)	2000-04-11	2003-04-29	Genentech Inc	Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados
EP1274720A4 (de)	2000-04-12	2004-08-18	Human Genome Sciences Inc	Albumin enthaltende fusionsproteine
US7495070B2 (en) *	2000-04-24	2009-02-24	Yale University	Protein binding miniature proteins
US7297762B2 (en) *	2000-04-24	2007-11-20	Yale University	Modified avian pancreatic polypeptide miniature binding proteins
US7030219B2 (en)	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
CA2407715C (en)	2000-04-29	2009-03-24	University Of Iowa Research Foundation	Diagnostics and therapeutics for macular degeneration-related disorders
EP1714661A3 (de)	2000-05-19	2012-03-14	The Center for Blood Research, INC.	Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
US20030031675A1 (en)	2000-06-06	2003-02-13	Mikesell Glen E.	B7-related nucleic acids and polypeptides useful for immunomodulation
WO2001093892A1 (en)	2000-06-08	2001-12-13	The Center For Blood Research, Inc.	Methods and compositions for inhibiting immunoglobulin-mediated__reperfusion injury
EP1294949A4 (de)	2000-06-15	2004-08-25	Human Genome Sciences Inc	Menschlicher tumornekrosefaktor delta und epsilon
ATE494304T1 (de)	2000-06-16	2011-01-15	Human Genome Sciences Inc	Immunspezifisch bindende antikörper gegen blys
US20020115068A1 (en) *	2000-06-23	2002-08-22	Ian Tomlinson	Matrix screening method
US20020055110A1 (en) *	2000-06-23	2002-05-09	Ian Tomlinson	Matrix screening method
AU2001273096B8 (en)	2000-06-28	2005-10-13	Dana-Farber Cancer Institute, Inc.	PD-L2 molecules: novel PD-1 ligands and uses therefor
SK1152003A3 (en)	2000-06-29	2003-07-01	Abbott Lab	Dual specificity antibodies and methods of making and using
DE60143986D1 (de)	2000-07-14	2011-03-17	Cropdesign Nv	Inhibitoren für cyclin-dependent-kinase von pflanzen
CA2415473A1 (en)	2000-07-27	2002-02-07	Genentech, Inc.	Apo-2l receptor agonist and cpt-11 synergism
US6902734B2 (en)	2000-08-07	2005-06-07	Centocor, Inc.	Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk)	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en)	2000-08-07	2007-10-30	Centocor, Inc.	Anti-dual integrin antibodies, compositions, methods and uses
CA2417432C (en)	2000-09-01	2010-11-02	The Center For Blood Research, Inc.	Modified polypeptides stabilized in a desired conformation and methods for producing same
GB0022978D0 (en)	2000-09-19	2000-11-01	Oxford Glycosciences Uk Ltd	Detection of peptides
EP1339427A4 (de)	2000-11-01	2004-09-15	Elusys Therapeutics Inc	Verfahren zur herstellung biospezifischer moleküle durch protein-transsplicing
TWI327599B (en)	2000-11-28	2010-07-21	Medimmune Llc	Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
WO2002044419A2 (en)	2000-11-28	2002-06-06	Wyeth	Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US6821731B2 (en)	2000-11-28	2004-11-23	Wyeth	Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US20020165149A1 (en) *	2000-12-08	2002-11-07	Kranz David M.	Mutated class II major histocompatibility proteins
US7408041B2 (en)	2000-12-08	2008-08-05	Alexion Pharmaceuticals, Inc.	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) *	2000-12-08	2004-10-07	Bowdish Katherine S.	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) *	2000-12-08	2016-02-02	Alexion Pharmaceuticals, Inc.	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CA2436595C (en) *	2000-12-08	2011-11-08	Alexion Pharmaceuticals, Inc.	Chronic lymphocytic leukemia cell line and its use for producing an antibody
US20060057651A1 (en) *	2000-12-08	2006-03-16	Bowdish Katherine S	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
PT1355919E (pt)	2000-12-12	2011-03-02	Medimmune Llc	Moléculas com semivida longa, composições que as contêm e suas utilizações
US6933109B2 (en) *	2000-12-22	2005-08-23	Large Scale Proteomics Corporation	Rapid particle detection
AU2002231736A1 (en)	2000-12-22	2002-07-08	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Use of repulsive guidance molecule (rgm) and its modulators
US20040001839A1 (en) *	2000-12-29	2004-01-01	Avigdor Levanon	Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001822A1 (en) *	2000-12-29	2004-01-01	Avigdor Levanon	Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) *	2000-12-29	2004-01-01	Janette Lazarovits	Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7132510B2 (en) *	2000-12-29	2006-11-07	Bio-Technology General (Israel) Ltd.	Specific human antibodies for selective cancer therapy
AU2002231368C1 (en)	2001-01-05	2018-08-16	Amgen Fremont Inc.	Antibodies to insulin-like growth factor I receptor
WO2008048300A2 (en)	2005-11-30	2008-04-24	Massachusetts Institute Of Technology	Pathogen detection biosensor
WO2002064612A2 (en)	2001-02-09	2002-08-22	Human Genome Sciences, Inc.	Human g-protein chemokine receptor (ccr5) hdgnr10
EP2123749A3 (de)	2001-02-23	2010-02-24	DSM IP Assets B.V.	Neuartige Gene zur Kodierung von neuartigen proteolytischen Enzymen
US20020160527A1 (en)	2001-02-26	2002-10-31	3M Innovative Properties Company	Combinatorial library comprising pouches as packages for library members and method therefor
WO2002098370A2 (en) *	2001-03-02	2002-12-12	Medimmune, Inc.	Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
ATE497603T1 (de)	2001-03-02	2011-02-15	Gpc Biotech Ag	Drei-hybrid-assaysystem
IL157794A0 (en)	2001-03-07	2004-03-28	Childrens Medical Center	Method to screen peptide display libraries using minicell display
CA2342376C (en) *	2001-03-20	2013-11-12	Marco Colonna	A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) *	2001-03-20	2009-03-26	Bioxell S.P.A.	Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) *	2001-03-20	2012-07-31	Cosmo Research & Development S.P.A.	Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en)	2001-03-20	2015-03-17	Novo Nordisk A/S	Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
WO2002076196A1 (en)	2001-03-22	2002-10-03	Abbott Gmbh & Co. Kg	Transgenic animals expressing antibodies specific for genes of interest and uses thereof
US7514263B2 (en)	2001-04-02	2009-04-07	3M Innovative Properties Company	Continuous process for the production of combinatorial libraries of materials
MXPA03008959A (es)	2001-04-02	2004-10-15	Wyeth Corp	Pd-1, un receptor para b7-4 y sus usos.
US20020146753A1 (en) *	2001-04-06	2002-10-10	Henrik Ditzel	Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
CA2444632A1 (en)	2001-04-13	2002-10-24	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
EP1572868A4 (de)	2001-04-16	2007-04-04	Wyeth Corp	Neue, polypeptidantigene codierende offene leseraster aus streptococcus pneumoniae und verwendungen davon
US20050089932A1 (en) *	2001-04-26	2005-04-28	Avidia Research Institute	Novel proteins with targeted binding
US20050048512A1 (en) *	2001-04-26	2005-03-03	Avidia Research Institute	Combinatorial libraries of monomer domains
EP1390535B1 (de) *	2001-04-26	2010-06-30	Amgen Mountain View Inc.	Kombinatorische bibliotheken von monomerdomänen
US20050053973A1 (en) *	2001-04-26	2005-03-10	Avidia Research Institute	Novel proteins with targeted binding
US20040175756A1 (en) *	2001-04-26	2004-09-09	Avidia Research Institute	Methods for using combinatorial libraries of monomer domains
US20030157561A1 (en) *	2001-11-19	2003-08-21	Kolkman Joost A.	Combinatorial libraries of monomer domains
WO2002094985A2 (en)	2001-05-22	2002-11-28	Merck & Co., Inc.	Beta-secretase substrates and uses thereof
JP4309758B2 (ja)	2001-05-25	2009-08-05	ヒューマンジノームサイエンシーズ，インコーポレイテッド	Ｔｒａｉｌレセプターに免疫特異的に結合する抗体
WO2002096910A1 (en) *	2001-05-31	2002-12-05	Medarex, Inc.	Cytotoxins, prodrugs, linkers and stabilizers useful therefor
AU2002322033A1 (en) *	2001-06-04	2002-12-16	Ikonisys Inc.	Method for detecting infectious agents using computer controlled automated image analysis
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2385745C (en)	2001-06-08	2015-02-17	Abbott Laboratories (Bermuda) Ltd.	Methods of administering anti-tnf.alpha. antibodies
CA2633171C (en)	2001-06-20	2012-11-20	Genentech, Inc.	Antibodies against tumor-associated antigenic target (tat) polypeptides
US7803915B2 (en) *	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) *	2001-06-20	2005-05-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
BR0210593A (pt)	2001-06-22	2007-01-02	Pioneer Hi Bred Int	polinucleotìdeos de defensina e métodos de uso
CA2450236A1 (en) *	2001-07-06	2003-01-16	Genentech, Inc.	Phage displayed pdz domain ligands
US6867189B2 (en) *	2001-07-26	2005-03-15	Genset S.A.	Use of adipsin/complement factor D in the treatment of metabolic related disorders
US6833441B2 (en)	2001-08-01	2004-12-21	Abmaxis, Inc.	Compositions and methods for generating chimeric heteromultimers
JP4360906B2 (ja) *	2001-09-14	2009-11-11	サイトスバイオテクノロジーアーゲー	ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
US20040142325A1 (en)	2001-09-14	2004-07-22	Liat Mintz	Methods and systems for annotating biomolecular sequences
DE60238143D1 (de)	2001-09-18	2010-12-09	Genentech Inc	Zusammensetzungen und verfahren für die diagnose von tumoren
WO2003024191A2 (en) *	2001-09-21	2003-03-27	Raven Biotechnologies, Inc.	Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
US6894149B2 (en)	2001-10-11	2005-05-17	Protein Design Labs, Inc.	Anti-HLA-DA antibodies and the methods of using thereof
US20040005709A1 (en) *	2001-10-24	2004-01-08	Hoogenboom Henricus Renerus Jacobus Mattheus	Hybridization control of sequence variation
US7175983B2 (en) *	2001-11-02	2007-02-13	Abmaxis, Inc.	Adapter-directed display systems
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
DE60232688D1 (de)	2001-11-20	2009-07-30	Univ Duke	Grenzflächen-biomaterialien
DK1461428T3 (da)	2001-12-03	2012-06-04	Alexion Pharma Inc	Fremgangsmåde til at fremstille hybridantistoffer
EP1458754B1 (de)	2001-12-18	2009-12-09	Endocube SAS	Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind
US7858297B2 (en)	2001-12-18	2010-12-28	Centre National De La Recherche Scientifique Cnrs	Chemokine-binding protein and methods of use
AU2002359721A1 (en)	2001-12-19	2003-07-09	Bristol-Myers Squibb Company	Pichia pastoris formate dehydrogenase and uses therefor
EP2277888A3 (de)	2001-12-21	2011-04-27	Human Genome Sciences, Inc.	Fusionsprotein von Albumin und Erythropoietin
WO2003057160A2 (en)	2002-01-02	2003-07-17	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US20070166704A1 (en) *	2002-01-18	2007-07-19	Fei Huang	Identification of polynucleotides and polypeptide for predicting activity of compounds that interact with protein tyrosine kinases and/or protein tyrosine kinase pathways
US7094579B2 (en)	2002-02-13	2006-08-22	Xoma Technology Ltd.	Eukaryotic signal sequences for prokaryotic expression
ES2329565T3 (es) *	2002-03-01	2009-11-27	Siemens Healthcare Diagnostics Inc.	Pruebas para monitorear pacientes con cancer, basadas en los niveles de analito de dominio extracelular (ecd) del factor receptor del crecimiento epidermico (egfr),solo o en combinacion con otros analitos,en muestras de fluidos corporales.
US20030180819A1 (en) *	2002-03-01	2003-09-25	Carney Walter P.	Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
EP1572149A2 (de)	2002-03-07	2005-09-14	The Forsyth Institute	Immunogenität von glucan-bindungsprotein
WO2009095742A1 (en)	2008-01-31	2009-08-06	Cellectis	New i-crei derived single-chain meganuclease and uses thereof
EP1497445A2 (de) *	2002-04-01	2005-01-19	Human Genome Sciences, Inc.	Spezifisch an gmad bindende antikörper
GB0207533D0 (en)	2002-04-02	2002-05-08	Oxford Glycosciences Uk Ltd	Protein
US7745192B2 (en)	2002-04-03	2010-06-29	Venomics Pty Limited	Prothrombin activating protein
EP1572927A4 (de)	2002-04-08	2007-10-17	Pioneer Hi Bred Int	Verstärktes austreiben von seide unter stress
EP2270049A3 (de)	2002-04-12	2011-03-09	Medimmune, Inc.	Rekombinante Anti-Interleukin-9-Antikörper
EP1492870A4 (de) *	2002-04-12	2005-08-03	Raven Biotechnologies Inc	An integrin-alpha-v-beta-6 bindende antikörper sowie verfahren zur verwendung davon
MXPA04010092A (es)	2002-04-16	2004-12-13	Genentech Inc	Composiciones y metodos para el diagnostico y tratamiento de tumores.
ATE459880T1 (de)	2002-04-17	2010-03-15	Deutsches Krebsforsch	Verfahren zum screening einer substanz zur modulierung der wnt -signalkaskade.
US20030206898A1 (en)	2002-04-26	2003-11-06	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
US20040048319A1 (en) *	2002-05-03	2004-03-11	Mather Jennie P.	ALCAM and ALCAM modulators
CA2486147A1 (en)	2002-05-17	2003-11-27	Protein Design Labs, Inc.	Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
ES2347550T3 (es)	2002-05-21	2010-11-02	Dsm Ip Assets B.V.	Nuevas fosfolipasas y usos de las mismas.
EP2305710A3 (de)	2002-06-03	2013-05-29	Genentech, Inc.	Synthetische Antikörperphagenbibliotheken
EP1513879B1 (de) *	2002-06-03	2018-08-22	Genentech, Inc.	Bibliotheken synthetischer antikörperphagen
CN100418981C (zh)	2002-06-10	2008-09-17	瓦西尼斯公司	在乳腺癌和膀胱癌中差异表达的基因及编码多肽
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7527969B2 (en)	2002-06-19	2009-05-05	Raven Biotechnologies, Inc.	RAAG10 cell surface target and a family of antibodies recognizing that target
WO2004000220A2 (en) *	2002-06-21	2003-12-31	Genetix Pharmaceuticals, Inc.	Methods for purifying viral particles for gene therapy
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
AU2002368055B2 (en)	2002-06-28	2008-09-18	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
US20040202665A1 (en) *	2002-07-01	2004-10-14	Janette Lazarovits	Compositions and methods for therapeutic treatment
US20040208877A1 (en) *	2002-07-01	2004-10-21	Avigdor Levanon	Antibodies and uses thereof
US20040175378A1 (en)	2002-07-15	2004-09-09	Board Of Regents, The University Of Texas System	Selected antibody compositions and methods for binding to aminophospholipids
PT2314629E (pt)	2002-07-18	2014-01-22	Merus B V	Produção recombinante de misturas de anticorpos
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
KR20140058649A (ko)	2002-07-19	2014-05-14	애브비 바이오테크놀로지 리미티드	ＴＮＦα 관련 질환의 치료
US7250551B2 (en)	2002-07-24	2007-07-31	President And Fellows Of Harvard College	Transgenic mice expressing inducible human p25
AU2003253193B2 (en)	2002-07-30	2009-07-02	Morphosys Ag	Novel tricistronic vectors and uses therefor
EA200500330A1 (ru)	2002-08-10	2006-06-30	Йейл Юниверсити	Антагонисты nogo рецепторов
WO2004016750A2 (en)	2002-08-14	2004-02-26	Macrogenics, Inc.	FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP1530630A2 (de)	2002-08-19	2005-05-18	DSM IP Assets B.V.	Neue lipasen und deren verwendung
KR20050058407A (ko)	2002-08-20	2005-06-16	밀레니엄 파머슈티컬스 인코퍼레이티드	자궁경부암의 확인, 평가, 예방 및 요법을 위한 조성물, 키트 및 방법
AU2003250518A1 (en)	2002-08-20	2004-03-11	Yeda Research And Development Co. Ltd.	Akap84 and its use for visualization of biological structures
US8277753B2 (en)	2002-08-23	2012-10-02	Life Technologies Corporation	Microfluidic transfer pin
AU2003268486A1 (en)	2002-09-04	2004-03-29	Biopolymer Engineering, Inc.	Cancer therapy using whole glucan particles and antibodies
EP1539234A4 (de) *	2002-09-05	2006-02-15	Medimmune Inc	Verfahren zur prävention oder behandlung von zellmalignität durch verabreichung von cd2-antagonisten
WO2010011999A2 (en)	2008-07-25	2010-01-28	The Regents Of The University Of California	Methods and compositions for eliciting an amyloid-selective immune response
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
US20060147450A1 (en) *	2002-10-04	2006-07-06	Shelton David L	Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
RU2338555C2 (ru) *	2002-10-08	2008-11-20	Ринат Ньюросайенс Корп.	Способы лечения послеоперационной боли введением антагониста фактора роста нервов и композиции, содержащие фактор роста нервов
UA80447C2 (en)	2002-10-08	2007-09-25		Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
AU2003304238A1 (en)	2002-10-08	2005-01-13	Rinat Neuroscience Corp.	Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
HUE034378T2 (en)	2002-10-16	2018-02-28	Purdue Pharma Lp	Cell-associated CA 125 / O722P binding antibodies and methods of use
TW200509968A (en)	2002-11-01	2005-03-16	Elan Pharm Inc	Prevention and treatment of synucleinopathic disease
US8506959B2 (en)	2002-11-01	2013-08-13	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2004044161A2 (en) *	2002-11-06	2004-05-27	Fraunhofer Usa	Expression of foreign sequences in plants using trans-activation system
US7683238B2 (en) *	2002-11-12	2010-03-23	iBio, Inc. and Fraunhofer USA, Inc.	Production of pharmaceutically active proteins in sprouted seedlings
US7692063B2 (en) *	2002-11-12	2010-04-06	Ibio, Inc.	Production of foreign nucleic acids and polypeptides in sprout systems
US7405061B2 (en) *	2002-11-13	2008-07-29	Raven Biotechnologies, Inc.	Antigen PIPA and antibodies that bind thereto
AU2003302470A1 (en) *	2002-11-26	2004-06-18	Dyax Corporation	Methods and compositions for controlling valency of phage display
CA2521999A1 (en)	2002-12-20	2004-09-02	Biotrove, Inc.	Assay apparatus and method using microfluidic arrays
US20060094108A1 (en) *	2002-12-20	2006-05-04	Karl Yoder	Thermal cycler for microfluidic array assays
US20050089521A1 (en) *	2002-12-23	2005-04-28	Shelton David L.	Methods for treating taxol-induced sensory neuropathy
US7569364B2 (en) *	2002-12-24	2009-08-04	Pfizer Inc.	Anti-NGF antibodies and methods using same
US9498530B2 (en)	2002-12-24	2016-11-22	Rinat Neuroscience Corp.	Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
SI1575517T1 (sl) *	2002-12-24	2012-06-29	Rinat Neuroscience Corp	Protitelesa proti ĺ˝iväśnemu rastnemu dejavniku in metode njihove uporabe
PT1587907E (pt)	2003-01-07	2011-04-08	Dyax Corp	Biblioteca de domínios de kunitz
US20050079574A1 (en) *	2003-01-16	2005-04-14	Genentech, Inc.	Synthetic antibody phage libraries
US20060147932A1 (en) *	2003-01-18	2006-07-06	Alun Davies	Methods of screening for modulators of nerve growth factor
AU2004206250B8 (en) *	2003-01-21	2009-09-17	Bristol-Myers Squibb Company	Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
US20060153826A1 (en)	2003-01-28	2006-07-13	Sylvain Arnould	Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2004209660A1 (en)	2003-02-03	2004-08-19	Fraunhofer Usa, Inc.	System for expression of genes in plants
PL379983A1 (pl)	2003-02-19	2006-11-27	Rinat Neuroscience Corp.	Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
EP2289559B1 (de)	2003-02-20	2014-02-12	Seattle Genetics, Inc.	Anti-CD70-Antikörper-Arzneimittelkonjugate und deren Verwendung zur Behandlung von Krebs und Immunerkrankungen
US20040180387A1 (en)	2003-03-13	2004-09-16	Fujirebio Diagnostics, Inc.	Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
GEP20094629B (en)	2003-03-19	2009-03-10	Biogen Idec Inc	Nogo receptor binding protein
EP1620127A4 (de) *	2003-03-20	2007-04-04	Rinat Neuroscience Corp	Verfahren zur behandlung von taxol-induzierten darmstörungen
US7294701B2 (en) *	2003-04-02	2007-11-13	Technion Research & Development Foundation Ltd.	Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US20040202995A1 (en) *	2003-04-09	2004-10-14	Domantis	Nucleic acids, proteins, and screening methods
KR20110094361A (ko)	2003-04-11	2011-08-23	메디뮨 엘엘씨	재조합 ｉｌ９ 항체 및 그의 용도
US20040208876A1 (en)	2003-04-18	2004-10-21	Kim Kyung Jin	Monoclonal antibodies to hepatocyte growth factor
US7321065B2 (en)	2003-04-18	2008-01-22	The Regents Of The University Of California	Thyronamine derivatives and analogs and methods of use thereof
US20050025763A1 (en)	2003-05-08	2005-02-03	Protein Design Laboratories, Inc.	Therapeutic use of anti-CS1 antibodies
US7709610B2 (en)	2003-05-08	2010-05-04	Facet Biotech Corporation	Therapeutic use of anti-CS1 antibodies
US20050014932A1 (en)	2003-05-15	2005-01-20	Iogenetics, Llc	Targeted biocides
US7358331B2 (en)	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
CA2526900C (en)	2003-05-19	2015-11-24	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in lewy body disease
AU2004272972A1 (en)	2003-05-22	2005-03-24	Fraunhofer Usa, Inc.	Recombinant carrier molecule for expression, delivery and purification of target polypeptides
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
US9708410B2 (en)	2003-05-30	2017-07-18	Janssen Biotech, Inc.	Anti-tissue factor antibodies and compositions
ES2408582T3 (es)	2003-05-30	2013-06-21	Merus B.V.	Biblioteca de Fab para la preparación de una mezcla de anticuerpos
WO2005005462A2 (en)	2003-06-05	2005-01-20	Genentech, Inc.	Blys antagonists and uses thereof
CN1279056C (zh) *	2003-06-06	2006-10-11	马菁	肿瘤相关抗原sm5－1的特异性抗体及其应用
US20050232926A1 (en) *	2003-06-06	2005-10-20	Oncomax Acquisition Corp.	Antibodies specific for cancer associated antigen SM5-1 and uses thereof
WO2005001486A1 (en)	2003-06-06	2005-01-06	Genentech, Inc.	Modulating the interaction between hgf beta chain and c-met
EP2508608A1 (de)	2003-06-09	2012-10-10	Alnylam Pharmaceuticals Inc.	Verfahren zur Behandlung neurodegenerativer Erkrankungen
US20050266009A1 (en) *	2003-06-30	2005-12-01	Savient Pharmaceuticals, Inc.	Antibodies and uses thereof
US20050069955A1 (en) *	2003-06-30	2005-03-31	Daniel Plaksin	Antibodies and uses thereof
US20050152906A1 (en) *	2003-06-30	2005-07-14	Avigdor Levanon	Specific human antibodies
US8153410B2 (en)	2003-07-07	2012-04-10	Fox Chase Cancer Center	Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
US20060162014A1 (en)	2003-07-07	2006-07-20	Jaffe Eileen K	Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
EP2277908A3 (de)	2003-07-08	2011-12-14	Genentech, Inc.	Heterologe IL-17A/F-Polypeptide, Antikörper und deren therapeutische Verwendungen
US7393534B2 (en) *	2003-07-15	2008-07-01	Barros Research Institute	Compositions and methods for immunotherapy of cancer and infectious diseases
US20050058658A1 (en) *	2003-07-15	2005-03-17	Barros Research Institute	Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
US7727752B2 (en)	2003-07-29	2010-06-01	Life Technologies Corporation	Kinase and phosphatase assays
CA2445420A1 (en) *	2003-07-29	2005-01-29	Invitrogen Corporation	Kinase and phosphatase assays
US7619059B2 (en)	2003-07-29	2009-11-17	Life Technologies Corporation	Bimolecular optical probes
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
US7758859B2 (en) *	2003-08-01	2010-07-20	Genentech, Inc.	Anti-VEGF antibodies
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
WO2005014795A2 (en)	2003-08-08	2005-02-17	Genenews Inc.	Osteoarthritis biomarkers and uses thereof
WO2005019831A2 (en) *	2003-08-18	2005-03-03	Tethys Bioscience, Inc.	Methods for reducing complexity of a sample using small epitope antibodies
ES2458636T3 (es)	2003-08-18	2014-05-06	Medimmune, Llc	Humanización de anticuerpos
US20060228350A1 (en) *	2003-08-18	2006-10-12	Medimmune, Inc.	Framework-shuffling of antibodies
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
US7046714B2 (en) *	2003-09-10	2006-05-16	Intel Corporation	Method and apparatus for Raman ring resonator based laser/wavelength converter
SG146644A1 (en) *	2003-09-18	2008-10-30	Raven Biotechnologies Inc	Kid3 and kid3 antibodies that bind thereto
IL158287A0 (en)	2003-10-07	2004-05-12	Yeda Res & Dev	Antibodies to nik, their preparation and use
US7799518B2 (en)	2003-10-07	2010-09-21	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
EP2157192B1 (de)	2003-10-10	2013-08-28	Deutsches Krebsforschungszentrum	Zusammensetzungen zur Diagnose und Therapie für mit aberranter Expression von Futrins (R-Spondins) assoziierten Krankheiten
GB0325836D0 (en) *	2003-11-05	2003-12-10	Celltech R&D Ltd	Biological products
US20050100965A1 (en)	2003-11-12	2005-05-12	Tariq Ghayur	IL-18 binding proteins
EP1689432B1 (de)	2003-11-17	2009-12-30	Genentech, Inc.	Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
HUE026260T2 (en)	2003-11-21	2016-06-28	Ucb Biopharma Sprl	A method for treating multiple sclerosis by inhibiting IL-17 activity
US20050158323A1 (en) *	2003-12-04	2005-07-21	Vaccinex, Inc.	Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
EP2418220B1 (de)	2003-12-10	2017-08-02	E. R. Squibb & Sons, L.L.C.	Interferon-Alpha-Antikörper und deren Verwendungen
JP4942487B2 (ja)	2003-12-10	2012-05-30	メダレックスインコーポレーティッド	Ｉｐ−１０抗体およびその用途
CA2548282A1 (en)	2003-12-11	2005-06-30	Genentech, Inc.	Methods and compositions for inhibiting c-met dimerization and activation
GB0329825D0 (en) *	2003-12-23	2004-01-28	Celltech R&D Ltd	Biological products
US20050266425A1 (en) *	2003-12-31	2005-12-01	Vaccinex, Inc.	Methods for producing and identifying multispecific antibodies
EP2311873B1 (de)	2004-01-07	2018-08-29	Novartis Vaccines and Diagnostics, Inc.	M-csf spezifischer monoclonaler antikörper und dessen verwendungen
MX350383B (es)	2004-01-09	2017-09-04	Pfizer	Anticuerpos contra madcam.
EP1737971B1 (de)	2004-01-20	2017-08-16	Merus N.V.	Gemische bindender proteine
EP2444805A3 (de)	2004-01-21	2012-06-20	Fujirebio America, Inc.	Erkennung von Mesothelin-/Megakaryozyten zur Potenzierung von faktorbezogenen Peptiden in peritonealer Flüssigkeit zur Bewertung des Peritoneum und Peritonealhöhle
EP1713900A4 (de) *	2004-01-27	2009-06-17	Compugen Ltd	Verfahren und systeme zur kommentierung biomolekularer sequenzen
KR101184391B1 (ko)	2004-02-09	2013-03-14	휴먼 게놈 사이언시즈, 인코포레이티드	알부민 융합 단백질
EP2168986A3 (de)	2004-02-19	2010-07-28	Genentech, Inc.	Antikörper mit korrigiertem CDR
WO2005081905A2 (en) *	2004-02-20	2005-09-09	Fraunhofer Usa Inc.	Systems and methods for clonal expression in plants
DE602005026260D1 (de)	2004-03-01	2011-03-24	Immune Disease Inst Inc	Natürliche igm-antikörper und inhibitoren davon
CA2559171A1 (en)	2004-03-12	2005-09-29	Biotrove, Inc.	Nanoliter array loading
US7157233B2 (en)	2004-03-24	2007-01-02	Tripath Imaging, Inc.	Methods and compositions for the detection of cervical disease
EP1786463A4 (de) *	2004-03-26	2009-05-20	Human Genome Sciences Inc	Antikörper gegen nogo-rezeptor
JP5301152B2 (ja) *	2004-04-07	2013-09-25	ライナットニューロサイエンスコーポレイション	神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
US7785903B2 (en) *	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
TWI439284B (zh)	2004-04-09	2014-06-01	Abbvie Biotechnology Ltd	用於治療ＴＮＦα相關失調症之多重可變劑量療法
CA2955027A1 (en)	2004-04-15	2005-11-10	University Of Florida Research Foundation, Inc.	Neural proteins as biomarkers for nervous system injury and other neural disorders
ES2442386T3 (es)	2004-04-23	2014-02-11	Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr	Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
US20060292554A1 (en) *	2004-05-18	2006-12-28	Genentech, Inc.	Major coat protein variants for C-terminal and bi-terminal display
US7517903B2 (en) *	2004-05-19	2009-04-14	Medarex, Inc.	Cytotoxic compounds and conjugates
RU2402548C2 (ru) *	2004-05-19	2010-10-27	Медарекс, Инк.	Химические линкеры и их конъюгаты
EP2527447A1 (de)	2004-06-03	2012-11-28	Athlomics Pty Ltd	Mittel und Verfahren zur Diagnose von Stress
EP1765868B1 (de)	2004-06-07	2016-04-20	MacroGenics, Inc.	Antikörper gegen den transferrinrezeptor
US20060008844A1 (en)	2004-06-17	2006-01-12	Avidia Research Institute	c-Met kinase binding proteins
WO2006002177A2 (en)	2004-06-21	2006-01-05	Medarex, Inc.	Interferon alpha receptor 1 antibodies and their uses
GB0414054D0 (en)	2004-06-23	2004-07-28	Owen Mumford Ltd	Improvements relating to automatic injection devices
WO2006002437A2 (en) *	2004-06-24	2006-01-05	Biogen Idec Ma Inc.	Treatment of conditions involving demyelination
US7973134B2 (en)	2004-07-07	2011-07-05	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
ES2673972T3 (es)	2004-07-09	2018-06-26	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Formas solubles de la glicoproteína G de los virus hendra y nipah
US6986264B1 (en) *	2004-07-15	2006-01-17	Carrier Corporation	Economized dehumidification system
CA2573821A1 (en)	2004-07-16	2006-01-26	Pfizer Products Inc.	Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
US7342093B2 (en)	2004-07-23	2008-03-11	University Of Massachusetts	Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
TWI355389B (en)	2004-07-30	2012-01-01	Rinat Neuroscience Corp	Antibodies directed against amyloid-beta peptide a
EP2329714A1 (de)	2004-08-03	2011-06-08	Biogen Idec MA Inc.	Einfluss von TAJ in den neuronalen Funktionen
US20060105453A1 (en)	2004-09-09	2006-05-18	Brenan Colin J	Coating process for microfluidic sample arrays
US7572600B2 (en)	2004-08-04	2009-08-11	Chemocentryx, Inc.	Enzymatic activities in chemokine-mediated inflammation
EP1791975A4 (de) *	2004-08-05	2007-11-07	Biosite Inc	Zusammensetzungen und verfahren für phagen-display von polypeptiden
MX2007001679A (es)	2004-08-09	2007-05-23	Elan Pharm Inc	Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
US20060057105A1 (en) *	2004-08-20	2006-03-16	Stern Michael E	Methods of treating ocular inflammation and allergy
PL2990422T3 (pl) *	2004-09-03	2018-11-30	Genentech, Inc.	Humanizowani antagoniści anty-beta7 i ich zastosowania
FI20041204A0 (fi)	2004-09-16	2004-09-16	Riikka Lund	Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
US7700720B2 (en)	2004-09-21	2010-04-20	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
US7935790B2 (en)	2004-10-04	2011-05-03	Cell Singaling Technology, Inc.	Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
MX2007004176A (es)	2004-10-06	2007-06-15	Mayo Foundation	B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer.
WO2006047417A2 (en)	2004-10-21	2006-05-04	University Of Florida Research Foundation, Inc.	Detection of cannabinoid receptor biomarkers and uses thereof
JP5173426B2 (ja)	2004-10-25	2013-04-03	メルク・シャープ・エンド・ドーム・コーポレイション	抗ａｄｄｌ抗体およびこの使用
AU2005299355A1 (en)	2004-10-27	2006-05-04	Medimmune, Llc	Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1809583A2 (de) *	2004-11-01	2007-07-25	MedImmune, Inc.	Verfahren zum screening eines capture-lifts mit ultrahohem durchsatz
GB0426146D0 (en)	2004-11-29	2004-12-29	Bioxell Spa	Therapeutic peptides and method
PE20061329A1 (es)	2004-12-15	2006-12-08	Neuralab Ltd	Anticuerpos ab humanizados para mejorar la cognicion
US7807789B2 (en)	2004-12-21	2010-10-05	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US7850960B2 (en)	2004-12-30	2010-12-14	University Of Washington	Methods for regulation of stem cells
JP2008526256A (ja) *	2005-01-12	2008-07-24	レイベンバイオテクノロジーズ，インコーポレイティド	Ｋｉｄ３１およびｋｉｄ３１に結合する抗体
GT200600031A (es)	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
EP1846032A4 (de) *	2005-01-31	2009-01-28	Raven Biotechnologies Inc	Luca2 und daran bindende antikörper
WO2006084078A2 (en) *	2005-02-02	2006-08-10	Raven Biotechnologies, Inc.	Jam-3 and antibodies that bind thereto
EP1841794B1 (de)	2005-02-02	2013-11-20	MacroGenics West, Inc.	Adam-9-modulatoren
US7572896B2 (en)	2005-02-03	2009-08-11	Raven Biotechnologies, Inc.	Antibodies to oncostatin M receptor
AU2006210460B2 (en) *	2005-02-04	2012-04-05	Macrogenics West, Inc.	Antibodies that bind to EphA2 and methods of use thereof
CN103497993A (zh)	2005-02-07	2014-01-08	基因信息公司	轻度骨关节炎生物标志物及其用途
CN103920142A (zh)	2005-02-14	2014-07-16	爱荷华大学研究基金会	治疗和诊断年龄相关性黄斑变性的方法和试剂
WO2006089133A2 (en)	2005-02-15	2006-08-24	Duke University	Anti-cd19 antibodies and uses in oncology
US20090297438A1 (en) *	2005-02-18	2009-12-03	Haichun Huang	Human Monoclonal Antibodies to Prostate Specific Membrane Antigen (PSMA)
DE102005008765B4 (de) *	2005-02-25	2016-06-16	Siemens Healthcare Gmbh	Kontrastmittel auf der Basis von Bakteriophagen, diese enthaltende Zusammensetzung, deren Verwendung und Verfahren zu deren Herstellung
JP2008531730A (ja) *	2005-03-04	2008-08-14	キュアーディーエム、インク．	Ｉ型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物
US20090142338A1 (en) *	2005-03-04	2009-06-04	Curedm, Inc.	Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
WO2006095345A2 (en) *	2005-03-08	2006-09-14	Ramot At Tel-Aviv University Ltd.	Targeted drug-carrying bacteriophages
CN101175769A (zh)	2005-03-10	2008-05-07	健泰科生物技术公司	用于调控血管完整性的方法和组合物
JP5153613B2 (ja)	2005-03-18	2013-02-27	メディミューン，エルエルシー	抗体のフレームワーク・シャッフル
CA2601400A1 (en)	2005-03-19	2006-09-28	Medical Research Council	Improvements in or relating to treatment and prevention of viral infections
US7829673B2 (en)	2005-03-23	2010-11-09	Genmab A/S	Antibodies against CD38 for treatment of multiple myeloma
GB0506912D0 (en)	2005-04-05	2005-05-11	Celltech R&D Ltd	Biological products
US7714016B2 (en) *	2005-04-08	2010-05-11	Medarex, Inc.	Cytotoxic compounds and conjugates with cleavable substrates
EP3479844B1 (de)	2005-04-15	2023-11-22	MacroGenics, Inc.	Kovalente diabodies und verwendungen davon
US20060269556A1 (en) *	2005-04-18	2006-11-30	Karl Nocka	Mast cell activation using siglec 6 antibodies
AU2006236225C1 (en)	2005-04-19	2013-05-02	Seagen Inc.	Humanized anti-CD70 binding agents and uses thereof
AP2007004243A0 (en)	2005-04-25	2007-12-31	Pfizer	Antibodies to myostatin
AR054260A1 (es) *	2005-04-26	2007-06-13	Rinat Neuroscience Corp	Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
CA2604357C (en)	2005-04-26	2012-01-17	Pfizer Inc.	P-cadherin antibodies
US7595380B2 (en)	2005-04-27	2009-09-29	Tripath Imaging, Inc.	Monoclonal antibodies and methods for their use in the detection of cervical disease
UY29504A1 (es)	2005-04-29	2006-10-31	Rinat Neuroscience Corp	Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
JO3058B1 (ar)	2005-04-29	2017-03-15	Applied Molecular Evolution Inc	الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
EP2221316A1 (de)	2005-05-05	2010-08-25	Duke University	CD19-Antikörper-Therapie für Autoimmunerkrankungen
EP1896582A4 (de)	2005-05-09	2009-04-08	Ono Pharmaceutical Co	Menschliche monoklonale antikörper gegen programmierten zelltod 1 (pd-1) sowie verfahren zur krebsbehandlung mit anti-pd-1-antikörpern allein oder in kombination mit anderen immuntherapeutika
CA2903138A1 (en)	2005-05-16	2006-11-23	Abbvie Biotechnology Ltd.	Use of tnfa inhibitor for treatment of erosive polyarthritis
EP3263581B1 (de)	2005-05-17	2020-11-04	University of Connecticut	Zusammensetzungen und verfahren zur immunmodulation in einem organismus
TW200716174A (en)	2005-05-19	2007-05-01	Centocor Inc	Anti-MCP-1 antibodies, compositions, methods and uses
WO2006128083A2 (en) *	2005-05-25	2006-11-30	Curedm, Inc.	Human proislet peptide, derivatives and analogs thereof, and methods of using same
HUE030701T2 (hu)	2005-05-27	2017-05-29	Biogen Ma Inc	Tweak-kötõ antitestek
EA201100177A1 (ru)	2005-06-17	2011-06-30	Элан Фарма Интернэшнл Лимитед	СПОСОБЫ ОЧИСТКИ АНТИТЕЛ К β-АМИЛОИДУ
KR20080025174A (ko)	2005-06-23	2008-03-19	메디뮨 인코포레이티드	응집 및 단편화 프로파일이 최적화된 항체 제제
EP1907421A4 (de) *	2005-06-30	2012-03-28	Abbott Lab	Il-12/p40-bindende proteine
EP1896073B1 (de)	2005-06-30	2013-03-06	Janssen Biotech, Inc.	Anti-il-23-antikörper, zusammensetzungen, verfahren und verwendung
CN101248089A (zh)	2005-07-01	2008-08-20	米德列斯公司	抗程序性死亡配体1（pd-l1）的人单克隆抗体
EP1910565A4 (de)	2005-07-07	2009-10-28	Athlomics Pty Ltd	Polynukleotidmarkergene und deren expression zur diagnose von endotoxämie
EP2238986A3 (de)	2005-07-08	2010-11-03	Biogen Idec MA Inc.	Sp35-Antikörper und Verwendungen dafür
US7482124B2 (en) *	2005-07-08	2009-01-27	Bristol-Myers Squibb Company	Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
KR20080039929A (ko)	2005-07-22	2008-05-07	와이스 테라퓨틱스 가부시키가이샤	항-ｃｄ26 항체 및 이들의 사용 방법
EP1913027B1 (de)	2005-07-28	2015-03-04	Novartis AG	M-csf-spezifische monoklonale antikörper und anwendungen davon
EP1919504B1 (de) *	2005-08-03	2013-10-16	iBio, Inc.	Antikörper gegen bacillus anthracis protektiv antigen
NZ565631A (en)	2005-08-03	2011-01-28	Adelaide Res & Innovation Pty	Polysaccharide synthases
WO2007019620A1 (en) *	2005-08-15	2007-02-22	Arana Therapeutics Limited	Engineered antibodies with new world primate framework regions
US20070041905A1 (en)	2005-08-19	2007-02-22	Hoffman Rebecca S	Method of treating depression using a TNF-alpha antibody
SG2014010029A (en)	2005-08-19	2014-08-28	Abbott Lab	Dual variable domain immunoglobin and uses thereof
US20090215992A1 (en) *	2005-08-19	2009-08-27	Chengbin Wu	Dual variable domain immunoglobulin and uses thereof
EP2500355A3 (de)	2005-08-19	2012-10-24	Abbott Laboratories	Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US20070202512A1 (en) *	2005-08-19	2007-08-30	Bristol-Myers Squibb Company	Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
EP1934867A2 (de)	2005-08-31	2008-06-25	Cell Signaling Technology, Inc.	Reagentien zum nachweis der proteinphosphorylierung in leukämie-signalwegen
AU2006297571B2 (en)	2005-09-07	2012-03-15	Amgen Fremont Inc.	Human monoclonal antibodies to activin receptor-like kinase-1
US8945573B2 (en)	2005-09-08	2015-02-03	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Targeted identification of immunogenic peptides
WO2007030560A2 (en)	2005-09-08	2007-03-15	Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine	Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
AU2006290567A1 (en) *	2005-09-14	2007-03-22	Ucb Pharma S.A	Comb polymers
EP1945240B1 (de)	2005-09-16	2016-12-28	Raptor Pharmaceutical Inc	Zusammensetzungen mit rezeptor-assoziierten protein (rap) varianten, die für cr-haltige proteine spezifisch sind und ihre verwendungen
US20080279868A1 (en) *	2005-09-26	2008-11-13	Medarex, Inc.	Antibody-Drug Conjugates and Methods of Use
AU2006294663B2 (en)	2005-09-26	2012-03-22	Medarex, Inc.	Human monoclonal antibodies to CD70
US8906864B2 (en)	2005-09-30	2014-12-09	AbbVie Deutschland GmbH & Co. KG	Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
GB0521139D0 (en)	2005-10-18	2005-11-23	Univ Sheffield	Therapeutic agent
AR058104A1 (es)	2005-10-21	2008-01-23	Novartis Ag	Compuestos organicos
EP1945816B1 (de)	2005-10-21	2011-07-27	GeneNews Inc.	Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen
WO2007050793A2 (en)	2005-10-25	2007-05-03	The Johns Hopkins University	Methods and compositions for the treatment of marfan syndrome and associated disorders
DK1940789T3 (da)	2005-10-26	2012-03-19	Medarex Inc	Fremgangsmåder og forbindelser til fremstilling af CC-1065-analoger
WO2007051077A2 (en)	2005-10-28	2007-05-03	The Regents Of The University Of California	Methods and compounds for lymphoma cell detection and isolation
AU2006337105B2 (en)	2005-11-01	2013-05-02	Abbvie Biotechnology Ltd	Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
US20070099246A1 (en) *	2005-11-03	2007-05-03	Sandy John D	Antibodies, assays and kits to quantitate cartilage destruction
CA2628451A1 (en)	2005-11-04	2007-05-18	Biogen Idec Ma Inc.	Methods for promoting neurite outgrowth and survival of dopaminergic neurons
US20100028358A1 (en)	2005-11-07	2010-02-04	Wolfram Ruf	Compositions and Methods for Controlling Tissue Factor Signaling Specificity
ES2577292T3 (es)	2005-11-07	2016-07-14	Genentech, Inc.	Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
UA96139C2 (uk)	2005-11-08	2011-10-10	Дженентек, Інк.	Антитіло до нейропіліну-1 (nrp1)
CA2627190A1 (en)	2005-11-10	2007-05-24	Medarex, Inc.	Duocarmycin derivatives as novel cytotoxic compounds and conjugates
DK3045182T3 (en)	2005-11-14	2018-03-19	Teva Pharmaceuticals Int Gmbh	ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT
ATE547709T1 (de)	2005-11-14	2012-03-15	Metamol Theranostics Llc	Tumorinvasionsfördernde peptidsequenz
CA2626522A1 (en)	2005-11-16	2007-05-24	Ambrx, Inc.	Methods and compositions comprising non-natural amino acids
WO2007111714A2 (en)	2005-11-28	2007-10-04	Zymogenetics, Inc.	Il-21 antagonists
RS53270B2 (sr)	2005-11-30	2018-05-31	Abbvie Deutschland	Monoklonalna antitela protiv amiloidnog beta proteina i njihova upotreba
AU2006319358B2 (en)	2005-11-30	2012-01-19	AbbVie Deutschland GmbH & Co. KG	Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US9829494B2 (en)	2005-12-01	2017-11-28	Adrenomed Ag	Methods of treatment using ADM antibodies
EP1957540B1 (de) *	2005-12-02	2012-06-13	Genentech, Inc.	Bindungspolypeptide und verwendung davon
CA2631181A1 (en)	2005-12-02	2007-06-07	Biogen Idec Ma Inc.	Treatment of conditions involving demyelination
CN101356195B (zh)	2005-12-08	2013-04-03	米德列斯公司	抗岩藻糖基-gm1的人单克隆抗体及使用抗岩藻糖基-gm1抗体的方法
JP5183484B2 (ja)	2005-12-09	2013-04-17	ユセベファルマソシエテアノニム	ヒトｉｌ−６に対して特異性を有する抗体分子
DOP2006000277A (es)	2005-12-12	2007-08-31	Bayer Pharmaceuticals Corp	Anticuerpos anti mn y métodos para su utilización
US20070264687A1 (en)	2005-12-15	2007-11-15	Min-Yuan Chou	Recombinant triplex scaffold-based polypeptides
US10183986B2 (en)	2005-12-15	2019-01-22	Industrial Technology Research Institute	Trimeric collagen scaffold antibodies
US8014957B2 (en)	2005-12-15	2011-09-06	Fred Hutchinson Cancer Research Center	Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US7632498B2 (en)	2005-12-19	2009-12-15	Tripath Imaging, Inc.	MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
RS53685B1 (en)	2005-12-29	2015-04-30	Janssen Biotech Inc.	HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS
HUE028179T2 (en)	2006-01-12	2016-12-28	Alexion Pharma Inc	Antibodies to OX-2 / CD200 and their use
US20070166774A1 (en) *	2006-01-17	2007-07-19	Groman Ernest V	Functional immunoassay
US20120208824A1 (en)	2006-01-20	2012-08-16	Cell Signaling Technology, Inc.	ROS Kinase in Lung Cancer
JP5829373B2 (ja)	2006-01-27	2015-12-09	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	Ｎｏｇｏレセプターアンタゴニスト
WO2007090076A2 (en)	2006-01-27	2007-08-09	Tripath Imaging, Inc.	Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
WO2007090126A2 (en) *	2006-01-30	2007-08-09	Invitrogen Corporation	Compositions and methods for detecting and quantifying toxic substances in disease states
US20070175313A1 (en) *	2006-01-31	2007-08-02	Kevin Vandervliet	MP3 player holder assembly
MX2008009792A (es) *	2006-02-01	2008-09-01	Arana Therapeutics Ltd	Construccion de anticuerpo de dominio.
WO2008048344A2 (en) *	2006-02-13	2008-04-24	Fraunhofer Usa, Inc.	Bacillus anthracis antigens, vaccine compositions, and related methods
EP1984405A4 (de) *	2006-02-13	2010-06-30	Fraunhofer Usa Inc	Influenza-antigene, impfstoffzusammensetzungen und zugehörige verfahren
CA2642056A1 (en) *	2006-02-13	2007-08-23	Fraunhofer Usa, Inc.	Hpv antigens, vaccine compositions, and related methods
WO2007120975A2 (en)	2006-02-13	2007-10-25	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Variants in complement regulatory genes predict age-related macular degeneration
TWI417301B (zh)	2006-02-21	2013-12-01	Wyeth Corp	對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en)	2006-02-21	2007-12-16	Wyeth Corp	Methods of using antibodies against human IL-22
EP2495327B1 (de)	2006-03-03	2016-09-28	ProMIS Neurosciences Inc.	Verfahren und Zusammensetzungen zum Behandeln und Erkennen von missgefaltetem SOD 1-herbeigeführte Erkrankungen
EP2650306A1 (de)	2006-03-06	2013-10-16	Aeres Biomedical Limited	Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
US8097425B2 (en) *	2006-03-10	2012-01-17	Tethys Bioscience, Inc.	Multiplex protein fractionation
WO2007111661A2 (en)	2006-03-20	2007-10-04	Xoma Technology Ltd.	Human antibodies specific for gastrin materials and methods
BRPI0709917A2 (pt)	2006-03-30	2011-07-05	Novartis Ag	composições e métodos de uso para anticorpos de c-met
US7910798B2 (en)	2006-03-31	2011-03-22	Medarex, Inc.	Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
AR059922A1 (es)	2006-04-01	2008-05-07	Galaxy Biotech Llc	Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
WO2007126455A2 (en)	2006-04-05	2007-11-08	Genentech, Inc.	Method for using boc/cdo to modulate hedgehog signaling
KR20150006085A (ko)	2006-04-05	2015-01-15	애브비 바이오테크놀로지 리미티드	항체 정제
MX2008012754A (es)	2006-04-07	2009-04-27	Us Gov Health & Human Serv	Composiciones de anticuerpos y metodos para tratamiento de enfermedad neoplastica.
EP2666472A3 (de)	2006-04-10	2014-04-02	Abbott Biotechnology Ltd	Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
CA2564435A1 (en)	2006-04-10	2007-10-10	Abbott Biotechnology Ltd.	Methods for monitoring and treating intestinal disorders
EP2703010A3 (de)	2006-04-10	2014-08-06	AbbVie Biotechnology Ltd	Anwendungen und Zusammensetzungen zur Behandlung von rheumatoider Arthritis
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
WO2007124082A2 (en) *	2006-04-21	2007-11-01	Amgen, Inc.	Buffering agents for biopharmaceutical formulations
TWI395754B (zh)	2006-04-24	2013-05-11	Amgen Inc	人類化之ｃ-ｋｉｔ抗體
US7702468B2 (en)	2006-05-03	2010-04-20	Population Diagnostics, Inc.	Evaluating genetic disorders
US10522240B2 (en)	2006-05-03	2019-12-31	Population Bio, Inc.	Evaluating genetic disorders
WO2007134050A2 (en) *	2006-05-09	2007-11-22	Genentech, Inc.	Binding polypeptides with optimized scaffolds
GB0611116D0 (en)	2006-06-06	2006-07-19	Oxford Genome Sciences Uk Ltd	Proteins
CN103709252B (zh)	2006-06-07	2016-12-07	生物联合公司	识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
BRPI0713426A2 (pt)	2006-06-14	2012-10-09	Macrogenics Inc	métodos de tratar, diminuir a progressão, ou melhorar um ou mais sintomas de um distúrbio, e de prevenir ou retardar o inìcio de um distúrbio
CA2714867A1 (en)	2006-06-23	2007-12-27	Candace B. Pert	Non-aggregated pharmaceutically active peptide
WO2008019199A2 (en)	2006-06-26	2008-02-14	Macrogenics, Inc.	FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
CA2651992A1 (en)	2006-06-30	2008-01-10	Abbott Biotechnology Ltd.	Automatic injection device
JP4546578B2 (ja)	2006-07-05	2010-09-15	カタリスト・バイオサイエンシーズ・インコーポレイテッド	プロテアーゼスクリーニング方法およびそれにより同定されるプロテアーゼ
BRPI0714871A2 (pt)	2006-07-18	2013-05-07	Sanofi Aventis	anticorpo antagonista para o tratamento de cÂncer
ES2613957T3 (es)	2006-08-04	2017-05-29	Medimmune Limited	Anticuerpos contra ERBB2
RU2009107707A (ru)	2006-08-04	2010-09-10	Новартис АГ (CH)	СПЕЦИФИЧНОЕ К EphB3 АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
AU2007284651B2 (en)	2006-08-09	2014-03-20	Institute For Systems Biology	Organ-specific proteins and methods of their use
US7939636B2 (en)	2006-08-11	2011-05-10	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in c-Src signaling pathways
JP5244785B2 (ja)	2006-08-11	2013-07-24	小野薬品工業株式会社	ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体
CA2661446C (en)	2006-08-11	2017-11-21	Csl Limited	Treatment of pulmonary disease conditions
EP3415532A1 (de)	2006-08-18	2018-12-19	XOMA Technology Ltd.	Prlr-spezifischer antikörper und verwendungen davon
KR101314362B1 (ko)	2006-08-28	2013-10-10	라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지	길항성 인간 ｌｉｇｈｔ-특이적 인간 모노클로날 항체
KR20090088852A (ko)	2006-09-05	2009-08-20	메다렉스, 인코포레이티드	골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
MY188368A (en)	2006-09-08	2021-12-06	Abbott Lab	Interleukin-13 binding proteins
WO2008032833A1 (fr)	2006-09-14	2008-03-20	Medical & Biological Laboratories Co., Ltd.	Anticorps présentant une activité adcc accrue et son procédé de production
US20090252745A1 (en) *	2006-09-15	2009-10-08	Duke University	Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis
HUE044136T2 (hu)	2006-09-26	2019-09-30	Genmab As	Anti-CD38 plusz kortikoszteroidok plusz nem-kortikoszteroid kemoterápiás szer daganatok kezelésére
PL2066351T3 (pl)	2006-10-02	2016-02-29	Squibb & Sons Llc	Przeciwciała ludzkie wiążące CXCR4 i ich wykorzystanie
WO2008045373A2 (en) *	2006-10-06	2008-04-17	Amgen Inc.	Stable antibody formulations
JP2010506839A (ja)	2006-10-12	2010-03-04	ワイスエルエルシー	乳光の低減を伴う方法および組成物
JP5298021B2 (ja) *	2006-10-12	2013-09-25	ジェネンテック，インコーポレイテッド	リンホトキシン−αに対する抗体
US20100143254A1 (en)	2006-10-16	2010-06-10	Medimmune, Llc	Molecules with reduced half-lives, compositions and uses thereof
GB0620729D0 (en)	2006-10-18	2006-11-29	Ucb Sa	Biological products
EP1914242A1 (de) *	2006-10-19	2008-04-23	Sanofi-Aventis	Neue Antikörper gegen CD38 zur Behandlung von Krebs
CA2666682C (en)	2006-10-19	2014-07-08	Merck & Co., Inc.	Anti-il-13r.alpha.1 antibodies and their uses thereof
ES2925992T3 (es) *	2006-10-20	2022-10-20	Amgen Inc	Formulaciones estables de polipéptidos
US7846434B2 (en)	2006-10-24	2010-12-07	Trubion Pharmaceuticals, Inc.	Materials and methods for improved immunoglycoproteins
CA2666317C (en)	2006-11-03	2013-08-06	Wyeth	Glycolysis-inhibiting substances in cell culture
AU2007325872B2 (en) *	2006-11-08	2012-12-13	Macrogenics West, Inc.	TES7 and antibodies that bind thereto
CL2007003291A1 (es)	2006-11-15	2008-07-04	Medarex Inc	Anticuerpo monoclonal humano aislado que enlaza la proteina btla o fragmentos del mismo; acido nucleico que lo codifica; metodo de produccion; composicion e inmunoconjugado que los comprende; y metodo para inhibir el crecimiento de celulas de tumor e
AU2007323799B2 (en)	2006-11-15	2013-07-18	Eli Lilly And Company	Anti-TSG101 antibodies and their uses for treatment of viral infections
US7488807B2 (en)	2006-11-22	2009-02-10	3M Innovative Properties Company	Antibody with protein A selectivity
US8785400B2 (en) *	2006-11-22	2014-07-22	Curedm Group Holdings, Llc	Methods and compositions relating to islet cell neogenesis
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2609932B1 (de)	2006-12-01	2022-02-02	Seagen Inc.	Veränderliche target-bindemittel und verwendungen davon
US8377440B2 (en)	2006-12-01	2013-02-19	Selexys Pharmaceuticals Corporation	Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases
NZ578064A (en)	2006-12-01	2012-01-12	Medarex Inc	Human antibodies that bind cd22 and uses thereof
DK2121979T3 (en)	2006-12-05	2017-09-25	Decode Genetics Ehf	Genetic markers for risk management of cardiac arrhythmia
EP2687232A1 (de)	2006-12-06	2014-01-22	MedImmune, LLC	Verfahren zur Behandlung von systemischem Lupus erythematodes
BRPI0720437A2 (pt)	2006-12-07	2014-01-07	Novartis Ag	Anticorpos antafonísticos contra ephb3
US20080139790A1 (en) *	2006-12-08	2008-06-12	Jennings Philip A	Chimeric antibodies
CL2007003622A1 (es)	2006-12-13	2009-08-07	Medarex Inc	Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
KR20090088946A (ko)	2006-12-14	2009-08-20	메다렉스, 인코포레이티드	씨디70에 결합하는 인간 항체 및 이의 용도
WO2008077145A2 (en)	2006-12-20	2008-06-26	Xoma Technology Ltd.	Treatment of il-1-beta related diseases
WO2008079290A2 (en) *	2006-12-21	2008-07-03	Amgen Inc	Stable buffered formulations containing polypeptides
TW200833711A (en) *	2006-12-22	2008-08-16	Genentech Inc	Antibodies to insulin-like growth factor receptor
US8440185B2 (en)	2006-12-26	2013-05-14	The Johns Hopkins University	Compositions and methods for the treatment of immunologic disorders
NZ619576A (en)	2006-12-27	2014-07-25	Harvard College	Compositions and methods for the treatment of infections and tumors
US7989173B2 (en)	2006-12-27	2011-08-02	The Johns Hopkins University	Detection and diagnosis of inflammatory disorders
WO2008083239A2 (en)	2006-12-27	2008-07-10	The Johns Hopkins University	Compositions and methods for stimulating an immune response
TWI412367B (zh)	2006-12-28	2013-10-21	Medarex Llc	化學鏈接劑與可裂解基質以及其之綴合物
US8324350B2 (en) *	2006-12-29	2012-12-04	Abbott Laboratories	Dual-specific IL-1α/IL-1β antibodies
TR201807425T4 (tr)	2007-01-09	2018-06-21	Biogen Ma Inc	Sp35 antikorları ve bunların kullanımları.
US8128926B2 (en)	2007-01-09	2012-03-06	Biogen Idec Ma Inc.	Sp35 antibodies and uses thereof
PL2104682T3 (pl)	2007-01-11	2017-03-31	Michael Bacher	Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
JP2010520745A (ja)	2007-02-07	2010-06-17	デコード・ジェネティクス・イーエイチエフ	前立腺癌のリスクに寄与する遺伝子変異体
RU2009133784A (ru)	2007-02-09	2011-03-20	Дженентек, Инк. (Us)	АНТИ-Robo4-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
AU2008216418A1 (en) *	2007-02-09	2008-08-21	Medimmune, Llc	Antibody libray display by yeast cell plasma membrane
US8685666B2 (en) *	2007-02-16	2014-04-01	The Board Of Trustees Of Southern Illinois University	ARL-1 specific antibodies and uses thereof
KR101598229B1 (ko)	2007-02-16	2016-02-26	메리맥 파마슈티컬즈, 인크.	Ｅｒｂｂ3에 대한 항체 및 이의 용도
US8114606B2 (en) *	2007-02-16	2012-02-14	The Board Of Trustees Of Southern Illinois University	ARL-1 specific antibodies
JP5646179B2 (ja)	2007-02-21	2014-12-24	デコード・ジェネティクス・イーエイチエフ	循環器疾患に関連する遺伝的感受性変異体
AR065404A1 (es) *	2007-02-21	2009-06-03	Medarex Inc	Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero
ES2556380T3 (es)	2007-02-22	2016-01-15	Genentech, Inc.	Procedimientos para detectar una enfermedad inflamatoria del intestino
PT2118300E (pt)	2007-02-23	2015-09-22	Univ California	Prevenção e tratamento da doença sinucleinopática e amiloidogénica
PL2583978T3 (pl)	2007-02-23	2016-07-29	Prothena Biosciences Ltd Co	Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
EP3118221B1 (de)	2007-02-26	2019-08-21	Oxford BioTherapeutics Ltd	Proteine
WO2008104803A2 (en)	2007-02-26	2008-09-04	Oxford Genome Sciences (Uk) Limited	Proteins
EP2486928A1 (de)	2007-02-27	2012-08-15	Abbott GmbH & Co. KG	Verfahren zur Behandlung von Amyloidosen
US20090081659A1 (en)	2007-03-07	2009-03-26	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
JP4842400B2 (ja)	2007-03-22	2011-12-21	ヘプテアズ・セラピューティクス・リミテッド	Ｇタンパク質共役型受容体変異体及びその選択方法
CN103214577B (zh)	2007-03-22	2015-09-02	生物基因Ma公司	特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
US20090068684A1 (en)	2007-03-26	2009-03-12	Cell Signaling Technology, Inc.	Serine and threoninephosphorylation sites
WO2008118970A2 (en) *	2007-03-27	2008-10-02	Sea Lane Biotechnologies, Llc	Constructs and libraries comprising antibody surrogate light chain sequences
KR101540823B1 (ko)	2007-03-30	2015-07-30	메디뮨 엘엘씨	항체 제제
WO2008123999A2 (en)	2007-04-02	2008-10-16	Amgen Fremont Inc.	Anti-ige antibodies
EP2155777A2 (de)	2007-04-10	2010-02-24	The Administrators of the Tulane Educational Fund	Lösliche und membranverankerte formen von proteinuntereinheiten des lassavirus
US7807168B2 (en) *	2007-04-10	2010-10-05	Vaccinex, Inc.	Selection of human TNFα specific antibodies
RU2571931C2 (ru)	2007-04-13	2015-12-27	Каталист Биосайенсис, Инк.	Полипептиды на основе модифицированного фактора vii и их применение
US7977462B2 (en)	2007-04-19	2011-07-12	Cell Signaling Technology, Inc.	Tyrosine phosphorylation sites
EP2145902A3 (de)	2007-04-19	2010-09-29	Peter Hornbeck	Tyrosinphosphorylations-Stellen und spezifische Antikörper
EP1983003A3 (de)	2007-04-19	2009-03-11	Peter Hornbeck	Tyrosinphosphorylationsstellen und spezifische Antikörper
US8778348B2 (en) *	2007-04-28	2014-07-15	Ibio Inc.	Trypanosoma antigens, vaccine compositions, and related methods
US20090053831A1 (en)	2007-05-01	2009-02-26	Cell Signaling Technology, Inc.	Tyrosine phosphorylation sites
US20080280778A1 (en) *	2007-05-03	2008-11-13	Urdea Michael S	Binding reagents that contain small epitope binding molecules
EP2164868B1 (de)	2007-05-04	2015-03-25	Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA	Gentechnisch gewonnene variable domänen von kaninchen-antikörpern und deren verwendung
RU2549701C2 (ru)	2007-05-07	2015-04-27	Медиммун, Ллк	Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний
PL2068927T3 (pl)	2007-05-14	2016-06-30	Medimmune Llc	Sposoby redukcji poziomów eozynofilii
EP2158215B1 (de)	2007-05-17	2015-04-22	Genentech, Inc.	Kristallstrukturen von neuropilinfragmenten und neuropilin-antikörper-komplexen
MX2009012722A (es)	2007-05-25	2009-12-11	Decode Genetics Ehf	Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
PE20090329A1 (es) *	2007-05-30	2009-03-27	Abbott Lab	Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
US20090232801A1 (en) *	2007-05-30	2009-09-17	Abbot Laboratories	Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US7709215B2 (en)	2007-06-01	2010-05-04	Cytonics Corporation	Method for diagnosing and treating acute joint injury
US8999337B2 (en)	2007-06-11	2015-04-07	Abbvie Biotechnology Ltd.	Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
PL2170956T3 (pl)	2007-06-15	2015-04-30	Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts	Leczenie nowotworów z zastosowaniem specyficznego przeciwciała anty-L1
EP2158221B1 (de)	2007-06-21	2018-08-29	MacroGenics, Inc.	Kovalente diabodies und deren verwendung
EP2178558B1 (de)	2007-07-11	2014-04-30	iBio, Inc.	Yersinia pestis-antigene, impfstoffzusammensetzungen und zugehörige verfahren
CN101784564B (zh)	2007-07-13	2014-07-02	约翰霍普金斯大学	B7-dc变体
SG183044A1 (en)	2007-07-16	2012-08-30	Genentech Inc	Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
ES2381788T3 (es)	2007-07-16	2012-05-31	Genentech, Inc.	Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
EP2182943B1 (de)	2007-07-23	2016-10-26	Janssen Biotech, Inc.	Verfahren und zusammensetzungen zur behandlung von fibrosebedingten erkrankungen mit il-17-antagonisten
BRPI0814645A2 (pt) *	2007-07-25	2015-01-27	Alexion Pharma Inc	Métodos e composições para tratar de doença autoimune.
ES2498040T3 (es)	2007-07-27	2014-09-24	Janssen Alzheimer Immunotherapy	Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
EP2537529B1 (de)	2007-08-02	2018-10-17	Gilead Biologics, Inc.	Loxl2-hemmer antikörper und verwendungen davon
WO2009020477A1 (en) *	2007-08-06	2009-02-12	Yale University	Modified miniature proteins
JP5588866B2 (ja)	2007-08-10	2014-09-10	メダレックスエル．エル．シー．	Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
US9624309B2 (en)	2007-08-15	2017-04-18	Bayer Intellectual Property Gmbh	Monospecific and multispecific antibodies and method of use
US20110059130A1 (en) *	2007-08-20	2011-03-10	Fraunhofer Usa, Inc.	Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
DK2190987T3 (da)	2007-08-21	2013-02-18	Morphosys Ag	Fremgangsmåder til dannelse af disulfidbindinger
WO2009026274A1 (en)	2007-08-22	2009-02-26	Medarex, Inc.	Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
PT2193142E (pt) *	2007-08-30	2015-04-22	Curedm Group Holdings Llc	Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos
PL2769729T3 (pl)	2007-09-04	2019-09-30	Compugen Ltd.	Polipeptydy i polinukleotydy i ich zastosowanie jako cel dla leków do wytwarzania leków i środków biologicznych
GB0717337D0 (en)	2007-09-06	2007-10-17	Ucb Pharma Sa	Method of treatment
ES2622460T3 (es)	2007-09-26	2017-07-06	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
US8383114B2 (en)	2007-09-27	2013-02-26	Amgen Inc.	Pharmaceutical formulations
AU2008311251B9 (en) *	2007-10-11	2014-04-17	Biogen Ma Inc.	Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and TrkB agonists
AR068767A1 (es)	2007-10-12	2009-12-02	Novartis Ag	Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
HUE030134T2 (en)	2007-10-16	2017-04-28	Zymogenetics Inc	Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
EP2203558B1 (de)	2007-10-18	2016-05-04	Cell Signaling Technology, Inc.	Translokation und mutations-ros-kinase bei menschlichem nicht-kleinzelligem bronchialkarzinom
KR20100089851A (ko)	2007-10-23	2010-08-12	노파르티스 아게	호흡기 질환의 치료를 위한 ｔｒｋｂ 항체의 용도
WO2009059317A2 (en)	2007-11-01	2009-05-07	University Of Iowa Research Foundation	Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
AU2008320823B2 (en)	2007-11-02	2013-01-17	Novartis Ag	Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
CA2703705A1 (en)	2007-11-05	2009-05-14	Medimmune, Llc	Methods of treating scleroderma
US8236318B2 (en)	2007-11-07	2012-08-07	Celldex Therapeutics Inc.	Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
US20110123553A1 (en) *	2007-11-08	2011-05-26	Biogen Idec Ma Inc.	Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination
JP5809415B2 (ja)	2007-11-09	2015-11-10	ペレグリンファーマシューティカルズ，インコーポレーテッド	抗ｖｅｇｆ抗体の組成物および方法
WO2009064933A2 (en) *	2007-11-13	2009-05-22	Ikonisys, Inc.	Detection of circulating tumor cells in peripheral blood with an automated scanning fluorescence microscope
EP2219602A1 (de)	2007-11-15	2010-08-25	Amgen, Inc	Wässrige formulierung von mit antioxidantien stabilisiertem erythropoese-stimulierendem protein zur parenteralen verabreichung
WO2009067546A2 (en)	2007-11-19	2009-05-28	Celera Corpration	Lung cancer markers and uses thereof
CN101932712B (zh)	2007-11-20	2014-05-14	先锋国际良种公司	用于改善植物应激耐性的玉米乙烯信号转导基因及其调节
EP2062920A3 (de)	2007-11-21	2009-06-17	Peter Hornbeck	Proteinphosphorylation durch basophilische Serin-/Threonin-Kinasen in Insulinsignalisierungspfaden
EP2225275A4 (de) *	2007-11-28	2013-04-03	Medimmune Llc	Proteinformulierung
US8697360B2 (en)	2007-11-30	2014-04-15	Decode Genetics Ehf.	Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
TWI580694B (zh) *	2007-11-30	2017-05-01	建南德克公司	抗-ｖｅｇｆ抗體
GB0724051D0 (en)	2007-12-08	2008-01-16	Medical Res Council	Mutant proteins and methods for producing them
DK2222706T4 (en)	2007-12-14	2016-11-21	Novo Nordisk As	Antibodies that bind to NKG2D and its use
US8779088B2 (en)	2007-12-17	2014-07-15	Marfl Ab	Vaccine for the treatment of Mycobacterium related disorders
SG186669A1 (en)	2007-12-18	2013-01-30	Bioalliance Cv	Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
PL2391650T3 (pl)	2007-12-20	2015-03-31	Xoma Us Llc	Sposoby leczenia dny
GB0724860D0 (en)	2007-12-20	2008-01-30	Heptares Therapeutics Ltd	Screening
US8414893B2 (en)	2007-12-21	2013-04-09	Amgen Inc.	Anti-amyloid antibodies and uses thereof
WO2009082485A1 (en)	2007-12-26	2009-07-02	Vaccinex, Inc.	Anti-c35 antibody combination therapies and methods
CN102016059B (zh)	2007-12-28	2014-10-22	依兰制药公司	淀粉样变性的治疗和预防
GB0800277D0 (en)	2008-01-08	2008-02-13	Imagination Tech Ltd	Video motion compensation
CA2711771C (en)	2008-01-11	2017-01-24	Gene Techno Science Co., Ltd.	Humanized anti-.alpha.9 integrin antibodies and the uses thereof
ES2613963T3 (es)	2008-01-18	2017-05-29	Medimmune, Llc	Anticuerpos manipulados con cisteína para conjugación específica de sitio
EP2574628B1 (de)	2008-01-25	2015-05-20	Amgen Inc.	Ferroportin-Antikörper und Verwendungsverfahren
UA106586C2 (uk)	2008-01-31	2014-09-25	Дженентек, Інк.	Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
WO2009100110A1 (en)	2008-02-05	2009-08-13	Medarex, Inc.	Alpha 5 - beta 1 antibodies and their uses
PT2250279E (pt)	2008-02-08	2016-06-03	Medimmune Llc	Anticorpos anti-ifnár1 com afinidade reduzida para o ligando fc
GB0802474D0 (en)	2008-02-11	2008-03-19	Heptares Therapeutics Ltd	Mutant proteins and methods for selecting them
CA2715297A1 (en) *	2008-02-13	2009-08-20	Dyax Corp.	Improved methods for producing specific binding pairs
CA2714521A1 (en)	2008-02-14	2009-08-20	Decode Genetics Ehf	Susceptibility variants for lung cancer
AU2009219358A1 (en)	2008-02-28	2009-09-03	3M Innovative Properties Company	Antibodies to Clostridium difficile spores and uses thereof
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
US20090233809A1 (en) *	2008-03-04	2009-09-17	Affymetrix, Inc.	Resequencing methods for identification of sequence variants
US20110020368A1 (en)	2008-03-25	2011-01-27	Nancy Hynes	Treating cancer by down-regulating frizzled-4 and/or frizzled-1
CA2724666A1 (en)	2008-04-01	2009-10-08	Decode Genetics Ehf	Susceptibility variants for peripheral arterial disease and abdominal aortic aneurysm
BRPI0906309A2 (pt)	2008-04-02	2020-05-26	Macrogenics, Inc	Imunoglobulina, anticorpo, uso do anticorpo e composição farmacêutica
ES2654937T3 (es)	2008-04-02	2018-02-15	Macrogenics, Inc.	Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
EP2274437B1 (de)	2008-04-10	2015-12-23	Cell Signaling Technology, Inc.	Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs
SG189776A1 (en)	2008-04-11	2013-05-31	Seattle Genetics Inc	Detection and treatment of pancreatic, ovarian and other cancers
BRPI0911652A2 (pt)	2008-04-11	2015-08-04	Merrimack Pharmaceuticals Inc	Ligantes de albumina sérica humana e seus conjugados
GB0807413D0 (en)	2008-04-23	2008-05-28	Ucb Pharma Sa	Biological products
WO2009131256A1 (en)	2008-04-24	2009-10-29	Gene Techno Science Co., Ltd.	Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
KR101634719B1 (ko)	2008-04-25	2016-06-29	다이액스 코포레이션	Ｆｃｒｎ에 대한 항체 및 이들의 용도
US20090269786A1 (en) *	2008-04-25	2009-10-29	The Board Of Trustees Of The University Of Illinois	RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
EP2282769A4 (de)	2008-04-29	2012-04-25	Abbott Lab	Dual-variable- domain-immunglobuline und ihre verwendungen
US20100260668A1 (en) *	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
EP2294087B1 (de)	2008-05-01	2014-05-14	Amgen, Inc.	Anti-hepcidin-antikörper und verfahren zu ihrer verwendung
EP2282773B1 (de)	2008-05-02	2014-01-15	Seattle Genetics, Inc.	Verfahren und zusammensetzungen zur herstellung von antikörpern und antikörperderivaten mit reduzierter kernfukosylierung
ES2579554T3 (es)	2008-05-09	2016-08-12	Abbvie Deutschland Gmbh & Co Kg	Anticuerpos para el receptor de productos terminales de glicación avanzada (RAGE) y usos de los mismos
EP2279004B1 (de) *	2008-05-16	2015-01-14	F. Hoffmann-La Roche AG	Verwendung von biomarkern zur beurteilung der behandlung von entzündlichen magen-darm-erkrankungen mit beta7-integrin-antagonisten
US8101725B2 (en)	2008-05-29	2012-01-24	Galaxy Biotech, Llc	Monoclonal antibodies to basic fibroblast growth factor
EP2304439A4 (de)	2008-05-29	2012-07-04	Nuclea Biotechnologies Llc	Anti-phospho-akt-antikörper
RU2010153580A (ru)	2008-06-03	2012-07-20	Эбботт Лэборетриз (Us)	Иммуноглобулины с двумя вариабельными доменами и их применение
CA2725666A1 (en)	2008-06-03	2009-12-10	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof
WO2010033279A2 (en)	2008-06-04	2010-03-25	Macrogenics, Inc.	Antibodies with altered binding to fcrn and methods of using same
CN102124030B (zh) *	2008-06-20	2015-06-17	国立大学法人冈山大学	抗氧化LDL/β2GPI复合物的抗体及其用途
CA2729934A1 (en)	2008-07-07	2010-01-14	Decode Genetics Ehf	Genetic variants for breast cancer risk assessment
JP5674654B2 (ja) *	2008-07-08	2015-02-25	アッヴィ・インコーポレイテッド	プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
CN104829718A (zh)	2008-07-08	2015-08-12	艾伯维公司	前列腺素e2结合蛋白及其用途
US8058406B2 (en)	2008-07-09	2011-11-15	Biogen Idec Ma Inc.	Composition comprising antibodies to LINGO or fragments thereof
US8680020B2 (en)	2008-07-15	2014-03-25	Academia Sinica	Glycan arrays on PTFE-like aluminum coated glass slides and related methods
US8148088B2 (en)	2008-07-18	2012-04-03	Abgent	Regulation of autophagy pathway phosphorylation and uses thereof
WO2010010469A2 (en) *	2008-07-25	2010-01-28	Abbott Gmbh & Co. Kg	Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
US9182406B2 (en) *	2008-08-04	2015-11-10	Biodesy, Inc.	Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
NZ590634A (en)	2008-08-05	2012-07-27	Novartis Ag	Compositions and methods for antibodies targeting complement protein c5
AR072999A1 (es)	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010017598A1 (en)	2008-08-14	2010-02-18	Arana Therapeutics Limited	Anti-il-12/il-23 antibodies
CA3073384A1 (en)	2008-09-05	2010-03-11	President And Fellows Of Harvard College	Continuous directed evolution of proteins and nucleic acids
TWI516501B (zh)	2008-09-12	2016-01-11	禮納特神經系統科學公司	Ｐｃｓｋ９拮抗劑類
US20110287026A1 (en)	2008-09-23	2011-11-24	President And Fellows Of Harvard College	Sirt4 and uses thereof
EP2344180A2 (de)	2008-09-23	2011-07-20	Wyeth LLC	Verfahren zur vorhersage der produktion von aktivierenden signalen durch vernetzende bindungsproteine
EP3530672A1 (de)	2008-09-26	2019-08-28	Dana Farber Cancer Institute, Inc.	Menschliche anti-pd1-, pd-l1- und pd-l2-antikörper und verwendungen davon
JP2012503982A (ja)	2008-09-26	2012-02-16	ワイス・エルエルシー	適合性ディスプレイベクター系
US8734803B2 (en)	2008-09-28	2014-05-27	Ibio Inc.	Humanized neuraminidase antibody and methods of use thereof
TR201802130T4 (tr)	2008-10-10	2018-03-21	Beth Israel Deaconess Medical Ct Inc	Biyokimyasal olarak stabilize edilmiş HIV-1 env trimer aşısı.
EP2349329A4 (de)	2008-10-14	2012-10-31	Dyax Corp	Verwendung von igf-ii/igf-iie-bindung zur behandlung und prävention von systemischer sklerose im zusammenhang mit lungenfibrose
JP5390621B2 (ja)	2008-10-20	2014-01-15	グワンジュ・インスティテュート・オブ・サイエンス・アンド・テクノロジー	二座ペプチドバインダー
TW201024318A (en)	2008-10-20	2010-07-01	Abbott Lab	Isolation and purification of antibodies using protein A affinity chromatography
WO2010048615A2 (en)	2008-10-24	2010-04-29	The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention	Human ebola virus species and compositions and methods thereof
AR073997A1 (es)	2008-10-29	2010-12-15	Wyeth Corp	Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
CA2739352C (en)	2008-10-29	2021-07-13	Wyeth Llc	Methods for purification of single domain antigen binding molecules
DK3199553T3 (da)	2008-10-29	2019-07-22	Circular Commitment Company	Fremgangsmåder og midler til diagnosticering og behandling af hepatocellulært carcinom
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
MX2011004550A (es)	2008-10-31	2011-07-20	Centocor Ortho Biotech Inc	Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
LT2842573T (lt)	2008-11-07	2017-12-11	Galaxy Biotech, Llc	Monokloniniai antikūnai prieš fibroblastų augimo faktoriaus receptorių-2
CN102271703B (zh)	2008-11-10	2015-09-16	阿雷克森制药公司	用于治疗补体相关障碍的方法和组合物
ES2719496T3 (es)	2008-11-12	2019-07-10	Medimmune Llc	Formulación de anticuerpo
EP2361093A2 (de)	2008-11-26	2011-08-31	Five Prime Therapeutics, Inc.	Zusammensetzungen und verfahren zur regulierung der expression von kollagen und glattem muskel-actin durch serpin2
CN102282265B (zh)	2008-11-28	2020-07-24	埃默里大学	用于治疗传染病和肿瘤的方法
MX2011005953A (es) *	2008-12-04	2011-08-17	Abbott Lab	Inmunoglobulinas de dominio variable dual y usos de las mismas.
EP2373690B1 (de)	2008-12-08	2015-02-11	Compugen Ltd.	Tmem154-spezifische antikörper
CN102245640B (zh)	2008-12-09	2014-12-31	霍夫曼-拉罗奇有限公司	抗-pd-l1抗体及它们用于增强t细胞功能的用途
JP5985826B2 (ja)	2008-12-16	2016-09-06	ノバルティスアーゲー	酵母ディスプレイ系
KR101940059B1 (ko)	2008-12-19	2019-01-18	마크로제닉스, 인크.	공유결합형 디아바디 및 이의 용도
CA2748757A1 (en)	2008-12-31	2010-07-08	Biogen Idec Ma Inc.	Anti-lymphotoxin antibodies
US9181315B2 (en)	2009-01-08	2015-11-10	Dana-Farber Cancer Institute, Inc.	Compositions and methods for induced brown fat differentiation
GB0900425D0 (en)	2009-01-12	2009-02-11	Ucb Pharma Sa	Biological products
WO2010082134A1 (en)	2009-01-14	2010-07-22	Iq Therapeutics Bv	Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
BRPI1007345A2 (pt)	2009-01-20	2019-04-16	H. ZADEH Homayoun	regeneração óssea de anticorpo mediado
AU2010207552A1 (en)	2009-01-21	2011-09-01	Oxford Biotherapeutics Ltd.	PTA089 protein
US20100260752A1 (en)	2009-01-23	2010-10-14	Biosynexus Incorporated	Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
UA102722C2 (en) *	2009-01-29	2013-08-12	Эббви Инк.	Il-1 binding proteins
US20110165063A1 (en) *	2009-01-29	2011-07-07	Abbott Laboratories	Il-1 binding proteins
WO2010086828A2 (en)	2009-02-02	2010-08-05	Rinat Neuroscience Corporation	Agonist anti-trkb monoclonal antibodies
US8852608B2 (en)	2009-02-02	2014-10-07	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010093993A2 (en)	2009-02-12	2010-08-19	Human Genome Sciences, Inc.	Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
HUE035769T2 (en)	2009-02-12	2018-05-28	Cell Signaling Technology Inc	Mutant ROS expression in human liver cancer
WO2010093627A2 (en)	2009-02-12	2010-08-19	Centocor Ortho Biotech Inc.	Fibronectin type iii domain based scaffold compositions, methods and uses
PE20120211A1 (es) *	2009-02-17	2012-03-24	Ucb Pharma Sa	Anticuerpos que tienen especificidad por ox40 humana
US8030026B2 (en)	2009-02-24	2011-10-04	Abbott Laboratories	Antibodies to troponin I and methods of use thereof
US8716553B2 (en)	2009-03-02	2014-05-06	Pioneer Hi Bred International Inc	NAC transcriptional activators involved in abiotic stress tolerance
US8835610B2 (en)	2009-03-05	2014-09-16	Abbvie Inc.	IL-17 binding proteins
EP2403880A1 (de)	2009-03-05	2012-01-11	Tripath Imaging, Inc.	Monoklonale antikörper gegen matrixmetalloproteinase-7 (mmp-7) und verfahren zu ihrer verwendung beim nachweis von eierstockkrebs
BRPI1009232B1 (pt)	2009-03-05	2022-05-03	E.R. Squibb & Sons, Llc.	Anticorpo monoclonal isolado ou uma porção de ligação de antígeno do mesmo, ou um fragmento de anticorpo, composição que os compreende, molécula de ácido nucleico, hibridoma e métodos para a preparação de um anticorpo anti-cadm1
EP2405920A1 (de)	2009-03-06	2012-01-18	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Neue therapie gegen angstzustände
AU2010221188A1 (en)	2009-03-06	2011-10-20	Tripath Imaging, Inc.	Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
EP2406285B1 (de)	2009-03-10	2016-03-09	Gene Techno Science Co., Ltd.	Erzeugung, expression und charakterisierung des humanisierten monoklonalen antikörpers k33n
GB0904214D0 (en)	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products
ES2486673T3 (es)	2009-03-19	2014-08-19	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Uso de NKp46 para prevenir la diabetes tipo I
MX2011009797A (es)	2009-03-20	2012-01-12	Amgen Inc	Inhibidores peptidicos de kv1.3 potentes selectivos.
RU2587621C2 (ru)	2009-04-01	2016-06-20	Дженентек, Инк.	АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN102449165B (zh)	2009-04-03	2014-07-09	解码遗传学私营有限责任公司	用于心房颤动和中风的风险管理的遗传标志
ES2581488T3 (es)	2009-04-08	2016-09-06	Lipum Ab	Nuevos métodos para el tratamiento de enfermedades inflamatorias
EP2241323A1 (de)	2009-04-14	2010-10-20	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Tenascin-W und Hirnkrebs
WO2010119991A2 (en)	2009-04-17	2010-10-21	Takeda Pharmaceutical Company Limited	Novel method of treating cancer
SG10201401604VA (en)	2009-04-20	2014-08-28	Oxford Biotherapeutics Ltd	Antibodies Specific To Cadherin-17
WO2010124113A1 (en)	2009-04-23	2010-10-28	Infinity Pharmaceuticals, Inc.	Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
EA201101572A1 (ru)	2009-04-27	2012-05-30	Новартис Аг	Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
WO2010125566A2 (en)	2009-04-27	2010-11-04	Technion Research And Development Foundation Ltd.	Markers for cancer detection
AR076402A1 (es)	2009-04-27	2011-06-08	Novartis Ag	Composiciones y metodos para aumentar el crecimiento muscular
WO2010126972A1 (en)	2009-04-29	2010-11-04	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Erg monoclonal antibodies
BRPI1012162A2 (pt)	2009-04-29	2016-01-12	Abbott Biotech Ltd	dispositivo de injeção automática
TWI486171B (zh)	2009-05-04	2015-06-01	亞培研究公司	具有增進之體內穩定性之抗神經生長因子（ｎｇｆ）抗體
AU2010249046A1 (en)	2009-05-13	2011-12-01	Sea Lane Biotechnologies, Llc	Neutralizing molecules to influenza viruses
JP5797642B2 (ja) *	2009-05-20	2015-10-21	ノビミューンエスアー	合成ポリペプチドライブラリーおよび天然で多様化されたポリペプチドバリアントを作製するための方法
DK2435568T3 (da)	2009-05-29	2014-09-08	Morphosys Ag	Samling af syntetiske antistoffer til behandling af sygdom
EP2261242A1 (de)	2009-06-10	2010-12-15	Universite Catholique De Louvain	Aspartat-N-Acetyltransferaseenzym, Diagnoseverfahren und therapeutisches Verfahren
US9090690B2 (en)	2009-06-18	2015-07-28	Pfizer Inc.	Anti Notch-1 antibodies
BRPI1015234A2 (pt)	2009-06-22	2018-02-20	Medimmune Llc	regiões fc projetadas para conjugação sítio específica.
GB0910725D0 (en)	2009-06-22	2009-08-05	Heptares Therapeutics Ltd	Mutant proteins and methods for producing them
US20120101262A1 (en)	2009-06-25	2012-04-26	Bristol-Myers Squibb Company	Protein purification by caprylic acid (octanoic acid) precipitation
WO2010151808A1 (en) *	2009-06-26	2010-12-29	Sea Lane Biotechnologies, Llc	Expression of surrogate light chains
EP2272979A1 (de)	2009-06-30	2011-01-12	Centre National de la Recherche Scientifique (CNRS)	Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
CN102481380A (zh)	2009-07-09	2012-05-30	霍夫曼-拉罗奇有限公司	体内肿瘤血管系统成像
EP2451977A4 (de)	2009-07-10	2013-01-02	Decode Genetics Ehf	Genetische marker für das risiko von diabetes mellitus
TW201109438A (en) *	2009-07-29	2011-03-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
WO2011014771A1 (en)	2009-07-31	2011-02-03	Wayne State University	Monophosphorylated lipid a derivatives
US9259476B2 (en)	2009-07-31	2016-02-16	Wayne State University	Monophosphorylated lipid A derivatives
US20110035843A1 (en)	2009-08-05	2011-02-10	Pioneer Hi-Bred International, Inc.	Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
WO2011020024A2 (en)	2009-08-13	2011-02-17	The Johns Hopkins University	Methods of modulating immune function
ES2553440T3 (es) *	2009-08-13	2015-12-09	Crucell Holland B.V.	Anticuerpos contra el virus sincitial respiratorio humano (VSR) y método de uso
WO2011021146A1 (en)	2009-08-20	2011-02-24	Pfizer Inc.	Osteopontin antibodies
EP2292266A1 (de)	2009-08-27	2011-03-09	Novartis Forschungsstiftung, Zweigniederlassung	Behandlung von Krebs durch Modulation von Copine III
PE20121647A1 (es)	2009-08-29	2012-12-31	Abbvie Inc	Proteinas terapeuticas de union a dll4
CN102666581A (zh)	2009-08-31	2012-09-12	艾普利穆恩公司	用于抑制移植物排斥的方法和组合物
TW201119673A (en)	2009-09-01	2011-06-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
US20110059111A1 (en)	2009-09-01	2011-03-10	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
WO2011029823A1 (en)	2009-09-09	2011-03-17	Novartis Ag	Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
US20120283415A1 (en)	2009-09-10	2012-11-08	Ucb Pharma S.A.	Multivalent Antibodies
DK2477656T3 (en)	2009-09-15	2017-06-26	Csl Ltd	TREATMENT OF NEUROLOGICAL CONDITIONS
US20110189183A1 (en)	2009-09-18	2011-08-04	Robert Anthony Williamson	Antibodies against candida, collections thereof and methods of use
US20120244170A1 (en)	2009-09-22	2012-09-27	Rafal Ciosk	Treating cancer by modulating mex-3
WO2011037983A1 (en)	2009-09-23	2011-03-31	Medarex, Inc.	Cation exchange chromatography
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
WO2011038290A2 (en)	2009-09-25	2011-03-31	The U. S. A., As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to hiv-1 and their use
US8926976B2 (en)	2009-09-25	2015-01-06	Xoma Technology Ltd.	Modulators
AU2010298036B2 (en)	2009-09-25	2015-05-21	Xoma Technology Ltd.	Screening methods
WO2011041391A1 (en)	2009-09-29	2011-04-07	Fraunhofer Usa, Inc.	Influenza hemagglutinin antibodies, compositions, and related methods
CN102639700A (zh)	2009-09-30	2012-08-15	哈佛大学校长及研究员协会	通过调节自噬增强基因产物调节自噬的方法
AR078470A1 (es)	2009-10-02	2011-11-09	Sanofi Aventis	Anticuerpos que se unen especificamente al receptor epha2
WO2011043823A2 (en)	2009-10-09	2011-04-14	Georgetown University	Polypeptides that home to atherosclerotic plaque
WO2011047083A1 (en)	2009-10-13	2011-04-21	Oxford Biotherapeutics Ltd.	Antibodies against epha10
WO2011045352A2 (en)	2009-10-15	2011-04-21	Novartis Forschungsstiftung	Spleen tyrosine kinase and brain cancers
TW201119676A (en)	2009-10-15	2011-06-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
BR112012009289B8 (pt)	2009-10-20	2021-05-25	Abbott Laboratoires	método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp)
CA2778442A1 (en)	2009-10-22	2011-04-28	Genentech, Inc.	Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011051350A1 (en)	2009-10-27	2011-05-05	Ucb Pharma S.A.	Function modifying nav 1.7 antibodies
GB0922435D0 (en)	2009-12-22	2010-02-03	Ucb Pharma Sa	Method
GB0922434D0 (en)	2009-12-22	2010-02-03	Ucb Pharma Sa	antibodies and fragments thereof
US20110098862A1 (en)	2009-10-27	2011-04-28	ExxonMobil Research Engineering Company Law Department	Multi-stage processes and control thereof
US9234037B2 (en)	2009-10-27	2016-01-12	Ucb Biopharma Sprl	Method to generate antibodies to ion channels
UY32979A (es) *	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120213801A1 (en)	2009-10-30	2012-08-23	Ekaterina Gresko	Phosphorylated Twist1 and cancer
WO2011053707A1 (en)	2009-10-31	2011-05-05	Abbott Laboratories	Antibodies to receptor for advanced glycation end products (rage) and uses thereof
US20120282177A1 (en)	2009-11-02	2012-11-08	Christian Rohlff	ROR1 as Therapeutic and Diagnostic Target
EP2496243A2 (de)	2009-11-04	2012-09-12	Erasmus University Medical Center Rotterdam	Neuartige verbindungen zur modulierung der gefässneubildung und behandlungsverfahren mit diesen verbindungen
US9244063B2 (en)	2009-11-11	2016-01-26	Gentian As	Immunoassay for assessing related analytes of different origin
WO2011060272A2 (en)	2009-11-13	2011-05-19	Dana-Farber Cancer Institute, Inc.	Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
LT2501822T (lt)	2009-11-17	2017-10-25	E. R. Squibb & Sons, L.L.C.	Padidintos baltymų produkcijos būdai
GB0920127D0 (en)	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
GB0920324D0 (en)	2009-11-19	2010-01-06	Ucb Pharma Sa	Antibodies
MX2012005864A (es)	2009-11-20	2012-08-31	Amgen Inc	Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
CN102741294A (zh)	2009-11-30	2012-10-17	霍夫曼-拉罗奇有限公司	治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
US9428586B2 (en)	2009-12-01	2016-08-30	Compugen Ltd	Heparanase splice variant
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
MX2012006397A (es)	2009-12-02	2012-11-30	Amgen Inc	PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
CA2780069C (en) *	2009-12-08	2018-07-17	Abbott Gmbh & Co. Kg	Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
PL2510011T3 (pl)	2009-12-09	2015-02-27	Inst Nat Sante Rech Med	Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania
WO2011075185A1 (en)	2009-12-18	2011-06-23	Oligasis	Targeted drug phosphorylcholine polymer conjugates
TW201125583A (en) *	2009-12-23	2011-08-01	Bioalliance Cv	Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same
WO2011085103A2 (en)	2010-01-06	2011-07-14	Dyax Corp.	Plasma kallikrein binding proteins
RU2012134369A (ru)	2010-01-11	2014-02-20	Алексион Фармасьютикалз, Инк	Биомаркеры иммуномодулирующих эффектов у людей, подвергнутых лечению антиметаллами против cd200
GB201000467D0 (en)	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
WO2011088163A1 (en)	2010-01-14	2011-07-21	President And Fellows Of Harvard College	Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
TWI513466B (zh)	2010-01-20	2015-12-21	Boehringer Ingelheim Int	抗凝血劑解毒劑
US10429384B2 (en)	2010-01-22	2019-10-01	Dana-Farber Cancer Institute, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
CA2789168A1 (en)	2010-02-02	2011-08-11	Abbott Biotechnology Ltd.	Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor
TWI518325B (zh)	2010-02-04	2016-01-21	自治醫科大學	對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
WO2011097511A1 (en)	2010-02-05	2011-08-11	The United States Of America, As Represented By The Secretary Department Of Health & Human Services	REGULATORY B CELLS (tBREGS) AND THEIR USE
CA2789629A1 (en)	2010-02-10	2011-08-18	Immunogen, Inc.	Cd20 antibodies and uses thereof
JP5981853B2 (ja)	2010-02-18	2016-08-31	ジェネンテック，インコーポレイテッド	ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
EP2536432B1 (de)	2010-02-19	2018-08-08	Cornell University	Verfahren zur behandlung demyelinisierender autoimmunerkrankungen und anderer autoimmun- oder entzündungserkrankungen
PE20130214A1 (es)	2010-02-23	2013-03-11	Genentech Inc	Composiciones y metodos para el diagnostico y tratamiento de tumores
US8298535B2 (en)	2010-02-24	2012-10-30	Rinat Neuroscience Corp.	Anti-IL-7 receptor antibodies
SG10201501562VA (en)	2010-03-02	2015-04-29	Abbvie Inc	Therapeutic dll4 binding proteins
WO2011109398A2 (en)	2010-03-02	2011-09-09	President And Fellows Of Harvard College	Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
SG10201604336VA (en)	2010-03-04	2016-07-28	Macrogenics Inc	Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
US8802091B2 (en)	2010-03-04	2014-08-12	Macrogenics, Inc.	Antibodies reactive with B7-H3 and uses thereof
US20130004519A1 (en)	2010-03-05	2013-01-03	Ruth Chiquet-Ehrismann	Smoci, tenascin-c and brain cancers
PE20130393A1 (es)	2010-03-11	2013-04-07	Rinat Neuroscience Corp	Anticuerpos con union de antigenos dependiente de ph
US20110256135A1 (en)	2010-03-17	2011-10-20	Wolfgang Fraunhofer	Anti-nerve growth factor (ngf) antibody compositions
US10706955B2 (en)	2010-03-23	2020-07-07	Iogenetics, Llc	Bioinformatic processes for determination of peptide binding
GB201005064D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
US10472426B2 (en)	2010-03-25	2019-11-12	Ucb Biopharma Sprl	Disulfide stabilized DVD-Ig molecules
US20150231215A1 (en)	2012-06-22	2015-08-20	Randolph J. Noelle	VISTA Antagonist and Methods of Use
WO2011120013A2 (en)	2010-03-26	2011-09-29	Trustees Of Dartmouth College	Vista regulatory t cell mediator protein, vista binding agents and use thereof
US10745467B2 (en)	2010-03-26	2020-08-18	The Trustees Of Dartmouth College	VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
WO2011130332A1 (en)	2010-04-12	2011-10-20	Academia Sinica	Glycan arrays for high throughput screening of viruses
NZ602892A (en)	2010-04-13	2014-08-29	Celldex Therapeutics Inc	Antibodies that bind human cd27 and uses thereof
MX336196B (es)	2010-04-15	2016-01-11	Abbvie Inc	Proteinas de union a amiloide beta.
US20130034543A1 (en)	2010-04-19	2013-02-07	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear	Modulating xrn1
KR20130103300A (ko) *	2010-04-20	2013-09-23	광주과학기술원	Ｇｐｃｒ에 특이적으로 결합하는 ｇｐｃｒ-ｂｐｂ
WO2011132939A2 (ko) *	2010-04-20	2011-10-27	광주과학기술원	Rtk에 특이적으로 결합하는 rtk-bpb
KR20130103301A (ko) *	2010-04-20	2013-09-23	광주과학기술원	전사인자에 특이적으로 결합하는 ｔｆ-ｂｐｂ
KR20130103299A (ko) *	2010-04-20	2013-09-23	광주과학기술원	Ｒｔｋ에 특이적으로 결합하는 ｒｔｋ―ｂｐｂ
EP2380909A1 (de)	2010-04-26	2011-10-26	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	An Brustkrebs beteiligtes Protein PTK-7
SI2563813T1 (sl)	2010-04-30	2015-12-31	Alexion Pharmaceuticals, Inc.	Protitelesa anti-C5A in postopki uporabe protiteles
MX342239B (es)	2010-05-03	2016-09-21	Genentech Inc *	Composiciones y metodos para el diagnostico y tratamiento de tumores.
WO2011140151A1 (en)	2010-05-04	2011-11-10	Dyax Corp.	Antibodies against epidermal growth factor receptor (egfr)
CA2798273A1 (en)	2010-05-04	2011-11-10	Merrimack Pharmaceuticals, Inc.	Antibodies against epidermal growth factor receptor (egfr) and uses thereof
EP2566894A1 (de)	2010-05-06	2013-03-13	Novartis AG	Zusammensetzungen und verfahren zur verwendung von therapeutischen mehrwertigen antikörpern gegen ldl-assoziiertes protein 6 (lrp6)
NZ603829A (en)	2010-05-06	2015-03-27	Novartis Ag	Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
JP5947289B2 (ja)	2010-05-10	2016-07-06	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	抗インフルエンザ活性を有するザナミビルホスホネート同族体およびインフルエンザウイルスのオセルタミビルに対する感受性の決定
US20110293629A1 (en)	2010-05-14	2011-12-01	Bastid Jeremy	Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
HUE033063T2 (hu)	2010-05-14	2017-11-28	Abbvie Inc	IL-1 kötõ fehérjék
EP2575884B1 (de)	2010-06-03	2018-07-18	AbbVie Biotechnology Ltd	Anwendungen und zusammensetzungen zur behandlung von acne inversa
US9499813B2 (en)	2010-06-10	2016-11-22	President And Fellows Of Harvard College	Systems and methods for amplification and phage display
WO2011154485A1 (en)	2010-06-10	2011-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mammalian sterile 20-like kinase 3
SG186302A1 (en)	2010-06-16	2013-02-28	Abbott Lab	Comparison of protein samples
EP3327035A1 (de)	2010-06-22	2018-05-30	Precision Biologics Inc.	Für dickdarm- und bauchspeicheldrüsenkrebs spezifische antigene und antikörper
US20130315895A1 (en)	2010-07-01	2013-11-28	Takeda Pharmaceutical Company Limited	COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US20120009196A1 (en)	2010-07-08	2012-01-12	Abbott Laboratories	Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2590654B1 (de)	2010-07-09	2016-12-21	Exelixis, Inc.	Kombinationen aus kinasehemmern zur behandlung von krebs
AR082149A1 (es)	2010-07-09	2012-11-14	Calmune Corp	Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
SG186983A1 (en)	2010-07-09	2013-02-28	Genentech Inc	Anti-neuropilin antibodies and methods of use
CA2805414C (en)	2010-07-14	2020-07-07	Merck Sharp & Dohme Corp.	Anti-addl monoclonal antibody and uses thereof
WO2012007880A2 (en)	2010-07-16	2012-01-19	Ablynx Nv	Modified single domain antigen binding molecules and uses thereof
US8747844B2 (en)	2010-07-30	2014-06-10	Saint Louis University	Methods of treating pain
WO2012018387A2 (en)	2010-08-02	2012-02-09	Population Diagnotics, Inc.	Compositions and methods for discovery of causative mutations in genetic disorders
SG187682A1 (en)	2010-08-02	2013-03-28	Macrogenics Inc	Covalent diabodies and uses thereof
CA2807014A1 (en)	2010-08-03	2012-02-09	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
WO2012019061A2 (en)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Novel effectors and methods of use
US20120101108A1 (en)	2010-08-06	2012-04-26	Cell Signaling Technology, Inc.	Anaplastic Lymphoma Kinase In Kidney Cancer
CN103314296A (zh)	2010-08-10	2013-09-18	安姆根有限公司	用于检测针对靶抗体的中和抗体的双功能体外靶结合测定
EP2420250A1 (de)	2010-08-13	2012-02-22	Universitätsklinikum Münster	Anti-Syndecan-4-Antikörper
WO2012024187A1 (en)	2010-08-14	2012-02-23	Abbott Laboratories	Amyloid-beta binding proteins
US9505829B2 (en)	2010-08-19	2016-11-29	Zoetis Belgium S.A.	Anti-NGF antibodies and their use
GB201014033D0 (en)	2010-08-20	2010-10-06	Ucb Pharma Sa	Biological products
MY162825A (en)	2010-08-20	2017-07-31	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
CA2809433A1 (en)	2010-08-26	2012-03-01	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
MX2013002255A (es)	2010-08-27	2013-07-03	Stem Centrx Inc	Moduladores de proteina de notum y metodos de uso.
WO2012028703A1 (en)	2010-09-02	2012-03-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for the prognosis of the progression of cancer
CA2810016A1 (en)	2010-09-03	2012-03-08	Stem Centrx, Inc.	Novel modulators and methods of use
EP2614080A1 (de)	2010-09-10	2013-07-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Phosphoryliertes twist1 und metastasen
WO2012035518A1 (en)	2010-09-17	2012-03-22	Compugen Ltd.	Compositions and methods for treatment of drug resistant multiple myeloma
CA2810909A1 (en)	2010-09-20	2012-03-29	Abbvie Inc.	Purification of antibodies using simulated moving bed chromatography
EP2725034B1 (de)	2010-09-22	2019-04-03	Amgen Inc.	Trägerimmunglobuline die nicht an humane Gewebe binden und Verwendungen davon
CA2812556C (en)	2010-09-23	2023-02-14	Xue-Ping Wang	Colon and pancreas cancer peptidomimetics
KR102504750B1 (ko)	2010-09-29	2023-03-02	어젠시스 인코포레이티드	191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
US9005907B2 (en)	2010-10-01	2015-04-14	St. Jude Children's Research Hospital	Methods and compositions for typing molecular subgroups of medulloblastoma
EP2625203A1 (de)	2010-10-05	2013-08-14	Novartis AG	Anti-il12rbeta1-antikörper und ihre verwendung zur behanldung von autoimmun- und entzündungserkrankungen
UA118646C2 (uk)	2010-10-13	2019-02-25	Янссен Байотек, Інк.	Виділене антитіло, яке специфіічно зв'язується з онкостатином м (оm) людини
WO2012052391A1 (en)	2010-10-19	2012-04-26	Glaxo Group Limited	Polypeptide with jmjd3 catalytic activity
EP3581206A1 (de)	2010-10-22	2019-12-18	Seattle Genetics, Inc.	Synergiewirkung zwischen auristatin-basierten antikörper-wirkstoffkonjugaten und hemmern des p13k-akt-mtor-wegs
EP2632489B1 (de)	2010-10-27	2020-01-15	The Research Foundation for The State University of New York	Zusammensetzungen zur anzielung der löslichen extrazellulären domäne von e-cadherin sowie zugehörige krebstherapieverfahren
US20140080810A1 (en)	2010-11-15	2014-03-20	Exelixis, Inc.	Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
EP2640367A2 (de)	2010-11-15	2013-09-25	Exelixis, Inc.	Benzoxazepine als pi3k/mtor-hemmer sowie verfahren zur ihrer verwendung und herstellung
US20140093506A1 (en)	2010-11-15	2014-04-03	Marc Buehler	Anti-fungal-agents
US9072766B2 (en)	2010-11-18	2015-07-07	Beth Israel Deaconess Medical Center, Inc.	Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
ES2696548T3 (es)	2010-11-19	2019-01-16	Morphosys Ag	Una colección de secuencias de anticuerpos y su uso
US20130245233A1 (en)	2010-11-24	2013-09-19	Ming Lei	Multispecific Molecules
WO2012071509A2 (en)	2010-11-24	2012-05-31	Exelixis, Inc.	Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
SG10201510041QA (en)	2010-12-06	2016-01-28	Seattle Genetics Inc	Humanized antibodies to liv-1 and use of same to treat cancer
CA2820885A1 (en)	2010-12-08	2012-09-07	Stem Centrx, Inc.	Novel modulators and methods of use
CA2821130C (en)	2010-12-15	2017-11-07	Wyeth Llc	Anti-notch1 antibodies
RU2627171C2 (ru)	2010-12-21	2017-08-03	Эббви Инк.	Il-1 альфа и бета биспецифические иммуноглобулины с двойными вариабельными доменами и их применение
US20120275996A1 (en)	2010-12-21	2012-11-01	Abbott Laboratories	IL-1 Binding Proteins
EP3202903B1 (de)	2010-12-22	2020-02-12	President and Fellows of Harvard College	Kontinuierliche gerichtete evolution
KR101941514B1 (ko)	2010-12-22	2019-01-23	테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디	개선된 반감기를 가지는 변형된 항체
JP2014504503A (ja)	2010-12-28	2014-02-24	ゾーマテクノロジーリミテッド	Ｐｄｚドメインを用いた細胞表面提示
WO2012089814A1 (en)	2010-12-30	2012-07-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antigen binding formats for use in therapeutic treatments or diagnostic assays
EP2474612A1 (de)	2011-01-05	2012-07-11	University College Dublin, National University of Ireland Dublin	Affinitätstrennungsmittel und ihre Verwendungen zur Trennung, Reinigung und Konzentration von Zielmolekülen
GB201100282D0 (en)	2011-01-07	2011-02-23	Ucb Pharma Sa	Biological methods
US10208349B2 (en)	2011-01-07	2019-02-19	Ucb Biopharma Sprl	Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
PT2663579T (pt)	2011-01-14	2017-07-28	Univ California	Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
SG10201510762YA (en)	2011-01-14	2016-01-28	Ucb Pharma Sa	Antibody molecules which bind il-17a and il-17f
US20120185956A1 (en)	2011-01-18	2012-07-19	Gingras Jacinthe	Global nav1.7 knockout mice and uses
EP3187216B1 (de)	2011-01-24	2019-08-21	AbbVie Biotechnology Ltd.	Automatische injektionsvorrichtungen mit umspritzten greifflächen
US20120189633A1 (en)	2011-01-26	2012-07-26	Kolltan Pharmaceuticals, Inc.	Anti-kit antibodies and uses thereof
JP6150734B2 (ja)	2011-02-03	2017-06-21	アレクシオンファーマシューティカルズ，インコーポレイテッド	同種移植片の生存を長期化するための抗ｃｄ２００抗体の使用
WO2012109238A2 (en)	2011-02-07	2012-08-16	President And Fellows Of Harvard College	Methods for increasing immune responses using agents that directly bind to and activate ire-1
WO2012110824A1 (en)	2011-02-18	2012-08-23	Astrazeneca Ab	Binding agents with specificity for a nucleic acid modification
SA112330278B1 (ar)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	مواد ضابطة جديدة وطرق للاستخدام
MY181093A (en)	2011-03-02	2020-12-17	Berg Llc	Interrogatory cell-based assays and uses thereof
AU2012225574A1 (en)	2011-03-07	2013-09-26	University Of Louisville Research Foundation, Inc.	Predictive marker of DNMT1 inhibitor therapeutic efficacy and methods of using the marker
KR20190006083A (ko)	2011-03-09	2019-01-16	셀 시그널링 테크놀러지, 인크.	모노클로날 항체를 생성하는 방법 및 시약
WO2012125735A1 (en)	2011-03-15	2012-09-20	Abott Laboratories	An integrated approach to the isolation and purification of antibodies
AU2012230899A1 (en)	2011-03-21	2013-10-10	Biodesy, Llc	Classification of kinase inhibitors using nonlinear optical techniques
WO2012128810A1 (en)	2011-03-23	2012-09-27	Abbott Laboratories	Methods and systems for the analysis of protein samples
KR20140018299A (ko)	2011-03-30	2014-02-12	아블린쓰 엔.브이.	Ｔｎｆ-알파에 대한 단일 도메인 항체를 이용하여 면역 장애를 치료하는 방법
AP2013007046A0 (en)	2011-03-30	2013-08-31	Boehringer Ingelheim Int	Anticoagulant antidotes
WO2012134813A1 (en)	2011-03-31	2012-10-04	St. Jude Children's Research Hospital	Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
WO2012139058A1 (en)	2011-04-08	2012-10-11	Biogen Idec Ma Inc.	BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
US20140186340A1 (en)	2011-04-08	2014-07-03	Gilead Biologics, Inc.	Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2
WO2012142164A1 (en)	2011-04-12	2012-10-18	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
WO2012140627A1 (en)	2011-04-15	2012-10-18	Compugen Ltd.	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2699264B1 (de)	2011-04-20	2018-03-14	Medlmmune, LLC	Antikörper und andere moleküle zur bindung von b7-h1 und pd-1
US9376495B2 (en)	2011-05-21	2016-06-28	Macrogenics, Inc.	Deimmunized serum-binding domains and their use in extending serum half-life
UA115402C2 (uk)	2011-05-21	2017-10-25	Макродженікс, Інк.	Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
SG10201603962TA (en)	2011-05-25	2016-07-28	Innate Pharma Sa	Anti-kir antibodies for the treatment of inflammatory disorders
EP2966089B1 (de)	2011-06-02	2020-03-25	Dyax Corp.	Fc-rezeptor-bindende proteine
US8691231B2 (en)	2011-06-03	2014-04-08	Merrimack Pharmaceuticals, Inc.	Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
EP2714735B1 (de)	2011-06-03	2021-07-21	XOMA Technology Ltd.	Tgf-beta-spezifische antikörper
EP2717911A1 (de)	2011-06-06	2014-04-16	Novartis Forschungsstiftung, Zweigniederlassung	Proteintyrosinphosphatase, nicht-rezeptor typ 11 (ptpn11) und dreifach negativer brustkrebs
WO2012170742A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en)	2011-06-07	2016-01-26	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
HUE038509T2 (hu)	2011-06-10	2018-10-29	Medimmune Ltd	Pseudomonas PSL elleni kötõmolekula és alkalmazása
WO2012172495A1 (en)	2011-06-14	2012-12-20	Novartis Ag	Compositions and methods for antibodies targeting tem8
AU2012271413B2 (en)	2011-06-17	2017-07-13	President And Fellows Of Harvard College	Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
JP2014527036A (ja)	2011-06-27	2014-10-09	ザジャクソンラボラトリー	癌および自己免疫疾患の処置のための方法および組成物
NZ618503A (en)	2011-06-28	2016-03-31	Oxford Biotherapeutics Ltd	Antibodies to adp-ribosyl cyclase 2
JP6113721B2 (ja)	2011-06-28	2017-04-12	オックスフォードビオトヘラペウトイクスエルティーディー．	治療標的及び診断標的
WO2013001517A1 (en)	2011-06-30	2013-01-03	Compugen Ltd.	Polypeptides and uses thereof for treatment of autoimmune disorders and infection
HUE040276T2 (hu)	2011-07-01	2019-02-28	Novartis Ag	Eljárás metabolikus rendellenességek kezelésére
MX2014000531A (es)	2011-07-13	2014-12-05	Abbvie Inc	Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13.
GB201112056D0 (en)	2011-07-14	2011-08-31	Univ Leuven Kath	Antibodies
US9238689B2 (en)	2011-07-15	2016-01-19	Morpho Sys AG	Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
CA2842860A1 (en)	2011-07-28	2013-01-31	Sea Lane Biotechnologies, Llc	Sur-binding proteins
AU2012296613B2 (en)	2011-08-15	2016-05-12	Amplimmune, Inc.	Anti-B7-H4 antibodies and their uses
ES2704126T3 (es)	2011-08-23	2019-03-14	Found Medicine Inc	Moléculas de fusión KIF5B-RET y usos de las mismas
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
EP2753697A1 (de)	2011-09-05	2014-07-16	ETH Zürich	Biosynthetischer gencluster zur herstellung von peptid- bzw. protein-analoga
US9447192B2 (en)	2011-09-09	2016-09-20	Medimmune Limited	Anti-Siglec-15 antibodies and uses thereof
CA2848368C (en)	2011-09-13	2023-02-14	Dana-Farber Cancer Institute, Inc.	Compositions and methods for brown fat induction and activity using fndc5
BR112014005720A2 (pt)	2011-09-15	2017-12-12	Genentech Inc	método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
EP2771349B1 (de)	2011-09-16	2020-02-26	Iogenetics, LLC.	Bioinformatikverfahren zur bestimmung von peptidbindungen
CA2851388C (en)	2011-10-10	2023-11-21	The Hospital For Sick Children	Methods and compositions for screening and treating developmental disorders
ES2769786T3 (es)	2011-10-14	2020-06-29	Recordati Ag	Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
RU2014119426A (ru)	2011-10-15	2015-11-20	Дженентек, Инк.	Способы применения антагонистов scd1
WO2013063114A1 (en)	2011-10-24	2013-05-02	Abbvie Inc.	Immunobinders directed against tnf
AR088513A1 (es)	2011-10-24	2014-06-18	Abbvie Inc	Inmunoenlazantes dirigidos contra esclerostina
CN103906835A (zh)	2011-10-25	2014-07-02	先锋国际良种公司	改变植物细胞壁组成以改善生物燃料生产和青贮饲料可消化性的方法
WO2013067060A1 (en)	2011-11-01	2013-05-10	Bionomics, Inc.	Anti-gpr49 antibodies
US9221906B2 (en)	2011-11-01	2015-12-29	Bionomics Inc.	Methods of inhibiting solid tumor growth by administering GPR49 antibodies
WO2013067057A1 (en)	2011-11-01	2013-05-10	Bionomics, Inc.	Anti-gpr49 antibodies
AU2012332588B2 (en)	2011-11-01	2017-09-07	Bionomics, Inc.	Methods of blocking cancer stem cell growth
US10527526B2 (en)	2011-11-03	2020-01-07	Tripath Imaging, Inc.	Methods and compositions for preparing samples for immunostaining
US11180807B2 (en)	2011-11-04	2021-11-23	Population Bio, Inc.	Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
ES2859323T3 (es)	2011-11-07	2021-10-01	Medimmune Ltd	Terapias de combinación que usan moléculas de unión anti-Psl y PcrV de Pseudomonas
US20140314787A1 (en)	2011-11-08	2014-10-23	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute	Treatment for neurodegenerative diseases
EP2776838A1 (de)	2011-11-08	2014-09-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Frühe diagnose neurodegenerativer erkrankungen
CN104271599A (zh)	2011-11-08	2015-01-07	辉瑞公司	使用抗m-csf抗体治疗炎性疾病的方法
SG11201401699WA (en)	2011-11-11	2014-09-26	Rinat Neuroscience Corp	Antibodies specific for trop-2 and their uses
SG11201401649VA (en)	2011-11-11	2014-07-30	Ucb Pharma Sa	Albumin binding antibodies and binding fragments thereof
EP2594588B1 (de)	2011-11-16	2014-05-21	AdrenoMed AG	Anti-Adrenomedullin-Antikörper (ADM) oder Anti-ADM-Antikörperfragment oder Anti-ADM-non-Ig Proteingerüst zur Verwendung bei der Behandlung
CA2856136A1 (en)	2011-11-16	2013-05-23	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
ES2707878T3 (es)	2011-11-16	2019-04-05	Adrenomed Ag	Anticuerpo antiadrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje no Ig anti-ADM para regular el equilibrio de líquidos en un paciente que presenta una enfermedad crónica o aguda
PL2780717T3 (pl)	2011-11-16	2017-06-30	Sphingotec Gmbh	Oznaczenia adrenomeduliny i sposoby do oznaczania dojrzałej adrenomeduliny
WO2013072513A1 (en)	2011-11-16	2013-05-23	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
SI3553084T1 (sl)	2011-11-16	2023-05-31	Adrenomed Ag	Protitelo anti-adrenomedulina (ADM) ali fragment protitelesa anti-ADM ali anti-ADM non-IG ogrodje za preprečevanje ali zmanjšanje disfunkcije organa ali odpovedi organa pri pacientu s kronično ali akutno boleznijo ali akutnim stanjem
WO2013080050A2 (en)	2011-11-30	2013-06-06	Universitaetsklinikum Erlangen	Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
EA201491107A1 (ru)	2011-12-05	2014-11-28	Новартис Аг	Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
CN104159924B (zh)	2011-12-05	2018-03-16	诺华股份有限公司	表皮生长因子受体3(her3)的抗体
US10118958B2 (en)	2011-12-14	2018-11-06	AbbVie Deutschland GmbH & Co. KG	Composition and method for the diagnosis and treatment of iron-related disorders
CA2855570A1 (en)	2011-12-14	2013-06-20	AbbVie Deutschland GmbH & Co. KG	Composition and method for the diagnosis and treatment of iron-related disorders
EP2794657B1 (de)	2011-12-19	2017-10-11	Xoma (Us) Llc	Verfahren zur behandlung von akne
EP2794656B1 (de)	2011-12-21	2019-02-27	Novartis AG	Zusammensetzungen die gegen faktor p und c5 gerichtete antikörper enthalten
EP2793940B1 (de)	2011-12-22	2018-11-14	i2 Pharmaceuticals, Inc.	Surrogatbindungsproteine
EP2794659A1 (de)	2011-12-22	2014-10-29	Rinat Neuroscience Corp.	Antikörper gegen den menschlichen wachstumshormon-rezeptorantagonisten und verwendungsverfahren dafür
WO2013093693A1 (en)	2011-12-22	2013-06-27	Rinat Neuroscience Corp.	Staphylococcus aureus specific antibodies and uses thereof
ES2721882T3 (es)	2011-12-23	2019-08-06	Pfizer	Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
BR112014015851A2 (pt)	2011-12-30	2019-09-24	Abbvie Inc	proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
WO2013102825A1 (en)	2012-01-02	2013-07-11	Novartis Ag	Cdcp1 and breast cancer
GB201200259D0 (en)	2012-01-09	2012-02-22	Ohlin Per M	Novel therapies
WO2013109856A2 (en)	2012-01-18	2013-07-25	Genentech, Inc.	Methods of using fgf19 modulators
GB201201332D0 (en)	2012-01-26	2012-03-14	Imp Innovations Ltd	Method
ES2676725T3 (es)	2012-01-27	2018-07-24	AbbVie Deutschland GmbH & Co. KG	Composición y método para el diagnóstico y el tratamiento de enfermedades asociadas con la degeneración de las neuritas
SG2014008304A (en)	2012-02-01	2014-06-27	Compugen Ltd	C10rf32 antibodies, and uses thereof for treatment of cancer
WO2013120018A1 (en)	2012-02-09	2013-08-15	Population Diagnostics, Inc.	Methods and compositions for screening and treating developmental disorders
ES2725569T3 (es)	2012-02-10	2019-09-24	Seattle Genetics Inc	Diagnóstico y tratamiento de cánceres que expresan CD30
EP2812350B1 (de)	2012-02-11	2019-04-03	F.Hoffmann-La Roche Ag	R-spondin-translokationen und verfahren damit
US9550830B2 (en)	2012-02-15	2017-01-24	Novo Nordisk A/S	Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
PL2814842T3 (pl)	2012-02-15	2018-12-31	Novo Nordisk A/S	Przeciwciała wiążące białko 1 rozpoznające peptydoglikan
CN108103069B (zh)	2012-02-15	2021-08-10	诺和诺德股份有限公司	结合并阻断髓样细胞表达的触发受体-1 (trem-1)的抗体
GB201203051D0 (en)	2012-02-22	2012-04-04	Ucb Pharma Sa	Biological products
GB201203071D0 (en)	2012-02-22	2012-04-04	Ucb Pharma Sa	Biological products
AU2013222188A1 (en)	2012-02-22	2014-09-11	Amgen Inc.	Autologous mammalian models derived from induced pluripotent stem cells and related methods
CA2865404C (en)	2012-02-24	2019-08-27	Stem Centrx, Inc.	Dll3-binding antibodies and drug conjugates thereof to treat cancer
EP2825200A4 (de)	2012-03-15	2015-08-26	Janssen Biotech Inc	Menschliche anti-cd27-antikörper, verfahren und verwendungen
US9139863B2 (en)	2012-03-16	2015-09-22	Genentech, Inc.	Engineered conformationally-stabilized proteins
WO2013137920A1 (en)	2012-03-16	2013-09-19	Genentech, Inc.	Engineered conformationally-stabilized proteins
CN104168898A (zh)	2012-03-16	2014-11-26	霍夫曼-拉罗奇有限公司	以pak1抑制剂治疗黑色素瘤的方法
EP2828291A1 (de)	2012-03-21	2015-01-28	Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.	Aus der d1-domäne von nkp46 abgeleitete peptide
CA2866185C (en)	2012-03-23	2021-04-06	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pathogenic phlebovirus isolates and compositions and methods of use
US20150266961A1 (en)	2012-03-29	2015-09-24	Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute	Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
BR112014024537A2 (pt)	2012-04-02	2017-08-08	Berg Llc	métodos para identificar moduladores de um sistema biológico, de um processo de doença, e de angiogênese
WO2013151649A1 (en)	2012-04-04	2013-10-10	Sialix Inc	Glycan-interacting compounds
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
HUE037856T2 (hu)	2012-04-18	2018-09-28	Cell Signaling Technology Inc	EGFR és ROS1 rákban
WO2013158275A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Cell culture methods to reduce acidic species
WO2013158279A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Protein purification methods to reduce acidic species
US9181572B2 (en)	2012-04-20	2015-11-10	Abbvie, Inc.	Methods to modulate lysine variant distribution
HUE045944T2 (hu)	2012-04-20	2020-02-28	Merus Nv	Eljárások és eszközök heterodimerikus IG-szerû molekulák elõállítására
EP2841951B1 (de)	2012-04-25	2019-12-11	Biodesy, Inc.	Verfahren zum nachweis von allosterischen proteinmodulatoren
WO2013170191A1 (en)	2012-05-11	2013-11-14	Genentech, Inc.	Methods of using antagonists of nad biosynthesis from nicotinamide
JP2015518829A (ja)	2012-05-14	2015-07-06	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
BR112014028306A2 (pt)	2012-05-15	2018-04-17	Morphotek, Inc.	métodos para tratamento de câncer gástrico.
US9238676B2 (en)	2012-05-17	2016-01-19	Ra Pharmaceuticals, Inc.	Peptide and peptidomimetic inhibitors
US20130309223A1 (en)	2012-05-18	2013-11-21	Seattle Genetics, Inc.	CD33 Antibodies And Use Of Same To Treat Cancer
WO2013177115A2 (en)	2012-05-21	2013-11-28	Abbvie Inc.	Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2013176754A1 (en)	2012-05-24	2013-11-28	Abbvie Inc.	Novel purification of antibodies using hydrophobic interaction chromatography
JP6629069B2 (ja)	2012-06-06	2020-01-15	ゾエティス・エルエルシー	イヌ化抗ｎｇｆ抗体およびその方法
US9890215B2 (en)	2012-06-22	2018-02-13	King's College London	Vista modulators for diagnosis and treatment of cancer
AU2013277051B2 (en)	2012-06-22	2018-06-07	King's College London	Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
BR112014032916A2 (pt)	2012-06-28	2017-08-01	Pfizer	anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
US10048253B2 (en)	2012-06-28	2018-08-14	Ucb Biopharma Sprl	Method for identifying compounds of therapeutic interest
WO2014001482A1 (en)	2012-06-29	2014-01-03	Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research	Treating diseases by modulating a specific isoform of mkl1
CA2877948C (en)	2012-07-02	2019-07-30	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Paramyxovirus and methods of use
AR091649A1 (es)	2012-07-02	2015-02-18	Bristol Myers Squibb Co	Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP2870242A1 (de)	2012-07-05	2015-05-13	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Neue behandlung für neurodegenerative erkrankungen
WO2014006115A1 (en)	2012-07-06	2014-01-09	Novartis Ag	Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
US9670276B2 (en)	2012-07-12	2017-06-06	Abbvie Inc.	IL-1 binding proteins
PT3338794T (pt)	2012-07-13	2020-04-24	Childrens Hospital Philadelphia	Gestão de toxicidade para atividade antitumoral de cars
GB201213652D0 (en)	2012-08-01	2012-09-12	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
WO2014020140A1 (en)	2012-08-02	2014-02-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of transferrin receptor antagonist for the treatment of thalassemia
EP3613765A1 (de)	2012-08-03	2020-02-26	Dana-Farber Cancer Institute, Inc.	Antikörper gegen abstossungs führung molekül b (rgmb)
US8603470B1 (en)	2012-08-07	2013-12-10	National Cheng Kung University	Use of IL-20 antagonists for treating liver diseases
JP6302909B2 (ja)	2012-08-18	2018-03-28	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	シアリダーゼの同定および画像化のための細胞透過性プローブ
AU2013305827A1 (en)	2012-08-21	2015-03-05	Academia Sinica	Benzocyclooctyne compounds and uses thereof
CA2882745C (en)	2012-08-23	2022-03-29	Agensys, Inc.	Antibody drug conjugates (adc) that bind to 158p1d7 proteins
CA2881966C (en)	2012-08-24	2020-10-06	The Regents Of The University Of California	Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
WO2014039860A2 (en)	2012-09-07	2014-03-13	University Of Louisville Research Foundation, Inc.	Compositions and methods for modulating dnmt1 inhibitor activity
CN109793893B (zh)	2012-09-07	2023-05-26	达特茅斯大学理事会	用于诊断和治疗癌症的vista调节剂
JOP20200308A1 (ar)	2012-09-07	2017-06-16	Novartis Ag	جزيئات إرتباط il-18
DK2895621T3 (da)	2012-09-14	2020-11-30	Population Bio Inc	Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
CA2922005A1 (en)	2012-09-27	2014-04-03	Population Diagnostics, Inc.	Methods and compositions for screening and treating developmental disorders
WO2014055442A2 (en)	2012-10-01	2014-04-10	The Trustees Of The University Of Pennsylvania	Compositions and methods for targeting stromal cells for the treatment of cancer
UA118441C2 (uk)	2012-10-08	2019-01-25	Протена Біосаєнсиз Лімітед	Антитіло, що розпізнає альфа-синуклеїн
EP3750560A3 (de)	2012-10-09	2021-03-24	Biogen MA Inc.	Kombinationstherapien und deren verwendungen zur behandlung von demyelinisierungserkrankungen
WO2014059251A1 (en)	2012-10-12	2014-04-17	The Brigham And Women's Hospital, Inc.	Enhancement of the immune response
SG11201503412RA (en)	2012-11-01	2015-05-28	Abbvie Inc	Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
CA2889764C (en)	2012-11-01	2023-10-10	Martin Lipp	An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
AU2013337277B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel NTRK1 fusion molecules and uses thereof
WO2014074942A1 (en)	2012-11-08	2014-05-15	Illumina, Inc.	Risk variants of alzheimer's disease
WO2014074905A1 (en)	2012-11-08	2014-05-15	Eleven Biotherapeutics, Inc.	Il-6 antagonists and uses thereof
AU2013343099A1 (en)	2012-11-09	2015-05-14	Pfizer Inc.	Platelet-derived growth factor B specific antibodies and compositions and uses thereof
SI3447069T1 (sl)	2012-11-21	2021-02-26	Janssen Biotech, Inc.	Bispecifična protitelesa EGFR/C-MET
JP6133431B2 (ja)	2012-11-24	2017-05-24	ハンジョウディーエーシーバイオテックシーオー．，エルティディ．ＨａｎｇｚｈｏｕＤａｃＢｉｏｔｅｃｈＣｏ．，Ｌｔｄ．	親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
MX368067B (es)	2012-12-05	2019-09-18	Novartis Ag	Composiciones y métodos para dirigir anticuerpos a la eritropoyetina (epo).
PT2928923T (pt)	2012-12-10	2020-03-27	Biogen Ma Inc	Anticorpos antígenos 2 de células dendríticas anti-sangue e os seus usos
UY35195A (es)	2012-12-18	2014-07-31	Novartis Ag	Composiciones y metodos para proteinas de accion prolongada
US9550986B2 (en)	2012-12-21	2017-01-24	Abbvie Inc.	High-throughput antibody humanization
CA2896091C (en)	2012-12-21	2018-06-19	Amplimmune, Inc.	Anti-h7cr antibodies
GB201223276D0 (en)	2012-12-21	2013-02-06	Ucb Pharma Sa	Antibodies and methods of producing same
AU2013202668B2 (en)	2012-12-24	2014-12-18	Adelaide Research & Innovation Pty Ltd	Inhibition of cancer growth and metastasis
AU2013370171B2 (en)	2012-12-28	2018-09-13	Precision Biologics, Inc.	Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
US10717965B2 (en)	2013-01-10	2020-07-21	Gloriana Therapeutics, Inc.	Mammalian cell culture-produced neublastin antibodies
EP3939614A1 (de)	2013-01-18	2022-01-19	Foundation Medicine, Inc.	Verfahren zur behandlung cholangiokarzinom
PT2953969T (pt)	2013-02-08	2019-12-03	Novartis Ag	Anticorpos anti-il-17a e utilização dos mesmos no tratamento de distúrbios autoimunes e inflamatórios
GB201302447D0 (en)	2013-02-12	2013-03-27	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
WO2014129895A1 (en)	2013-02-19	2014-08-28	Stichting Vu-Vumc	Means and method for increasing the sensitivity of cancers for radiotherapy
PL2958944T3 (pl)	2013-02-22	2019-09-30	Abbvie Stemcentrx Llc	Koniugaty przeciwciało anty-DLL3-PBD i ich zastosowania
KR20150118159A (ko)	2013-02-22	2015-10-21	에프. 호프만-라 로슈 아게	암의 치료 방법 및 약물 내성의 예방 방법
US9487587B2 (en)	2013-03-05	2016-11-08	Macrogenics, Inc.	Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US9925240B2 (en)	2013-03-06	2018-03-27	Genentech, Inc.	Methods of treating and preventing cancer drug resistance
JP6674888B2 (ja)	2013-03-13	2020-04-01	プロセナバイオサイエンシーズリミテッド	タウ免疫療法
CA2926301A1 (en)	2013-03-14	2014-10-02	Abbvie Inc.	Low acidic species compositions and methods for producing and using the same
SI2968520T1 (sl)	2013-03-14	2022-01-31	Macrogenics, Inc.	Bispecifične molekule, ki so imunoreaktivne z imunskimi efektorskimi celicami, ki izražajo aktivacijski receptor
MX2015011606A (es)	2013-03-14	2016-05-17	Genentech Inc	Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
MX2015012922A (es)	2013-03-14	2016-04-04	Ren Liu	Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular.
BR112015023239A8 (pt)	2013-03-14	2018-04-17	Abbott Lab	ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
EP2970375A1 (de)	2013-03-14	2016-01-20	AbbVie Inc.	Schwach saure zusammensetzungen und verfahren zu ihrer herstellung durch verdrängungschromatografie
WO2014142882A1 (en)	2013-03-14	2014-09-18	Abbvie Inc.	Protein purification using displacement chromatography
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
JP6739329B2 (ja)	2013-03-14	2020-08-12	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	Ｈｃｖコア脂質結合ドメインモノクローナル抗体
EP2970479B1 (de)	2013-03-14	2019-04-24	Novartis AG	Antikörper gegen notch 3
MX2015012824A (es)	2013-03-14	2016-06-24	Abbott Lab	Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos.
RU2015144186A (ru)	2013-03-15	2017-04-24	Эббви Инк.	Очистка конъюгата антитело-лекарственное средство (аdс)
AU2014235453A1 (en)	2013-03-15	2015-10-08	Genentech, Inc.	Biomarkers and methods of treating PD-1 and PD-L1 related conditions
WO2014143765A1 (en)	2013-03-15	2014-09-18	Abbvie Deutschland Gmbh & Co.Kg	Anti-egfr antibody drug conjugate formulations
CN105324396A (zh)	2013-03-15	2016-02-10	艾伯维公司	针对IL-1β和/或IL-17的双重特异性结合蛋白
WO2014152507A2 (en)	2013-03-15	2014-09-25	Pioneer Hi-Bred International, Inc.	Modulation of acc deaminase expression
CN105392801A (zh)	2013-03-15	2016-03-09	比奥根Ma公司	使用抗αvβ5抗体治疗和预防急性肾损伤
MX2015011899A (es)	2013-03-15	2016-05-05	Genentech Inc	Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
US9469686B2 (en)	2013-03-15	2016-10-18	Abbott Laboratories	Anti-GP73 monoclonal antibodies and methods of obtaining the same
EP2968508B1 (de)	2013-03-15	2022-04-27	Sanofi Pasteur Biologics, LLC	Antikörper gegen clostridium-difficile-toxine und verfahren zur verwendung davon
CN105051068A (zh)	2013-03-15	2015-11-11	戴埃克斯有限公司	抗血浆激肽释放酶抗体
US10598674B2 (en)	2013-03-20	2020-03-24	Sphingotec Gmbh	Adrenomedullin to guide therapy of blood pressure decline
US9499621B2 (en)	2013-04-08	2016-11-22	Cytodyn, Inc.	Felinized antibodies and methods of treating retroviral infections in felines
EP3457138A3 (de)	2013-04-30	2019-06-19	Université de Montréal	Neuartige biomarker für akute myeloische leukämie
JP2016521283A (ja)	2013-05-06	2016-07-21	スカラーロックインコーポレイテッドＳｃｈｏｌａｒＲｏｃｋ，Ｉｎｃ．	成長因子モジュレーションのための組成物および方法
RU2015147721A (ru)	2013-05-07	2017-06-15	Ринат Нейросаенз Корпорэйшн	Антитела против рецептора глюкагона и способы их использования
SG11201509284VA (en)	2013-05-17	2015-12-30	Centre Nat Rech Scient	Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
CA2913312A1 (en)	2013-05-24	2014-11-27	Medimmune, Llc	Anti-b7-h5 antibodies and their uses
SG11201509982UA (de)	2013-06-06	2016-04-28	Igenica Biotherapeutics Inc
EP3004877A4 (de)	2013-06-06	2017-04-19	Dana-Farber Cancer Institute, Inc.	Zusammensetzungen und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
JP6581572B2 (ja)	2013-06-07	2019-09-25	デュークユニバーシティ	補体因子ｈ阻害薬
AU2014278833A1 (en)	2013-06-13	2016-01-07	Fast Forward Pharmaceuticals B.V.	CD40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an TGR5-receptor agonist, an FXR agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
CN105308073B (zh)	2013-06-14	2019-08-13	加利福尼亚太平洋生物科学股份有限公司	双生物素化标签
AR096601A1 (es)	2013-06-21	2016-01-20	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
WO2014210397A1 (en)	2013-06-26	2014-12-31	Academia Sinica	Rm2 antigens and use thereof
US9981030B2 (en)	2013-06-27	2018-05-29	Academia Sinica	Glycan conjugates and use thereof
JP6450381B2 (ja)	2013-07-05	2019-01-09	ユニバーシティオブワシントンスルーイッツセンターフォーコマーシャリゼーション	がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体
WO2015004632A1 (en)	2013-07-12	2015-01-15	Neotope Biosciences Limited	Antibodies that recognize iapp
US9951131B2 (en)	2013-07-12	2018-04-24	Prothena Biosciences Limited	Antibodies that recognize IAPP
US10208125B2 (en)	2013-07-15	2019-02-19	University of Pittsburgh—of the Commonwealth System of Higher Education	Anti-mucin 1 binding agents and uses thereof
CA2919477A1 (en)	2013-07-31	2015-02-05	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
JP2015030666A (ja)	2013-07-31	2015-02-16	学校法人順天堂	抗ヒトｃｄ２６モノクローナル抗体又はその抗原結合性断片
EP3027220A1 (de)	2013-08-01	2016-06-08	Agensys, Inc.	An cd37-proteine bindende antikörper-wirkstoffkonjugate (adc)
AR097102A1 (es)	2013-08-02	2016-02-17	Pfizer	Anticuerpo anti-cxcr4 y conjugados de anticuerpo y fármaco
EP3030902B1 (de)	2013-08-07	2019-09-25	Friedrich Miescher Institute for Biomedical Research	Neues screening-verfahren zur behandlung von friedreich-ataxie
US20150044192A1 (en)	2013-08-09	2015-02-12	President And Fellows Of Harvard College	Methods for identifying a target site of a cas9 nuclease
TN2016000057A1 (en)	2013-08-14	2017-07-05	Novartis Ag	Methods of treating sporadic inclusion body myositis
DK3036320T3 (da)	2013-08-19	2021-07-12	Biogen Ma Inc	Styring af proteinglycosylering ved hjælp af dyrkningsmedietilsætning og cellekulturprocesparametre
KR20160054501A (ko)	2013-08-26	2016-05-16	맵백스 테라퓨틱스, 인코포레이티드	시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
JP2016538318A (ja)	2013-08-28	2016-12-08	ステムセントリックス，インコーポレイテッド	新規ｓｅｚ６モジュレーターおよび使用方法
PE20160674A1 (es)	2013-08-28	2016-07-21	Stemcentrx Inc	Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
US9340800B2 (en)	2013-09-06	2016-05-17	President And Fellows Of Harvard College	Extended DNA-sensing GRNAS
CN105682666B (zh)	2013-09-06	2021-06-01	中央研究院	使用醣脂激活人类iNKT细胞
PL3041513T3 (pl)	2013-09-08	2021-01-25	Kodiak Sciences Inc.	Obojnaczojonowe polimerowe koniugaty czynnika viii
EP3521431A1 (de)	2013-09-25	2019-08-07	Cornell University	Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
WO2015048330A2 (en)	2013-09-25	2015-04-02	Biogen Idec Ma Inc.	On-column viral inactivation methods
WO2015048312A1 (en)	2013-09-26	2015-04-02	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
WO2015048635A1 (en)	2013-09-27	2015-04-02	Duke University	Mper-liposome conjugates and uses thereof
EP3470081A1 (de)	2013-10-01	2019-04-17	Mayo Foundation for Medical Education and Research	Verfahren zur behandlung von krebs bei patienten mit erhöhten bim-werten
WO2015057939A1 (en)	2013-10-18	2015-04-23	Biogen Idec Ma Inc.	Anti-s1p4 antibodies and uses thereof
AU2014342528A1 (en)	2013-10-28	2016-04-28	Dots Technology Corp.	Allergen detection
EP4331590A3 (de)	2013-10-29	2024-04-17	President and Fellows of Harvard College	Verfahren und zusammensetzungen zur hemmung von oxidativem stress
JP6556742B2 (ja)	2013-11-06	2019-08-07	ヤンセンバイオテツク，インコーポレーテツド	抗ｃｃｌ１７抗体
US20160272674A1 (en)	2013-11-07	2016-09-22	Abbvie Inc.	Isolation and purification of antibodies
EP2871189A1 (de)	2013-11-07	2015-05-13	Institut Pasteur	Hochaffiner, monoklonaler Anti-Strep-Tag-Antikörper
EP2891722B1 (de)	2013-11-12	2018-10-10	Population Bio, Inc.	Verfahren und Zusammensetzungen zur Diagnose, Prognose und Behandlung von Endometriose
WO2015073580A1 (en)	2013-11-13	2015-05-21	Pfizer Inc.	Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
BR112016011046A2 (pt)	2013-11-15	2019-01-29	Centre Nat Rech Scient	método para genotipagem, método para a detecção de uma infecção, kit para detectar uma infecção e método para detectar em uma amostra biológica.
WO2015087187A1 (en)	2013-12-10	2015-06-18	Rinat Neuroscience Corp.	Anti-sclerostin antibodies
US8986694B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Targeting human nav1.7 variants for treatment of pain
US9045545B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
US8992927B1 (en)	2014-07-15	2015-03-31	Kymab Limited	Targeting human NAV1.7 variants for treatment of pain
US9067998B1 (en)	2014-07-15	2015-06-30	Kymab Limited	Targeting PD-1 variants for treatment of cancer
RU2714902C2 (ru)	2013-12-19	2020-02-20	Новартис Аг	Химерные рецепторы антигена против мезотелина человека и их применение
WO2015095809A1 (en)	2013-12-20	2015-06-25	Biogen Idec Ma Inc.	Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
WO2015095868A1 (en)	2013-12-20	2015-06-25	Wake Forest University Health Sciences	Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
EP2960252A1 (de)	2014-06-26	2015-12-30	Institut Pasteur	Phospholipase zur Behandlung von Immunosuppression
CA2935378C (en)	2013-12-24	2023-04-18	Janssen Pharmaceutica Nv	Anti-vista antibodies and fragments
US11014987B2 (en)	2013-12-24	2021-05-25	Janssen Pharmaceutics Nv	Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
WO2016114819A1 (en)	2015-01-16	2016-07-21	Academia Sinica	Compositions and methods for treatment and detection of cancers
EP3094352B1 (de)	2014-01-16	2020-09-23	Academia Sinica	Zusammensetzungen und verfahren zur behandlung und zum nachweis von krebs
WO2015109212A1 (en)	2014-01-17	2015-07-23	Pfizer Inc.	Anti-il-2 antibodies and compositions and uses thereof
US10179911B2 (en)	2014-01-20	2019-01-15	President And Fellows Of Harvard College	Negative selection and stringency modulation in continuous evolution systems
CN106132442B (zh)	2014-01-21	2023-07-14	武田药品工业株式会社	血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015116902A1 (en)	2014-01-31	2015-08-06	Genentech, Inc.	G-protein coupled receptors in hedgehog signaling
CA3212977A1 (en)	2014-02-11	2015-08-20	Visterra, Inc.	Antibody molecules to dengue virus and uses thereof
WO2015127407A1 (en)	2014-02-21	2015-08-27	Stemcentrx, Inc.	Anti-dll3 antibodies and drug conjugates for use in melanoma
PT3122757T (pt)	2014-02-28	2023-11-03	Hangzhou Dac Biotech Co Ltd	Ligantes carregados e as suas utilizações em conjugação
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
JP2017514458A (ja)	2014-03-12	2017-06-08	プロセナバイオサイエンシーズリミテッド	Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
TW201623331A (zh)	2014-03-12	2016-07-01	普羅帝納生物科學公司	抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
JP2017512772A (ja)	2014-03-12	2017-05-25	プロセナバイオサイエンシーズリミテッド	Ｌｇ１〜３に特異的な抗ラミニン４抗体
WO2015136469A1 (en)	2014-03-12	2015-09-17	Prothena Biosciences Limited	Anti-mcam antibodies and associated methods of use
US9738702B2 (en)	2014-03-14	2017-08-22	Janssen Biotech, Inc.	Antibodies with improved half-life in ferrets
TWI777174B (zh)	2014-03-14	2022-09-11	瑞士商諾華公司	針對lag-3之抗體分子及其用途
PE20161439A1 (es)	2014-03-21	2017-01-26	Teva Pharmaceuticals Int Gmbh	Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
DK3122869T3 (da)	2014-03-24	2019-09-09	Biogen Ma Inc	Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
EP3129767B1 (de)	2014-03-27	2021-09-01	Academia Sinica	Reaktive markierungsverbindungen und ihre verwendungen
CN106536556B (zh)	2014-04-04	2020-02-07	生态学有限公司	结合lgr5的人源化抗体
US10562973B2 (en)	2014-04-08	2020-02-18	Prothena Bioscience Limited	Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TW201622746A (zh)	2014-04-24	2016-07-01	諾華公司	改善或加速髖部骨折術後身體復原之方法
CA3225091A1 (en)	2014-05-05	2015-11-12	Regeneron Pharmaceuticals, Inc.	Humanized c5 and c3 animals
IL248511B (en)	2014-05-13	2022-07-01	Bavarian Nordic As	Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3
US20170267780A1 (en)	2014-05-16	2017-09-21	Medimmune, Llc	Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
WO2015179654A1 (en)	2014-05-22	2015-11-26	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti b7-h1 antibodies
RU2016144405A (ru)	2014-05-23	2018-06-26	Дженентек, Инк.	MiT БИОМАРКЕРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
TWI679020B (zh)	2014-05-27	2019-12-11	中央研究院	抗ｈｅｒ２醣抗體及其用途
TWI717319B (zh)	2014-05-27	2021-02-01	中央研究院	得自類桿菌屬之岩藻糖苷酶及其用途
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20170003720A (ko)	2014-05-27	2017-01-09	아카데미아 시니카	항-ｃｄ20 글리코항체 및 이의 용도
NZ726513A (en)	2014-05-28	2023-07-28	Memorial Sloan Kettering Cancer Center	Anti-gitr antibodies and methods of use thereof
KR102494193B1 (ko)	2014-05-28	2023-01-31	아카데미아 시니카	항-ｔｎｆ-알파 글리코항체 및 이의 용도
GB201409558D0 (en)	2014-05-29	2014-07-16	Ucb Biopharma Sprl	Method
NZ726520A (en)	2014-05-29	2018-12-21	Macrogenics Inc	Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
US9416172B2 (en)	2014-06-03	2016-08-16	Xbiotech, Inc.	Compositions and methods for treating and preventing Staphylococcus aureus infections
NZ764877A (en)	2014-06-04	2023-12-22	Biontech Res And Development Inc	Human monoclonal antibodies to ganglioside gd2
RS59643B1 (sr)	2014-06-06	2020-01-31	Bristol Myers Squibb Co	Antitela na glukokortikoidom indukovani receptor faktora nekroze tumora (gitr) i njihova primena
MX2016016310A (es)	2014-06-11	2017-10-20	A Green Kathy	Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
US10106579B2 (en)	2014-06-12	2018-10-23	Ra Pharmaceuticals, Inc.	Modulation of complement activity
CN107073121A (zh)	2014-06-13	2017-08-18	基因泰克公司	治疗及预防癌症药物抗性的方法
EP3154579A1 (de)	2014-06-13	2017-04-19	Friedrich Miescher Institute for Biomedical Research	Neue behandlung gegen das influenzavirus
CN114057857A (zh)	2014-06-20	2022-02-18	豪夫迈·罗氏有限公司	基于chagasin的支架组合物、方法和应用
WO2015198202A1 (en)	2014-06-23	2015-12-30	Friedrich Miescher Institute For Biomedical Research	Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
TWI713453B (zh)	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
WO2015198240A2 (en)	2014-06-25	2015-12-30	Novartis Ag	Compositions and methods for long acting proteins
US20170290876A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Compositions and methods for long acting proteins
US20170291939A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Antibodies specific for il-17a fused to hyaluronan binding peptide tags
GB201411320D0 (en)	2014-06-25	2014-08-06	Ucb Biopharma Sprl	Antibody construct
TWI693232B (zh)	2014-06-26	2020-05-11	美商宏觀基因股份有限公司	與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10273311B2 (en)	2014-06-26	2019-04-30	Yale University	Compositions to regulate renalase in the treatment of diseases and disorders
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
WO2016001830A1 (en)	2014-07-01	2016-01-07	Friedrich Miescher Institute For Biomedical Research	Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US10132818B2 (en)	2014-07-08	2018-11-20	New York University	Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
US9139648B1 (en)	2014-07-15	2015-09-22	Kymab Limited	Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
GB201412659D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
TN2017000008A1 (en)	2014-07-17	2018-07-04	Novo Nordisk As	Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
US9777061B2 (en)	2014-07-21	2017-10-03	Novartis Ag	Treatment of cancer using a CD33 chimeric antigen receptor
US10517875B2 (en)	2014-07-23	2019-12-31	Mayo Foundation for Medical Engineering and Research	Targeting DNA-PKcs and B7-H1 to treat cancer
WO2016012623A1 (en)	2014-07-25	2016-01-28	Theravectys	Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
CA2956224A1 (en)	2014-07-30	2016-02-11	President And Fellows Of Harvard College	Cas9 proteins including ligand-dependent inteins
EP3194437B1 (de)	2014-08-07	2021-01-20	Novartis AG	Antikörper gegen angiopoietinähnliches protein 4 und deren verwendung
PE20170287A1 (es)	2014-08-07	2017-04-05	Novartis Ag	Anticuerpos anti-proteina similar a angiopoyetina 4 y metodos de uso
JP6919118B2 (ja)	2014-08-14	2021-08-18	ノバルティスアーゲー	ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
BR112017003104A2 (pt)	2014-08-19	2017-12-05	Novartis Ag	tratamento de câncer usando um receptor antigênico quimérico anti-cd123
GB2558326B (en)	2014-09-05	2021-01-20	Population Bio Inc	Methods and compositions for inhibiting and treating neurological conditions
CN107001404B (zh)	2014-09-08	2021-06-29	中央研究院	使用醣脂激活人类iNKT细胞
MX2017003115A (es)	2014-09-09	2017-11-17	Janssen Biotech Inc	Terapias de combinacion con anticuerpos anti-cd38.
US20160075772A1 (en)	2014-09-12	2016-03-17	Regeneron Pharmaceuticals, Inc.	Treatment of Fibrodysplasia Ossificans Progressiva
MX2017003227A (es)	2014-09-13	2017-12-04	Novartis Ag	Terapias de combinacion de inhibidores de alk.
EP3194435A1 (de)	2014-09-15	2017-07-26	Amgen Inc.	Bispezifische anti-cgrp-rezeptor/pac1-rezeptor-antigenbindende proteine und verwendungen davon
US10450376B2 (en)	2014-09-16	2019-10-22	Symphogen A/S	Anti-MET antibodies and compositions
EP3197557A1 (de)	2014-09-24	2017-08-02	Friedrich Miescher Institute for Biomedical Research	Lats und brustrkrebs
JP6932639B2 (ja)	2014-09-29	2021-09-08	デュークユニバーシティ	Ｈｉｖ‐１エンベロープ標的化アームを備える二重特異性分子
EP3200822B1 (de)	2014-09-30	2021-04-14	Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts	Bindungsmoleküle, insbesondere antikörper die sich an l1cam (cd171) binden
RU2021125449A (ru)	2014-10-01	2021-09-16	Медиммьюн Лимитед	Антитела к тикагрелору и способы применения
ES2774448T3 (es)	2014-10-03	2020-07-21	Novartis Ag	Terapias de combinación
SG10201902924RA (en)	2014-10-03	2019-05-30	Massachusetts Inst Technology	Antibodies that bind ebola glycoprotein and uses thereof
TWI716362B (zh)	2014-10-14	2021-01-21	瑞士商諾華公司	針對ｐｄ－ｌ１之抗體分子及其用途
US10202616B2 (en)	2014-10-15	2019-02-12	Amgen Inc.	Promoter and regulatory elements for improved expression of heterologous genes in host cells
MA41685A (fr)	2014-10-17	2017-08-22	Biogen Ma Inc	Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
EP3207128B1 (de)	2014-10-17	2022-07-27	Kodiak Sciences Inc.	Zwitterionische butyrylcholinesterasepolymerkonjugate
WO2016077052A2 (en)	2014-10-22	2016-05-19	President And Fellows Of Harvard College	Evolution of proteases
MA40864A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
WO2016073401A1 (en)	2014-11-03	2016-05-12	Bristol-Myers Squibb Company	Use of caprylic acid precipitation for protein purification
WO2016073685A1 (en)	2014-11-05	2016-05-12	Annexon, Inc.	Humanized anti-complement factor c1q antibodies and uses thereof
IL251858B (en)	2014-11-07	2022-09-01	Eleven Biotherapeutics Inc	Improved il–6 antagonists
WO2016073894A1 (en)	2014-11-07	2016-05-12	Eleven Biotherapeutics, Inc.	Therapeutic agents with increased ocular retention
MX2017006167A (es)	2014-11-12	2018-03-23	Siamab Therapeutics Inc	Compuestos que interactúan con glicanos y métodos de uso.
US9879087B2 (en)	2014-11-12	2018-01-30	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
WO2016079219A1 (en)	2014-11-19	2016-05-26	Koninklijke Philips N.V.	Diagnostic method employing hnl
CN113773388A (zh)	2014-11-21	2021-12-10	百时美施贵宝公司	抗cd73抗体及其用途
US11033637B2 (en)	2014-11-21	2021-06-15	University Of Maryland, Baltimore	Targeted structure-specific particulate delivery systems
JP2018505911A (ja)	2014-12-05	2018-03-01	イミュネクスト，インコーポレーテッド	推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
TWI595006B (zh)	2014-12-09	2017-08-11	禮納特神經系統科學公司	抗ｐｄ－１抗體類和使用彼等之方法
PT3333191T (pt)	2014-12-11	2020-12-15	Pf Medicament	Anticorpos anti-c10orf54 e suas utilizações
WO2016094881A2 (en)	2014-12-11	2016-06-16	Abbvie Inc.	Lrp-8 binding proteins
CA2971542A1 (en)	2014-12-19	2016-06-23	Regenesance B.V.	Antibodies that bind human c6 and uses thereof
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
EP3233918A1 (de)	2014-12-19	2017-10-25	Novartis AG	Kombinationstherapien
US10221248B2 (en)	2014-12-22	2019-03-05	The Rockefeller University	Anti-MERTK agonistic antibodies and uses thereof
WO2016106286A1 (en)	2014-12-23	2016-06-30	Biodesy, Inc.	Attachment of proteins to interfaces for use in nonlinear optical detection
TWI708786B (zh)	2014-12-23	2020-11-01	美商必治妥美雅史谷比公司	針對ｔｉｇｉｔ之抗體
EP3242893A1 (de)	2015-01-08	2017-11-15	Biogen MA Inc.	Lingo-1-antagonisten und verwendungen zur behandlung von demyelinisierungserkrankungen
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
JP6779887B2 (ja)	2015-01-24	2020-11-04	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	新規なグリカンコンジュゲートおよびその使用方法
JP6602875B2 (ja)	2015-01-26	2019-11-06	マクロジェニクス，インコーポレーテッド	Ｄｒ５結合ドメインを含む多価分子
TWI718121B (zh)	2015-01-28	2021-02-11	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
EP3250230B9 (de)	2015-01-28	2022-02-23	RA Pharmaceuticals, Inc.	Modulatoren der komplementaktivität
TWI769570B (zh)	2015-01-28	2022-07-01	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
TWI786505B (zh)	2015-01-28	2022-12-11	愛爾蘭商普羅佘納生物科技有限公司	抗甲狀腺素運送蛋白抗體
KR102620346B1 (ko)	2015-01-30	2024-01-02	아카데미아 시니카	증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
EP4177267A1 (de)	2015-02-02	2023-05-10	Children's Health Care d/b/a Children's Minnesota	Leichtkettige anti-surrogate-antikörper
US10266584B2 (en)	2015-02-09	2019-04-23	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Antibodies specific to glycoprotein (GP) of Ebolavirus and uses for the treatment and diagnosis of ebola virus infection
PL3265123T3 (pl)	2015-03-03	2023-03-13	Kymab Limited	Przeciwciała, zastosowania i sposoby
EP3265491A1 (de)	2015-03-03	2018-01-10	Xoma (Us) Llc	Behandlung von postprandialer hyperinsulinämie und hyperglykämie nach bariatrischer chirurgie
US20180042998A1 (en)	2015-03-10	2018-02-15	University Of Massachusetts	Targeting gdf6 and bmp signaling for anti-melanoma therapy
SG11201707330RA (en)	2015-03-13	2017-10-30	Bristol Myers Squibb Co	Use of alkaline washes during chromatography to remove impurities
WO2016153978A1 (en)	2015-03-20	2016-09-29	Bristol-Myers Squibb Company	Use of dextran to enhance protein purification by affinity chromatography
US20180105555A1 (en)	2015-03-20	2018-04-19	Bristol-Myers Squibb Company	Use of dextran for protein purification
WO2016154588A1 (en)	2015-03-25	2016-09-29	Children's Hospital Medical Center	Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation
CA2981142A1 (en)	2015-03-27	2016-10-06	University Of Southern California	Car t-cell therapy directed to lhr for the treatment of solid tumors
AU2016243160B2 (en)	2015-03-30	2022-02-24	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
ES2820768T3 (es)	2015-04-03	2021-04-22	Xoma Technology Ltd	Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
TWI787645B (zh)	2015-04-13	2022-12-21	美商輝瑞股份有限公司	Ｃｄ３特異性抗體、治療性雙特異性抗體及其用途
US11299729B2 (en)	2015-04-17	2022-04-12	President And Fellows Of Harvard College	Vector-based mutagenesis system
EP3285811A1 (de)	2015-04-21	2018-02-28	Institut Gustave Roussy	Therapeutische verfahren, produkte und zusammensetzungen zur hemmung von znf555
GB201506870D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
GB201506869D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
CN116063543A (zh)	2015-04-24	2023-05-05	豪夫迈·罗氏有限公司	多特异性抗原结合蛋白
EP3286214B1 (de)	2015-04-24	2023-12-06	The Regents of the University of California	Modulatoren der ror1-ror2-bindung
EP3288976B1 (de)	2015-04-29	2020-04-08	Regeneron Pharmaceuticals, Inc.	Behandlung von fibrodysplasia ossificans progressiva
EP3288542B1 (de)	2015-04-29	2021-12-29	University Of South Australia	Zusammensetzungen und verfahren zur verabreichung von antikörpern
EP3291836A4 (de)	2015-05-06	2018-11-14	Janssen Biotech, Inc.	Bispezifische bindemittel für prostataspezifisches membranantigen (psma) und verwendungen davon
CA2983996A1 (en)	2015-05-06	2016-11-10	Poc Medical Systems Inc.	Devices and methods for detection of biomarkers
AU2016256911B2 (en)	2015-05-07	2022-03-31	Agenus Inc.	Anti-OX40 antibodies and methods of use thereof
US20180104331A1 (en)	2015-05-11	2018-04-19	The Johns Hopkins University	Autoimmune antibodies for use in inhibiting cancer cell growth
FI3447075T3 (fi)	2015-05-15	2023-11-07	Massachusetts Gen Hospital	Antagonistisia anti-tuumorinekroositekijäreseptorin superperheen vasta-aineita
EP3297729A4 (de)	2015-05-20	2019-04-10	Janssen Biotech, Inc.	Anti-cd38-antikörper zur behandlung von leichtkettigen amyloidosen und anderen cd38-positiven hämatologischen malignitäten
MY195000A (en)	2015-05-27	2022-12-30	Ucb Biopharma Sprl	Method for the treatment of neurological disease
HUE061253T2 (hu)	2015-05-29	2023-06-28	Bristol Myers Squibb Co	Antitestek OX40 ellen és azok felhasználásai
PE20180193A1 (es)	2015-05-29	2018-01-26	Abbvie Inc	Anticuerpos anti-cd40 y sus usos
HUE050750T2 (hu)	2015-05-29	2021-01-28	Agenus Inc	CTLA-4 elleni antitestek és eljárások alkalmazásukra
EP3302559B1 (de)	2015-06-04	2022-01-12	University of Southern California	Auf lym-1 und lym-2 abgerichtete car-zellen-immuntherapie
TN2017000417A1 (en)	2015-06-05	2019-01-16	Novartis Ag	Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
TWI773646B (zh)	2015-06-08	2022-08-11	美商宏觀基因股份有限公司	結合lag-3的分子和其使用方法
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
GB201510758D0 (en)	2015-06-18	2015-08-05	Ucb Biopharma Sprl	Novel TNFa structure for use in therapy
PE20181323A1 (es)	2015-06-22	2018-08-14	Janssen Biotech Inc	Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina
CN107922497B (zh)	2015-06-24	2022-04-12	詹森药业有限公司	抗vista抗体和片段
PE20181090A1 (es)	2015-06-24	2018-07-09	Janssen Biotech Inc	Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
MX2017016502A (es)	2015-06-29	2018-03-12	Univ Rockefeller	Anticuerpos contra cd40 con actividad agonista mejorada.
CN113350518A (zh)	2015-07-12	2021-09-07	杭州多禧生物科技有限公司	与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en)	2015-07-15	2017-12-12	Suzhou M-Conj Biotech Co., Ltd.	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
GB201601075D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies molecules
GB201601073D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
WO2017015334A1 (en)	2015-07-21	2017-01-26	Saint Louis University	Compositions and methods for diagnosing and treating endometriosis-related infertility
CN108137705B (zh)	2015-07-21	2022-11-08	武田药品工业株式会社	一种因子xiia的单克隆抗体抑制剂
US10392674B2 (en)	2015-07-22	2019-08-27	President And Fellows Of Harvard College	Evolution of site-specific recombinases
US11524983B2 (en)	2015-07-23	2022-12-13	President And Fellows Of Harvard College	Evolution of Bt toxins
WO2017015619A1 (en)	2015-07-23	2017-01-26	The Regents Of The University Of California	Antibodies to coagulation factor xia and uses thereof
SI3317301T1 (sl)	2015-07-29	2021-10-29	Novartis Ag	Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
WO2017019897A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
EP3328419B1 (de)	2015-07-30	2021-08-25	MacroGenics, Inc.	Pd-1-bindende moleküle und verfahren zur verwendung davon
WO2017019895A1 (en)	2015-07-30	2017-02-02	President And Fellows Of Harvard College	Evolution of talens
CN115043944A (zh)	2015-08-03	2022-09-13	诺华股份有限公司	治疗fgf21相关病症的方法
EP3331563B1 (de)	2015-08-05	2023-04-19	Janssen Biotech, Inc.	Anti-cd154-antikörper und verfahren zur verwendung davon
EP3331562A2 (de)	2015-08-06	2018-06-13	Xoma (Us) Llc	Antikörperfragmente gegen den insulinrezeptor und verwendungen davon zur behandlung von hypoglykämie
US10988528B2 (en)	2015-08-13	2021-04-27	New York University	Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
EP3341415B1 (de)	2015-08-28	2021-03-24	H. Hoffnabb-La Roche Ag	Anti-hypusin-antikörper und verwendungen davon
WO2017040790A1 (en)	2015-09-01	2017-03-09	Agenus Inc.	Anti-pd-1 antibodies and methods of use thereof
US10407484B2 (en)	2015-09-02	2019-09-10	The Regents Of The University Of Colorado, A Body Corporate	Compositions and methods for modulating T-cell mediated immune response
EP3344806A4 (de)	2015-09-04	2019-03-20	OBI Pharma, Inc.	Glycanarrays und verfahren zur verwendung
EP3347377B1 (de)	2015-09-09	2021-02-17	Novartis AG	Thymus-stroma-lymphopoietin(tslp)-bindende antikörper und verfahren zur verwendung der antikörper
TN2018000076A1 (en)	2015-09-09	2019-07-08	Novartis Ag	Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
CN108348780A (zh)	2015-09-10	2018-07-31	贝克顿·迪金森公司	用作用于环磷酰胺和异环磷酰胺的免疫分析的免疫原和分析缀合物的环磷酰胺类似物
EP3350220B1 (de)	2015-09-15	2021-05-19	Scholar Rock, Inc.	Anti-pro/latentes-myostatin-antikörper und verwendungen davon
EP3350216A1 (de)	2015-09-15	2018-07-25	Amgen Inc.	Tetravalente bispezifische und tetraspezifische antigenbindende proteine und verwendungen davon
CA2998716A1 (en)	2015-09-16	2017-03-23	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en)	2015-09-16	2017-03-23	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
PE20181363A1 (es)	2015-09-23	2018-08-27	Genentech Inc	Variantes optimizadas de anticuerpos anti-vegf
AU2016326721C1 (en)	2015-09-23	2021-06-03	Cytoimmune Therapeutics, Inc.	FLT3 directed car cells for immunotherapy
RU2638457C2 (ru)	2015-09-28	2017-12-13	Общество С Ограниченной Ответственностью "Онкомакс"	Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
BR112018006360A2 (pt)	2015-09-30	2018-10-09	Janssen Biotech Inc	anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
MX2018004177A (es)	2015-10-08	2018-09-11	Macrogenics Inc	Terapia de combinacion para el tratamiento de cancer.
US11207393B2 (en)	2015-10-16	2021-12-28	President And Fellows Of Harvard College	Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
EP3362472B1 (de)	2015-10-16	2023-08-30	The Trustees of Columbia University in the City of New York	Zusammensetzungen und verfahren zur hemmung von zelllinienspezifischen antigenen
AU2016340826C1 (en)	2015-10-19	2023-05-04	Takeda Pharmaceutical Company Limited	Immunoassay to detect cleaved high molecular weight kininogen
US10138298B2 (en)	2015-10-23	2018-11-27	The Regents Of The University Of California	Anti-IL-2 antibodies and compositions and uses thereof
IL310721A (en)	2015-10-23	2024-04-01	President And Fellows Of Harvard College	Nucleobase editors and their uses
BR112018008075A2 (pt)	2015-10-27	2018-12-04	Ucb Biopharma Sprl	métodos de tratamento usando anticorpos anti-il-17a/f
US20180348224A1 (en)	2015-10-28	2018-12-06	Friedrich Miescher Institute For Biomedical Resear Ch	Tenascin-w and biliary tract cancers
US20210106661A1 (en)	2015-10-29	2021-04-15	Dana-Farber Cancer Institute, Inc.	Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
WO2017075045A2 (en)	2015-10-30	2017-05-04	Mayo Foundation For Medical Education And Research	Antibodies to b7-h1
WO2017075484A2 (en)	2015-10-30	2017-05-04	Galaxy Biotech, Llc	Highly potent antibodies binding to death receptor 4 and death receptor 5
CN108473584B (zh)	2015-11-03	2022-01-14	詹森生物科技公司	特异性结合pd-1和tim-3的抗体及其用途
SG11201803678SA (en)	2015-11-03	2018-05-30	Janssen Biotech Inc	Subcutaneous formulations of anti-cd38 antibodies and their uses
EP3374379A4 (de)	2015-11-09	2019-05-15	The University Of British Columbia	N-terminale epitope in amyloid-beta und konformationsselektive antikörper dagegen
CN108350053A (zh)	2015-11-09	2018-07-31	英属哥伦比亚大学	淀粉样蛋白β表位及其抗体
KR20180085736A (ko)	2015-11-09	2018-07-27	더 유니버시티 오브 브리티쉬 콜롬비아	아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체
WO2017083515A2 (en)	2015-11-10	2017-05-18	Visterra, Inc.	Antibody molecule-drug conjugates and uses thereof
KR20180088381A (ko)	2015-11-12	2018-08-03	시아맙 쎄라퓨틱스, 인코포레이티드	글리칸-상호작용 화합물 및 사용방법
CN108738324B (zh)	2015-11-19	2022-06-21	百时美施贵宝公司	抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
WO2017084078A1 (en)	2015-11-19	2017-05-26	Zeling Cai	Ctla-4 antibodies and uses thereof
CA3006058A1 (en)	2015-11-25	2017-06-01	Visterra, Inc.	Antibody molecules to april and uses thereof
WO2017095823A1 (en)	2015-11-30	2017-06-08	The Regents Of The University Of California	Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
EP3383903A1 (de)	2015-11-30	2018-10-10	Bristol-Myers Squibb Company	Humane ip-10-antikörper und deren verwendung
CN109415437B (zh)	2015-12-02	2022-02-01	斯特库伯株式会社	与btn1a1免疫特异性结合的抗体和分子及其治疗用途
CN108925136B (zh)	2015-12-02	2022-02-01	斯特赛恩斯公司	特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
GB201521383D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl And Ucb Celltech	Method
GB201521391D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521382D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521389D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Method
GB201521393D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
EP3386542B1 (de)	2015-12-10	2020-11-18	Katholieke Universiteit Leuven	Anti-adamts13-antikörper und deren verwendung zur behandlung oder verhütung von hämorrhagischen störungen aufgrund einer ventrikulären unterstützungsvorrichtung
US11286307B2 (en)	2015-12-11	2022-03-29	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CR20180318A (es)	2015-12-14	2018-09-19	Macrogenics Inc	Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
DK3389692T3 (da)	2015-12-16	2020-03-30	Ra Pharmaceuticals Inc	Modulatorer af komplement-aktivitet
EP3390453A2 (de)	2015-12-17	2018-10-24	Janssen Biotech, Inc.	Antikörper mit spezifischer bindung von hla-dr und deren verwendungen
KR20180088907A (ko)	2015-12-17	2018-08-07	노파르티스 아게	Pd-1에 대한 항체 분자 및 그의 용도
RU2018125603A (ru)	2015-12-17	2020-01-21	Новартис Аг	Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения
CN109069623A (zh)	2015-12-18	2018-12-21	诺华股份有限公司	靶向CD32b的抗体及其使用方法
CA3048204A1 (en)	2015-12-23	2017-06-29	Moonshot Pharma Llc	Methods for inducing an immune response
RU2744860C2 (ru)	2015-12-30	2021-03-16	Кодиак Сайенсиз Инк.	Антитела и их конъюгаты
CN109071645A (zh)	2016-01-08	2018-12-21	供石公司	抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
ES2880731T3 (es)	2016-01-08	2021-11-25	Altrubio Inc	Anticuerpos anti-PSGL-1 tetravalentes y usos de los mismos
WO2017125897A1 (en)	2016-01-21	2017-07-27	Novartis Ag	Multispecific molecules targeting cll-1
ES2904593T3 (es)	2016-01-21	2022-04-05	Pfizer	Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
GB201602413D0 (en)	2016-02-10	2016-03-23	Nascient Ltd	Method
TWI756204B (zh)	2016-02-12	2022-03-01	比利時商楊森製藥公司	抗ｖｉｓｔａ抗體及片段、其用途及鑑定其之方法
AR108034A1 (es)	2016-02-17	2018-07-11	Macrogenics Inc	Moléculas de unión a ror1, y métodos de uso de las mismas
CN109476731A (zh)	2016-02-29	2019-03-15	基础医药有限公司	治疗癌症的方法
WO2017149513A1 (en)	2016-03-03	2017-09-08	Prothena Biosciences Limited	Anti-mcam antibodies and associated methods of use
EA201891925A1 (ru)	2016-03-04	2019-02-28	Зэ Рокфеллер Юниверсити	Антитела к cd40 с усиленной агонистической активностью
AU2017228470A1 (en)	2016-03-04	2018-08-30	Bristol-Myers Squibb Company	Combination therapy with anti-CD73 antibodies
CA3016170A1 (en)	2016-03-08	2017-09-14	Academia Sinica	Methods for modular synthesis of n-glycans and arrays thereof
US10287328B2 (en)	2016-03-08	2019-05-14	KeMyth Biotech Co., Ltd.	Treatment of diabetes, toll-like receptor 4 modulators and methods for using the same
WO2017153955A1 (en)	2016-03-09	2017-09-14	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en)	2016-03-09	2017-09-14	Prothena Biosciences Limited	Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
MX2018010771A (es)	2016-03-10	2019-05-15	Viela Bio Inc	Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
WO2017156500A1 (en)	2016-03-11	2017-09-14	Scholar Rock, Inc.	Tgfb1-binding immunoglobulins and use thereof
WO2017160599A1 (en)	2016-03-14	2017-09-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Use of cd300b antagonists to treat sepsis and septic shock
ES2831852T3 (es)	2016-03-17	2021-06-09	Univ Oslo Hf	Proteínas de fusión que se dirigen a macrófagos asociados a tumores para tratar el cáncer
WO2017165464A1 (en)	2016-03-21	2017-09-28	Elstar Therapeutics, Inc.	Multispecific and multifunctional molecules and uses thereof
US10745487B2 (en)	2016-03-22	2020-08-18	Bionomics Limited	Method of treating cancer by administering an anti-LGR5 monoclonal antibody
US20170274076A1 (en)	2016-03-25	2017-09-28	Visterra, Inc.	Formulations of antibody molecules to dengue virus
CA3019560A1 (en)	2016-03-29	2017-10-05	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
US10980894B2 (en)	2016-03-29	2021-04-20	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
WO2017172771A2 (en)	2016-03-29	2017-10-05	Janssen Biotech, Inc.	Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017175058A1 (en)	2016-04-07	2017-10-12	Janssen Pharmaceutica Nv	Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CN109414489B (zh)	2016-04-08	2022-08-16	埃缇健康公司D/B/A泽尔拜尔	网蛋白-1结合抗体及其用途
SG11201808633RA (en)	2016-04-15	2018-10-30	Immunext Inc	Anti-human vista antibodies and use thereof
US20170298119A1 (en)	2016-04-15	2017-10-19	Visterra, Inc.	Antibody molecules to zika virus and uses thereof
CN109069633A (zh)	2016-04-15	2018-12-21	宏观基因有限公司	新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
MA44723A (fr)	2016-04-18	2019-02-27	Celldex Therapeutics Inc	Anticorps agonistes se liant au cd40 humain et leurs utilisations
WO2017182561A1 (en)	2016-04-21	2017-10-26	Sphingotec Therapeutics Gmbh	Methods for determining dpp3 and therapeutic methods
KR20230110820A (ko)	2016-04-22	2023-07-25	오비아이 파머 인코퍼레이티드	글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
KR102471787B1 (ko)	2016-05-02	2022-11-29	프로테나 바이오사이언시즈 리미티드	타우 인식 항체
JP7194985B2 (ja)	2016-05-02	2022-12-23	プロセナバイオサイエンシーズリミテッド	タウ認識抗体
WO2017196663A1 (en)	2016-05-09	2017-11-16	Bristol-Myers Squibb Company	Tl1a antibodies and uses thereof
KR102419412B1 (ko)	2016-05-18	2022-07-12	베링거 인겔하임 인터내셔날 게엠베하	암 치료용 항-pd1 및 항-lag3 항체
WO2017201225A1 (en)	2016-05-19	2017-11-23	Poc Medical Systems, Inc.	Cancer screening via detection and quantification of multiple biomarkers
CN116333130A (zh)	2016-05-24	2023-06-27	英斯梅德股份有限公司	抗体及其制备方法
KR102366813B1 (ko)	2016-05-27	2022-02-24	아게누스 인코포레이티드	항-tim-3 항체 및 이의 사용 방법
WO2017208210A1 (en)	2016-06-03	2017-12-07	Prothena Biosciences Limited	Anti-mcam antibodies and associated methods of use
WO2017214170A2 (en)	2016-06-06	2017-12-14	City Of Hope	Baff-r antibodies and uses thereof
CA3026640A1 (en)	2016-06-06	2017-12-14	City Of Hope	Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
AU2017276706A1 (en)	2016-06-07	2019-01-03	Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft	Chimeric antigen receptor and CAR-T cells that bind BCMA
CN110381988A (zh)	2016-06-15	2019-10-25	诺华股份有限公司	使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
WO2018005559A1 (en)	2016-06-27	2018-01-04	Juno Therapeutics, Inc.	Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (fr)	2016-06-27	2019-05-01	Juno Therapeutics Inc	Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
MA45493A (fr)	2016-06-27	2019-05-01	Aicuris Anti Infective Cures Gmbh	Inhibiteurs d'entrée de hcmv.
EP3474895A1 (de)	2016-06-28	2019-05-01	UMC Utrecht Holding B.V.	Behandlung von ige-vermittelten erkrankungen mit spezifisch cd38 bindenden antikörpern
EP3478716A2 (de)	2016-07-02	2019-05-08	Prothena Biosciences Limited	Anti-transthyretin-antikörper
JP7016470B2 (ja)	2016-07-02	2022-02-07	プロセナバイオサイエンシーズリミテッド	抗トランスサイレチン抗体
EP3478714A2 (de)	2016-07-02	2019-05-08	Prothena Biosciences Limited	Anti-transthyretin-antikörper
AU2017292172A1 (en)	2016-07-06	2019-01-03	Prothena Biosciences Limited	Assay for detecting total and S129 phosphorylated alpha-synuclein
RU2019103403A (ru)	2016-07-08	2020-08-10	Сфинготек Гмбх	Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью
AU2017292184A1 (en)	2016-07-08	2019-02-07	Staten Biotechnology B.V.	Anti-Apoc3 antibodies and methods of use thereof
JP7149257B2 (ja)	2016-07-13	2022-10-06	バイオジェン・エムエイ・インコーポレイテッド	Ｌｉｎｇｏ－１アンタゴニストの投与計画及び脱髄障害の処置のための使用
PE20190418A1 (es)	2016-07-14	2019-03-19	Bristol Myers Squibb Co	Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
JP2019524721A (ja)	2016-07-15	2019-09-05	ポセイダセラピューティクス，インコーポレイテッド	キメラ抗原受容体および使用方法
CN110461315A (zh)	2016-07-15	2019-11-15	诺华股份有限公司	使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
EP3484927A1 (de)	2016-07-15	2019-05-22	Poseida Therapeutics, Inc.	Für muc1 spezifische chimäre antigenrezeptoren (autos) und verfahren zu deren verwendung
JP2019521171A (ja)	2016-07-20	2019-07-25	ヒブリジェニクス・エスアー	抗ｃｄ３８薬剤とのイネカルシトールの組み合わせ、及び癌を治療するためのその使用
MX2019000903A (es)	2016-07-22	2019-05-15	Amgen Inc	Metodos para purificar proteinas que contienen fc.
WO2018022479A1 (en)	2016-07-25	2018-02-01	Biogen Ma Inc.	Anti-hspa5 (grp78) antibodies and uses thereof
EP3490592A4 (de)	2016-07-27	2020-03-25	OBI Pharma, Inc.	Immunogene/therapeutische glycanzusammensetzungen und verwendungen davon
WO2018023121A1 (en)	2016-07-29	2018-02-01	Obi Pharma, Inc.	Human antibodies, pharmaceutical compositions and methods
EP3490600A1 (de)	2016-08-01	2019-06-05	Xoma (Us) Llc	Parathormon-rezeptor 1 (pth1r)-antikörper und verwendungen davon
RU2019104889A (ru)	2016-08-02	2020-09-04	Вистерра, Инк.	Генно-инженерные полипептиды и их применение
KR20230095129A (ko)	2016-08-03	2023-06-28	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	아데노신 핵염기 편집제 및 그의 용도
EP3494141A4 (de)	2016-08-03	2020-04-08	Bio-Techne Corporation	Identifizierung von vsig3/vista als ein neuartiger immuncheckpoint und verwendung davon zur immuntherapie
CN109804066A (zh)	2016-08-09	2019-05-24	哈佛大学的校长及成员们	可编程cas9-重组酶融合蛋白及其用途
CN109790201A (zh)	2016-08-12	2019-05-21	百时美施贵宝公司	纯化蛋白质的方法
US10669344B2 (en)	2016-08-12	2020-06-02	Janssen Biotech, Inc.	Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
MA45941A (fr)	2016-08-12	2019-06-19	Janssen Biotech Inc	Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation
JP7213549B2 (ja)	2016-08-22	2023-01-27	シーエイチオーファーマインコーポレイテッド	抗体、結合性断片、および使用の方法
US11542509B2 (en)	2016-08-24	2023-01-03	President And Fellows Of Harvard College	Incorporation of unnatural amino acids into proteins using base editing
US10981976B2 (en)	2016-08-31	2021-04-20	University Of Rochester	Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
JP2019534858A (ja)	2016-09-09	2019-12-05	ジェネンテック，インコーポレイテッド	Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤
EP3515936A1 (de)	2016-09-23	2019-07-31	Elstar Therapeutics, Inc.	Multispezifische antikörpermoleküle mit lambda- und kappa- leichtketten
CA3038679A1 (en)	2016-09-28	2018-04-05	Xoma (Us) Llc	Antibodies that bind interleukin-2 and uses thereof
GB201616596D0 (en)	2016-09-29	2016-11-16	Nascient Limited	Epitope and antibodies
CA3037961A1 (en)	2016-09-30	2018-04-05	Janssen Biotech, Inc.	Safe and effective method of treating psoriasis with anti-il23 specific antibody
MX2019003473A (es)	2016-10-03	2019-10-15	Abbott Lab	Metodos mejorados para evaluar el estado de ubiquitin carboxi-terminal hidrolasa l1 (uch-l1) en muestras de pacientes.
US10525083B2 (en)	2016-10-07	2020-01-07	Novartis Ag	Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
IL265800B2 (en)	2016-10-11	2023-10-01	Agenus Inc	Anti-LAG-3 antibodies and methods of using them
CA3040189A1 (en)	2016-10-13	2018-04-19	Massachusetts Institute Of Technology	Antibodies that bind zika virus envelope protein and uses thereof
WO2018071576A1 (en)	2016-10-14	2018-04-19	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Treatment of tumors by inhibition of cd300f
KR20240007715A (ko)	2016-10-14	2024-01-16	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	핵염기 에디터의 aav 전달
WO2018075408A1 (en)	2016-10-17	2018-04-26	Alexion Pharmaceuticals, Inc.	Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
EP3529268A1 (de)	2016-10-19	2019-08-28	The Scripps Research Institute	Chimäre antigenrezeptor-effektorzellen-switches mit humanisierten targeting-einheiten und/oder optimierten chimären antigen-rezeptor-interaktionsdomänen und verwendungen davon
WO2018085359A1 (en)	2016-11-02	2018-05-11	Immunogen, Inc.	Combination treatment with antibody-drug conjugates and parp inhibitors
US11779604B2 (en)	2016-11-03	2023-10-10	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses and methods
AU2017353939A1 (en)	2016-11-07	2019-06-06	Neuracle Science Co., Ltd.	Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
US20180125920A1 (en)	2016-11-09	2018-05-10	The University Of British Columbia	Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CN109996809A (zh)	2016-11-14	2019-07-09	诺华股份有限公司	与促融合蛋白minion相关的组合物、方法和治疗用途
MX2019005552A (es)	2016-11-14	2019-08-12	Amgen Inc	Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.
CN116143678A (zh)	2016-11-14	2023-05-23	杭州多禧生物科技有限公司	偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
KR20190078648A (ko)	2016-11-16	2019-07-04	얀센 바이오테크 인코포레이티드	항-il23 특이적 항체로 건선을 치료하는 방법
WO2018094143A1 (en)	2016-11-17	2018-05-24	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
EP3541414A4 (de)	2016-11-21	2020-11-11	OBI Pharma, Inc.	Konjugierte biologische moleküle, pharmazeutische zusammensetzungen und verfahren
WO2018102594A1 (en)	2016-12-01	2018-06-07	Alexion Pharmaceuticals, Inc.	Methods of treating solid tumors with anti-cd200 antibodies
US11198723B2 (en)	2016-12-05	2021-12-14	The Administrators Of The Tulane Educational Fund	Arenavirus monoclonal antibodies and uses
MX2019006527A (es)	2016-12-07	2019-08-01	Ra Pharmaceuticals Inc	Moduladores de la actividad del complemento.
KR102603681B1 (ko)	2016-12-07	2023-11-17	아게누스 인코포레이티드	항체 및 이의 사용방법
MA50949B1 (fr)	2016-12-07	2023-12-29	Memorial Sloan Kettering Cancer Center	Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3339324A1 (de)	2016-12-22	2018-06-27	sphingotec GmbH	Anti-adrenomedullin (adm)-antikörper oder anti-adm antikörperfragment oder anti-adm-nicht-ig-gerüst zur verwendung in einer intervention und therapie von verstopfung bei einem darauf angewiesenen patienten
US20200299372A1 (en)	2016-12-16	2020-09-24	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
GB201621635D0 (en)	2016-12-19	2017-02-01	Ucb Biopharma Sprl	Crystal structure
EP3360898A1 (de)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
HUE058664T2 (hu)	2016-12-23	2022-09-28	Immunogen Inc	ADAM9-et célzó immunkonjugátumok és eljárások azok felhasználására
WO2018119359A1 (en)	2016-12-23	2018-06-28	President And Fellows Of Harvard College	Editing of ccr5 receptor gene to protect against hiv infection
JP7128819B2 (ja)	2016-12-23	2022-08-31	マクロジェニクス，インコーポレーテッド	Ａｄａｍ９結合分子、およびその使用方法
AU2017382367A1 (en)	2016-12-23	2019-06-13	Visterra, Inc.	Binding polypeptides and methods of making the same
WO2018129395A1 (en)	2017-01-06	2018-07-12	Scholar Rock, Inc.	Methods for treating metabolic diseases by inhibiting myostatin activation
JP7157744B2 (ja)	2017-01-06	2022-10-20	スカラーロックインコーポレイテッド	アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用
EP4218817A3 (de)	2017-01-06	2023-09-06	Scholar Rock, Inc.	Verfahren zur behandlung von stoffwechselerkrankungen durch hemmung der myostatinaktivierung
TW201833140A (zh)	2017-01-09	2018-09-16	美商莫瑞麥克製藥公司	抗fgfr抗體及使用方法
WO2018130660A1 (en)	2017-01-13	2018-07-19	Academia Sinica	Reloadable hydrogel system for treating myocardial infarction
US11382983B2 (en)	2017-01-13	2022-07-12	Academia Sinica	Reloadable hydrogel system for treating brain conditions
US11890319B2 (en)	2017-01-18	2024-02-06	Visterra, Inc.	Antibody molecule-drug conjugates and uses thereof
EP3573658A4 (de)	2017-01-30	2021-07-21	Janssen Biotech, Inc.	Anti-tnf-antikörper, zusammensetzungen und verfahren zur behandlung von aktiver psoriatischer arthritis
US10240205B2 (en)	2017-02-03	2019-03-26	Population Bio, Inc.	Methods for assessing risk of developing a viral disease using a genetic test
JP2020506947A (ja)	2017-02-07	2020-03-05	ヤンセンバイオテツク，インコーポレーテツド	活動性強直性脊椎炎を治療するための抗ｔｎｆ抗体、組成物、及び方法
KR102572663B1 (ko)	2017-02-08	2023-09-01	노파르티스 아게	Fgf21 모방 항체 및 이의 용도
US20200291089A1 (en)	2017-02-16	2020-09-17	Elstar Therapeutics, Inc.	Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018152496A1 (en)	2017-02-17	2018-08-23	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Compositions and methods for the diagnosis and treatment of zika virus infection
SG11201906947SA (en)	2017-02-17	2019-08-27	Bristol Myers Squibb Co	Antibodies to alpha-synuclein and uses thereof
KR102602199B1 (ko)	2017-02-27	2023-11-15	리제너론 파아마슈티컬스, 인크.	신장 및 간 장애의 인간화 모델
EP3589650A1 (de)	2017-03-02	2020-01-08	Novartis AG	Manipulierte heterodimere proteine
US11198735B2 (en)	2017-03-03	2021-12-14	Rinat Neuroscience Corp.	Anti-GITR antibodies and methods of use thereof
EP3589319A4 (de)	2017-03-03	2021-07-14	Seagen Inc.	Glycaninteragierende verbindungen und verfahren zur verwendung
US11898179B2 (en)	2017-03-09	2024-02-13	President And Fellows Of Harvard College	Suppression of pain by gene editing
WO2018165629A1 (en)	2017-03-10	2018-09-13	President And Fellows Of Harvard College	Cytosine to guanine base editor
SG11201908418RA (en)	2017-03-13	2019-10-30	Poseida Therapeutics Inc	Compositions and methods for selective elimination and replacement of hematopoietic stem cells
CA3052513A1 (en)	2017-03-23	2018-09-27	Abbott Laboratories	Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
IL269458B2 (en)	2017-03-23	2024-02-01	Harvard College	Nucleic base editors that include nucleic acid programmable DNA binding proteins
US20200132673A1 (en)	2017-03-24	2020-04-30	The Regents Of The University Of California	Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
WO2018175460A1 (en)	2017-03-24	2018-09-27	Novartis Ag	Methods for preventing and treating heart disease
CN117024534A (zh)	2017-03-30	2023-11-10	约翰霍普金斯大学	用于纯化生物大分子的超分子高亲和力蛋白结合系统
JP2020515637A (ja)	2017-04-03	2020-05-28	オンコロジー、インコーポレイテッド	免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法
TWI788340B (zh)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	抗icos促效劑抗體及其用途
JP2020512825A (ja)	2017-04-12	2020-04-30	ファイザー・インク	条件的親和性を有する抗体およびその使用の方法
TW201841942A (zh)	2017-04-13	2018-12-01	美商艾吉納斯公司	抗ｃｄ１３７抗體及其使用方法
CA3059938A1 (en)	2017-04-14	2018-10-18	Kodiak Sciences Inc.	Complement factor d antagonist antibodies and conjugates thereof
JP7344797B2 (ja)	2017-04-15	2023-09-14	アボット・ラボラトリーズ	早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
WO2018195283A1 (en)	2017-04-19	2018-10-25	Elstar Therapeutics, Inc.	Multispecific molecules and uses thereof
EP3624820A1 (de)	2017-04-21	2020-03-25	H. Hoffnabb-La Roche Ag	Verwendung von klk5-antagonisten zur behandlung einer krankheit
EP3612560A1 (de)	2017-04-21	2020-02-26	Staten Biotechnology B.V.	Anti-apoc3-antikörper und verfahren zur verwendung davon
EP4230649A3 (de)	2017-04-25	2023-10-25	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Antikörper und verfahren zur diagnose und behandlung von epstein barr-virusinfektion
CA3059769A1 (en)	2017-04-28	2018-11-01	Elstar Therapeutics, Inc.	Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
CN110603449A (zh)	2017-04-28	2019-12-20	雅培实验室	用同一人受试者的至少两种样品的早期生物标记物帮助超急性诊断确定创伤性脑损伤的方法
MA50957A (fr)	2017-05-01	2020-10-14	Agenus Inc	Anticorps anti-tigit et leurs méthodes d'utilisation
US10865238B1 (en)	2017-05-05	2020-12-15	Duke University	Complement factor H antibodies
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها
US11560566B2 (en)	2017-05-12	2023-01-24	President And Fellows Of Harvard College	Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2018215535A1 (en)	2017-05-23	2018-11-29	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Novel cd73 antibody, preparation and uses thereof
CN110651190A (zh)	2017-05-25	2020-01-03	雅培实验室	用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
AU2018275235A1 (en)	2017-05-30	2019-10-31	Abbott Laboratories	Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
CN111051346A (zh)	2017-05-31	2020-04-21	斯特库伯株式会社	使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
WO2018222901A1 (en)	2017-05-31	2018-12-06	Elstar Therapeutics, Inc.	Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
CA3065301A1 (en)	2017-05-31	2018-12-06	Stcube & Co., Inc.	Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CA3006798A1 (en)	2017-06-02	2018-12-02	Pfizer Inc.	Antibodies specific for flt3 and their uses
CA3065171A1 (en)	2017-06-05	2018-12-13	Janssen Biotech, Inc.	Engineered multispecific antibodies and other multimeric proteins with asymmetrical ch2-ch3 region mutations
US11542331B2 (en)	2017-06-06	2023-01-03	Stcube & Co., Inc.	Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
KR20200015717A (ko)	2017-06-09	2020-02-12	프로비던스 헬스 앤드 서비시즈 - 오레곤	암 치료를 위한 인간 종양 반응성 t 세포의 확인을 위한 cd39 및 cd103의 활용
GB201709379D0 (en)	2017-06-13	2017-07-26	Univ Leuven Kath	Humanised ADAMTS13 binding antibodies
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
US20190062428A1 (en)	2017-06-19	2019-02-28	Surface Oncology, Inc.	Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
EP3641752A4 (de)	2017-06-22	2021-03-17	Moonshot Pharma LLC	Verfahren zur behandlung von krebs mit zusammensetzungen mit amlexanox und immunmodulatoren
US20200172628A1 (en)	2017-06-22	2020-06-04	Novartis Ag	Antibody molecules to cd73 and uses thereof
WO2019005817A2 (en)	2017-06-26	2019-01-03	Bio-Techne Corporation	HYBRIDOMIC CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND METHODS OF MAKING AND USING SAME
WO2019006007A1 (en)	2017-06-27	2019-01-03	Novartis Ag	POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
JP2020525421A (ja)	2017-06-28	2020-08-27	ノバルティスアーゲー	尿失禁を予防及び治療するための方法
EP3649474A1 (de)	2017-07-03	2020-05-13	Abbott Laboratories	Verbesserte verfahren zur messung von ubiquitin-carboxy-terminalen hydrolase-l1-konzentrationen in blut
US11447809B2 (en)	2017-07-06	2022-09-20	President And Fellows Of Harvard College	Evolution of tRNA synthetases
SG11201913137VA (en)	2017-07-11	2020-01-30	Compass Therapeutics Llc	Agonist antibodies that bind human cd137 and uses thereof
PE20200616A1 (es)	2017-07-14	2020-03-11	Pfizer	ANTICUERPOS CONTRA MAdCAM
CA3070085A1 (en)	2017-07-18	2019-01-24	Promis Neurosciences Inc.	Antibodies to amyloid beta
CN111094334A (zh)	2017-07-19	2020-05-01	美国卫生与公众服务部	用于诊断和治疗乙肝病毒感染的抗体和方法
EP3431496A1 (de)	2017-07-19	2019-01-23	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
CN111163798A (zh)	2017-07-20	2020-05-15	诺华股份有限公司	用于抗lag-3抗体的给药方案及其用途
WO2019016784A1 (en)	2017-07-21	2019-01-24	Universidade De Coimbra	ANTI-NUCLEOLIN ANTIBODIES
US11732274B2 (en)	2017-07-28	2023-08-22	President And Fellows Of Harvard College	Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
EP3658583A1 (de)	2017-07-28	2020-06-03	Scholar Rock, Inc.	Ltbp-komplex-spezifische inhibitoren von tgf-beta 1 und verwendungen davon
WO2019035938A1 (en)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3684811A2 (de)	2017-08-17	2020-07-29	Massachusetts Institute of Technology	Multispezifitätsbinder von cxc-chemokinen und ihre verwendung
KR20200038298A (ko)	2017-08-18	2020-04-10	더 존스 홉킨스 유니버시티	단백질 정제를 위한 초분자 필라멘트 조립체
US11643468B2 (en)	2017-08-23	2023-05-09	Max-Delbrück-Centrum für Molekulare Medizin in der Hemlholtz-Gemeinschaft	Chimeric antigen receptors and CAR-T cells that bind CXCR5 and methods of use thereof to treat medical disorders
BR112020003533A2 (pt)	2017-08-25	2020-11-17	Five Prime Therapeutics, Inc.	anticorpos b7-h4 e métodos de uso dos mesmos
CA3074128A1 (en)	2017-08-28	2019-03-07	Shanghai Yile Biotechnology Co., Ltd.	Polypeptide and antibody bound to polypeptide
EP3676376A2 (de)	2017-08-30	2020-07-08	President and Fellows of Harvard College	Hocheffiziente baseneditoren mit gam
EP3679145A2 (de)	2017-09-08	2020-07-15	Poseida Therapeutics, Inc.	Zusammensetzungen und verfahren für durch chimären ligandenrezeptor (clr) vermittelte bedingte genexpression
US11624130B2 (en)	2017-09-18	2023-04-11	President And Fellows Of Harvard College	Continuous evolution for stabilized proteins
CN110036119B (zh)	2017-09-20	2024-01-23	丰宥科技股份有限公司	卵巢癌生物标记及其应用
EP3684944A4 (de)	2017-09-21	2021-05-26	Becton, Dickinson and Company	Kit zur probenahme von gefährlichen schadstoffen und schnelltest
TW201922780A (zh)	2017-09-25	2019-06-16	美商健生生物科技公司	以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019057992A2 (en)	2017-09-25	2019-03-28	Adrenomed Ag	ANTI-ADRENOMEDULIN (ADM) BINDER FOR USE IN TREATING OR PREVENTING THE SYMPTOMS OF A DISEASE
US11761963B2 (en)	2017-09-27	2023-09-19	Alexion Pharmaceuticals, Inc.	Biomarker signature for predicting tumor response to anti-CD200 therapy
BR112020005419A2 (pt)	2017-10-02	2020-09-29	Visterra, Inc.	moléculas de anticorpo para cd138 e seus usos
ES2759622T3 (es)	2017-10-02	2020-05-11	Certest Biotec S L	Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
EP3692370A2 (de)	2017-10-04	2020-08-12	OPKO Pharmaceuticals, LLC	Artikel und verfahren zur personalisierten krebstherapie
US20200317783A1 (en)	2017-10-06	2020-10-08	Ono Pharmaceutical Co., Ltd.	Bispecific antibody
CN111630069A (zh)	2017-10-13	2020-09-04	勃林格殷格翰国际有限公司	针对Thomsen-nouvelle(Tn)抗原的人抗体
US11795443B2 (en)	2017-10-16	2023-10-24	The Broad Institute, Inc.	Uses of adenosine base editors
US20220268761A1 (en)	2017-10-18	2022-08-25	Adrenomed Ag	Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
SG11202003486UA (en)	2017-10-19	2020-05-28	Debiopharm Int Sa	Combination product for the treatment of cancer
US20200331975A1 (en)	2017-10-20	2020-10-22	Institut Curie	Dap10/12 based cars adapted for rush
AU2018356441A1 (en)	2017-10-25	2020-04-16	4TEEN4 Pharmaceuticals GmbH	DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
EP3700933A1 (de)	2017-10-25	2020-09-02	Novartis AG	Gegen cd32b gerichtete antikörper und verfahren zur verwendung davon
WO2019089753A2 (en)	2017-10-31	2019-05-09	Compass Therapeutics Llc	Cd137 antibodies and pd-1 antagonists and uses thereof
MA50514A (fr)	2017-10-31	2020-09-09	Janssen Biotech Inc	Méthodes de traitement du myélome multiple à haut risque
US20190160089A1 (en)	2017-10-31	2019-05-30	Immunogen, Inc.	Combination treatment with antibody-drug conjugates and cytarabine
BR112020008514A2 (pt)	2017-10-31	2020-10-20	Staten Biotechnology B.V.	anticorpos anti-apoc3 e métodos de uso dos mesmos
KR20200074201A (ko)	2017-11-02	2020-06-24	바이엘 악티엔게젤샤프트	Alk-1 및 bmpr-2에 결합하는 이중특이적 항체
JP2021502125A (ja)	2017-11-09	2021-01-28	ピンテオンセラピューティクスインコーポレイテッド	ヒト化コンホメーション特異的リン酸化タウ抗体の作製および使用のための方法および組成物
WO2019099838A1 (en)	2017-11-16	2019-05-23	Novartis Ag	Combination therapies
EP3713961A2 (de)	2017-11-20	2020-09-30	Compass Therapeutics LLC	Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung
CN111727075B (zh)	2017-11-27	2024-04-05	普渡制药公司	靶向人组织因子的人源化抗体
EP3720881A1 (de)	2017-12-08	2020-10-14	Elstar Therapeutics, Inc.	Multispezifische moleküle und verwendungen davon
WO2019113525A2 (en)	2017-12-09	2019-06-13	Abbott Laboratories	Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
WO2019112860A1 (en)	2017-12-09	2019-06-13	Abbott Laboratories	Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
US11795226B2 (en)	2017-12-12	2023-10-24	Macrogenics, Inc.	Bispecific CD16-binding molecules and their use in the treatment of disease
US20210087267A1 (en)	2017-12-20	2021-03-25	Alexion Pharmaceuticals, Inc.	Liquid formulations of anti-cd200 antibodies
US11802154B2 (en)	2017-12-20	2023-10-31	Alexion Pharmaceuticals, Inc.	Humanized anti-CD200 antibodies and uses thereof
US20190211098A1 (en)	2017-12-22	2019-07-11	Genentech, Inc.	Use of pilra binding agents for treatment of a disease
WO2019140216A1 (en)	2018-01-12	2019-07-18	Amgen Inc.	Pac1 antibodies and uses thereof
CN111886255A (zh)	2018-01-12	2020-11-03	百时美施贵宝公司	抗tim3抗体及其用途
SG11202006883QA (en)	2018-02-01	2020-08-28	Pfizer	Chimeric antigen receptors targeting cd70
AU2019215075A1 (en)	2018-02-01	2020-08-20	Pfizer Inc.	Antibodies specific for CD70 and their uses
EP3746477A1 (de)	2018-02-02	2020-12-09	Bio-Techne Corporation	Verbindungen, die die wechselwirkung von vista und vsig3 modulieren, und verfahren zur herstellung und verwendung
WO2019150309A1 (en)	2018-02-02	2019-08-08	Hammack Scott	Modulators of gpr68 and uses thereof for treating and preventing diseases
WO2019154900A1 (en)	2018-02-08	2019-08-15	Sphingotec Gmbh	Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
TWI804572B (zh)	2018-02-09	2023-06-11	日商小野藥品工業股份有限公司	雙特異性抗體
GB201802486D0 (en)	2018-02-15	2018-04-04	Ucb Biopharma Sprl	Methods
CN111787949A (zh)	2018-02-15	2020-10-16	宏观基因有限公司	变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
AU2019228600A1 (en)	2018-03-02	2020-09-24	Five Prime Therapeutics, Inc.	B7-H4 antibodies and methods of use thereof
KR20200129125A (ko)	2018-03-05	2020-11-17	얀센 바이오테크 인코포레이티드	항-il23 특이적 항체로 크론병을 치료하는 방법
WO2019177690A1 (en)	2018-03-12	2019-09-19	Zoetis Services Llc	Anti-ngf antibodies and methods thereof
NZ782442A (en)	2018-03-14	2022-01-28	Surface Oncology Inc	Antibodies that bind cd39 and uses thereof
US20210238280A1 (en)	2018-03-14	2021-08-05	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
EP3765516A2 (de)	2018-03-14	2021-01-20	Elstar Therapeutics, Inc.	Multifunktionale moleküle und verwendungen davon
US11332524B2 (en)	2018-03-22	2022-05-17	Surface Oncology, Inc.	Anti-IL-27 antibodies and uses thereof
TW202003565A (zh)	2018-03-23	2020-01-16	美商必治妥美雅史谷比公司	抗mica及/或micb抗體及其用途
WO2019180272A1 (en)	2018-03-23	2019-09-26	Fundación Instituto De Investigación Sanitaria De Santiago De Compostela	Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
ES2950740T3 (es)	2018-03-26	2023-10-13	Glycanostics S R O	Medios y métodos para el glicoperfilado de una proteína
US11913951B2 (en)	2018-03-26	2024-02-27	Alexion Pharmaceuticals, Inc.	High throughput method for measuring the protease activity of complement C3 convertase
WO2019191416A1 (en)	2018-03-29	2019-10-03	Bristol-Myers Squibb Company	Methods of purifying monomeric monoclonal antibodies
JOP20200240A1 (ar)	2018-04-02	2020-09-27	Bristol Myers Squibb Co	أجسام مضادة ضد- trem-1 واستخداماتها
WO2019200357A1 (en)	2018-04-12	2019-10-17	Surface Oncology, Inc.	Biomarker for cd47 targeting therapeutics and uses therefor
US20210147547A1 (en)	2018-04-13	2021-05-20	Novartis Ag	Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
SG11202009626QA (en)	2018-04-20	2020-10-29	Medizinische Hochschule Hannover	Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
US20210230255A1 (en)	2018-04-27	2021-07-29	Fondazione Ebri Rita Levi-Montalcini	Antibody directed against a tau-derived neurotoxic peptide and uses thereof
US20190345245A1 (en)	2018-05-11	2019-11-14	Janssen Biotech, Inc.	Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2019222130A1 (en)	2018-05-15	2019-11-21	Immunogen, Inc.	Combination treatment with antibody-drug conjugates and flt3 inhibitors
US20200190205A1 (en)	2018-05-16	2020-06-18	Janssen Biotech, Inc.	Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
EP3569614A1 (de)	2018-05-18	2019-11-20	Julius-Maximilians-Universität Würzburg	Verbindungen und verfahren zur immobilisierung von myostatin-inhibitoren auf der extrazellulären matrix durch transglutaminase
EP3569618A1 (de)	2018-05-19	2019-11-20	Boehringer Ingelheim International GmbH	Antagonisierender cd73-antikörper
US20200109195A1 (en)	2018-05-21	2020-04-09	Compass Therapeutics Llc	Compositions and methods for enhancing the killing of target cells by nk cells
WO2019226658A1 (en)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Multispecific antigen-binding compositions and methods of use
EP3797121A1 (de)	2018-05-23	2021-03-31	Pfizer Inc	Cd3-spezifische antikörper und verwendungen davon
CA3100829A1 (en)	2018-05-23	2019-11-28	Pfizer Inc.	Antibodies specific for gucy2c and uses thereof
MX2020012587A (es)	2018-05-24	2021-04-28	Janssen Biotech Inc	Anticuerpos anti-cd3 y usos de estos.
AU2019274652A1 (en)	2018-05-24	2020-11-26	Janssen Biotech, Inc.	Monospecific and multispecific anti-TMEFF2 antibodies and there uses
BR112020023872A2 (pt)	2018-05-24	2021-02-17	Janssen Biotech, Inc.	agentes de ligação de psma e seus usos
AR126019A1 (es)	2018-05-30	2023-09-06	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019241649A1 (en)	2018-06-14	2019-12-19	President And Fellows Of Harvard College	Evolution of cytidine deaminases
AU2019289176A1 (en)	2018-06-18	2020-12-24	Oxford University Innovation Limited	Gremlin-1 antagonist for the prevention and treatment of cancer
US20210238268A1 (en)	2018-06-19	2021-08-05	Atarga, Llc	Antibody molecules to complement component 5 and uses thereof
TW202016144A (zh)	2018-06-21	2020-05-01	日商第一三共股份有限公司	包括cd3抗原結合片段之組成物及其用途
EP3586865A1 (de)	2018-06-21	2020-01-01	Charité - Universitätsmedizin Berlin	Ergänzende anaphylatoxinbindemittel und deren verwendung in der behandlung einer person mit okularer wunde und/oder fibrose
BR112020025346A2 (pt)	2018-06-26	2021-05-25	Immunogen, Inc.	imunoconjugados que alvejam adam9 e métodos de uso dos mesmos
US11203645B2 (en)	2018-06-27	2021-12-21	Obi Pharma, Inc.	Glycosynthase variants for glycoprotein engineering and methods of use
WO2020010250A2 (en)	2018-07-03	2020-01-09	Elstar Therapeutics, Inc.	Anti-tcr antibody molecules and uses thereof
WO2020008083A1 (es)	2018-07-05	2020-01-09	Consejo Superior De Investigaciones Científicas	Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
JP2021531254A (ja)	2018-07-11	2021-11-18	スカラーロックインコーポレイテッドScholar Rock, Inc.	高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用
PT3677278T (pt)	2018-07-11	2022-02-03	Scholar Rock Inc	Inibidores seletivos da isoforma tgfbeta1 e sua utilização
EP3820896A1 (de)	2018-07-11	2021-05-19	Scholar Rock, Inc.	Tgfbeta1-inhibitoren und verwendung davon
WO2020016838A2 (en)	2018-07-18	2020-01-23	Janssen Biotech, Inc.	Sustained response predictors after treatment with anti-il23 specific antibody
WO2020016459A1 (en)	2018-07-20	2020-01-23	Pierre Fabre Medicament	Receptor for vista
CA3106833A1 (en)	2018-07-20	2020-01-23	Aicuris Gmbh & Co. Kg	Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
WO2020021465A1 (en)	2018-07-25	2020-01-30	Advanced Accelerator Applications (Italy) S.R.L.	Method of treatment of neuroendocrine tumors
SI3625368T1 (sl)	2018-08-08	2023-04-28	Pml Screening, Llc	Postopki z genetskim testiranjem za oceno tveganja za razvoj progresivne multifokalne levkoencefalopatije, ki jo povzroča virus John Cunningham
US20210388089A1 (en)	2018-08-09	2021-12-16	Compass Therapeutics Llc	Antigen binding agents that bind cd277 and uses thereof
US20210309746A1 (en)	2018-08-09	2021-10-07	Compass Therapeutics Llc	Antibodies that bind cd277 and uses thereof
WO2020033925A2 (en)	2018-08-09	2020-02-13	Compass Therapeutics Llc	Antibodies that bind cd277 and uses thereof
WO2020041360A1 (en)	2018-08-21	2020-02-27	Quidel Corporation	Dbpa antibodies and uses thereof
BR112021003670A2 (pt)	2018-08-28	2021-05-18	Vor Biopharma, Inc.	células-tronco hematopoéticas geneticamente modificadas e seus usos
BR112021003789A2 (pt)	2018-08-30	2021-05-18	Dyax Corp.	método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
AU2019342017A1 (en)	2018-09-18	2021-05-13	Merrimack Pharmaceuticals, Inc.	Anti-TNFR2 antibodies and uses thereof
SI3883606T1 (sl)	2018-09-24	2023-10-30	Janssen Biotech, Inc.	Varen in učinkovit postopek zdravljenja ulceroznega kolitisa s protitelesom proti IL12/IL23
CN113164777A (zh)	2018-09-27	2021-07-23	马伦戈治疗公司	Csf1r/ccr2多特异性抗体
AU2019349874A1 (en)	2018-09-28	2021-04-29	Lyvgen Biopharma Holdings Limited	Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof
EP3856773A1 (de)	2018-09-28	2021-08-04	Kyowa Kirin Co., Ltd.	Il-36-antikörper und verwendungen davon
JP2022504287A (ja)	2018-10-03	2022-01-13	スターテン・バイオテクノロジー・ベー・フェー	ヒト及びカニクイザルａｐｏｃ３に特異的な抗体、並びにその使用の方法
CA3113818A1 (en)	2018-10-05	2020-04-09	Bavarian Nordic A/S	Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
EP3867275A2 (de)	2018-10-17	2021-08-25	Janssen Biotech, Inc.	Verfahren zur subkutanen verabreichung von anti-cd38-antikörpern
SG11202101037QA (en)	2018-10-23	2021-02-25	Regeneron Pharma	Anti-npr1 antibodies and uses thereof
BR112021007765A2 (pt)	2018-10-23	2021-08-03	Scholar Rock, Inc.	inibidores seletivos de rgmc e uso dos mesmos
GB201817309D0 (en)	2018-10-24	2018-12-05	Ucb Biopharma Sprl	Antibodies
GB201817311D0 (en)	2018-10-24	2018-12-05	Ucb Biopharma Sprl	Antibodies
WO2020086408A1 (en)	2018-10-26	2020-04-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	A high-yield perfusion-based transient gene expression bioprocess
GB201818477D0 (en)	2018-11-13	2018-12-26	Emstopa Ltd	Tissue plasminogen activator antibodies and method of use thereof
PE20211284A1 (es)	2018-11-16	2021-07-19	Bristol Myers Squibb Co	Anticuerpos anti-nkg2a y usos de los mismos
SG11202104918PA (en)	2018-11-20	2021-06-29	Bavarian Nordic As	Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
US11548941B2 (en)	2018-11-20	2023-01-10	Janssen Biotech, Inc.	Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
KR20210094609A (ko)	2018-11-28	2021-07-29	포티 세븐, 인코포레이티드	절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
US20220098310A1 (en)	2018-12-06	2022-03-31	Alexion Pharmaceuticals, Inc.	Anti-alk2 antibodies and uses thereof
EP3897722A4 (de)	2018-12-18	2022-09-14	Janssen Biotech, Inc.	Sichere und wirksame methode zur behandlung von lupus mit anti-il12/il23-antikörper
JP2022514903A (ja)	2018-12-20	2022-02-16	協和キリン株式会社	Ｆｎ１４抗体及びその使用
CN113195539A (zh)	2018-12-20	2021-07-30	诺华股份有限公司	药物组合
CA3124103A1 (en)	2018-12-20	2020-06-25	Poseida Therapeutics, Inc.	Nanotransposon compositions and methods of use
JP2022516438A (ja)	2018-12-21	2022-02-28	４ティーン４ファーマシューティカルズゲゼルシャフトミットベシュレンクテルハフツング	アンジオテンシン受容体アゴニストおよび／またはその前駆体による治療のための治療ガイドおよび／または治療モニタリング
TW202043256A (zh)	2019-01-10	2020-12-01	美商健生生物科技公司	前列腺新抗原及其用途
MA54752A (fr)	2019-01-14	2021-11-24	Univ Virginia Patent Foundation	Utilisation d'inhibiteurs d'intégrine pour le traitement ou la prévention d'un trouble immunitaire neurologique et/ou d'une lésion du système nerveux
EP3911676A1 (de)	2019-01-15	2021-11-24	Janssen Biotech, Inc.	Anti-tnf-antikörperzusammensetzungen und verfahren zur behandlung von juveniler idiopathischer arthritis
MX2021008453A (es)	2019-01-16	2021-08-19	Compass Therapeutics Llc	Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
GB201900732D0 (en)	2019-01-18	2019-03-06	Ucb Biopharma Sprl	Antibodies
EP3914622A1 (de)	2019-01-22	2021-12-01	Bristol-Myers Squibb Company	Antikörper gegen il-7r-alpha-untereinheit und deren verwendungen
EP3918300A4 (de)	2019-01-28	2022-11-16	Becton, Dickinson and Company	Schadstoffsammelvorrichtung mit integriertem tupfer und testvorrichtung
SG11202108099WA (en)	2019-01-30	2021-08-30	Scholar Rock Inc	LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
US11738050B2 (en)	2019-02-01	2023-08-29	Regents Of The University Of Minnesota	Compounds binding to fibroblast activation protein alpha
EP3693063A1 (de)	2019-02-06	2020-08-12	Diaccurate	Verfahren und zusammensetzungen zur behandlung von krebs
EP3696191A1 (de)	2019-02-14	2020-08-19	Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC)	Car-t-zellen zur behandlung von cd1a-positivem krebs
US10871640B2 (en)	2019-02-15	2020-12-22	Perkinelmer Cellular Technologies Germany Gmbh	Methods and systems for automated imaging of three-dimensional objects
JP2022521751A (ja)	2019-02-21	2022-04-12	マレンゴ・セラピューティクス，インコーポレーテッド	抗ｔｃｒ抗体分子およびその使用
JP2022522662A (ja)	2019-02-21	2022-04-20	マレンゴ・セラピューティクス，インコーポレーテッド	Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
JP2022521750A (ja)	2019-02-21	2022-04-12	マレンゴ・セラピューティクス，インコーポレーテッド	カルレティキュリンに結合する多機能性分子およびその使用
SG11202109061YA (en)	2019-02-21	2021-09-29	Marengo Therapeutics Inc	Multifunctional molecules that bind to t cell related cancer cells and uses thereof
JP2022521937A (ja)	2019-02-21	2022-04-13	マレンゴ・セラピューティクス，インコーポレーテッド	ＮＫｐ３０に結合する抗体分子およびその使用
US11242407B2 (en)	2019-02-26	2022-02-08	Inspirna, Inc.	High-affinity anti-MERTK antibodies and uses thereof
CN113874083A (zh)	2019-03-01	2021-12-31	梅里麦克制药股份有限公司	抗-tnfr2抗体及其用途
EP3935083A4 (de)	2019-03-03	2022-11-30	Prothena Biosciences Limited	Antikörper zur erkennung von tau
KR20210141998A (ko)	2019-03-14	2021-11-23	얀센 바이오테크 인코포레이티드	항-tnf 항체 조성물의 제조 방법
MA55282A (fr)	2019-03-14	2022-01-19	Janssen Biotech Inc	Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
MA55283A (fr)	2019-03-14	2022-01-19	Janssen Biotech Inc	Procédés de production de compositions d'anticorps anti-tnf
JP2022525145A (ja)	2019-03-14	2022-05-11	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ１２／ｉｌ２３抗体組成物を生成するための製造方法
EA202192459A1 (ru)	2019-03-18	2021-11-25	Янссен Байотек, Инк.	Способ лечения псориаза антителом к il12/il23 у субъектов детского возраста
WO2020191248A1 (en)	2019-03-19	2020-09-24	The Broad Institute, Inc.	Method and compositions for editing nucleotide sequences
CA3130872A1 (en)	2019-03-25	2020-10-01	Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft	Enhancement of cytolytic t-cell activity by inhibiting ebag9
KR20220004985A (ko)	2019-03-27	2022-01-12	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	Cd40 활성화 특성을 가진 재조합 단백질
WO2020198731A2 (en)	2019-03-28	2020-10-01	Danisco Us Inc	Engineered antibodies
SG11202110732XA (en)	2019-03-29	2021-10-28	Atarga Llc	Anti fgf23 antibody
US20220042954A1 (en)	2019-03-29	2022-02-10	Bristol-Myers Squibb Company	Methods of measuring hydrophobicity of chromatographic resins
TW202102544A (zh)	2019-04-04	2021-01-16	日商小野藥品工業股份有限公司	雙特異性抗體
CA3136602A1 (en)	2019-04-15	2020-10-22	Qwixel Therapeutics Llc	Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
WO2020215037A1 (en)	2019-04-18	2020-10-22	The Regents Of The University Of Michigan	Combination with checkpoint inhibitors to treat cancer
CA3136888A1 (en)	2019-04-19	2020-10-22	Janssen Biotech, Inc.	Methods of treating prostate cancer with an anti- psma/cd3 antibody
WO2020227554A1 (en)	2019-05-09	2020-11-12	Genentech, Inc.	Methods of making antibodies
KR20220012883A (ko)	2019-05-23	2022-02-04	얀센 바이오테크 인코포레이티드	Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
US20220235148A1 (en)	2019-05-30	2022-07-28	Amgen Inc.	Engineering the hinge region to drive antibody dimerization
EP3976648A1 (de)	2019-06-03	2022-04-06	Janssen Biotech, Inc.	Anti-tnf-antikörperzusammensetzungen und verfahren zur behandlung von aktiver psoriasis-arthritis
CA3142580A1 (en)	2019-06-03	2020-12-10	Janssen Biotech, Inc.	Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
EP3983437A1 (de)	2019-06-12	2022-04-20	Novartis AG	Antikörper des natriuretischen peptidrezeptors 1 und verfahren zu deren verwendung
EP3983442A2 (de)	2019-06-17	2022-04-20	Visterra, Inc.	Humanisierte antikörpermoleküle gegen cd138 und verwendungen davon
GB201909135D0 (en)	2019-06-25	2019-08-07	Institute Of Cancer Res Royal Cancer Hospital	Means and methods for treating cancer
AU2020304671A1 (en)	2019-06-28	2022-01-20	Amgen Inc.	Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
JP6881658B2 (ja)	2019-07-05	2021-06-02	小野薬品工業株式会社	Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
BR112021005478A2 (pt)	2019-07-24	2021-06-15	H. Lundbeck A/S	anticorpos anti-mglur5 e uso dos mesmos
CA3147757A1 (en)	2019-07-26	2021-02-04	Visterra, Inc.	Interleukin-2 agents and uses thereof
KR20220039720A (ko)	2019-07-30	2022-03-29	오노 야꾸힝 고교 가부시키가이샤	이중 특이성 항체
SI4007777T1 (sl)	2019-08-02	2024-03-29	Fundacio De Recerca Clinic Barcelona-Institut D'investigacions Biomediques August Pi I Sunyer (Frcb-Idibaps)	Cart-t celice proti bcma za zdravljenje multiplega mieloma
EP4031658A1 (de)	2019-08-07	2022-07-27	DB Biotech, AS	Verbesserte meerrettichperoxidase-polypeptide
WO2021025140A1 (ja)	2019-08-08	2021-02-11	小野薬品工業株式会社	二重特異性タンパク質
CN114867751A (zh)	2019-08-12	2022-08-05	阿帕特夫研究和发展有限公司	4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
WO2021028752A1 (en)	2019-08-15	2021-02-18	Janssen Biotech, Inc.	Anti-tfn antibodies for treating type i diabetes
US20220307065A1 (en)	2019-08-30	2022-09-29	4TEEN4 Pharmaceuticals GmbH	Therapy guidance and/or therapy monitoring for treatment of shock
WO2021042019A1 (en)	2019-08-30	2021-03-04	Agenus Inc.	Anti-cd96 antibodies and methods of use thereof
CN114641501A (zh)	2019-09-04	2022-06-17	Y生物股份有限公司	抗vsig4抗体或抗原结合片段及其用途
US20220332799A1 (en)	2019-09-04	2022-10-20	Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne)	Herv inhibitors for use in treating tauopathies
US20220372105A1 (en)	2019-09-05	2022-11-24	Poseida Therapeutics, Inc.	Allogeneic cell compositions and methods of use
TW202124444A (zh)	2019-09-16	2021-07-01	美商表面腫瘤學公司	抗ｃｄ３９抗體組合物及方法
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
EP4031578A1 (de)	2019-09-18	2022-07-27	Novartis AG	Entpd2-antikörper, kombinationstherapien und verfahren zur verwendung der antikörper und kombinationstherapien
BR112022004302A2 (pt)	2019-09-25	2022-06-21	Surface Oncology Inc	Anticorpos anti-il-27 e usos dos mesmos
WO2021062323A1 (en)	2019-09-26	2021-04-01	Stcube & Co.	Antibodies specific to glycosylated ctla-4 and methods of use thereof
TW202128756A (zh)	2019-10-02	2021-08-01	德商百靈佳殷格翰國際股份有限公司	用於癌症治療之多重專一性結合蛋白
US20230165967A1 (en)	2019-10-04	2023-06-01	TAE Life Sciences	Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties for use in Treating Cancer, Immunological Disorders, and Methods Thereof
US20240050529A1 (en)	2019-10-07	2024-02-15	University Of Virginia Patent Foundation	Modulating lymphatic vessels in neurological disease
JP2022552282A (ja)	2019-10-09	2022-12-15	エスティーキューブアンドカンパニー	グリコシル化ｌａｇ３に対して特異的な抗体およびその使用方法
CA3157509A1 (en)	2019-10-10	2021-04-15	Kodiak Sciences Inc.	Methods of treating an eye disorder
EP4041773A1 (de)	2019-10-11	2022-08-17	Beth Israel Deaconess Medical Center, Inc.	Anti-tn-antikörper und verwendungen davon
JP2022553293A (ja)	2019-10-21	2022-12-22	ノバルティスアーゲー	ベネトクラックスおよびｔｉｍ－３阻害剤を用いた併用療法
CA3157665A1 (en)	2019-10-21	2021-04-29	Novartis Ag	Tim-3 inhibitors and uses thereof
US11459389B2 (en)	2019-10-24	2022-10-04	Massachusetts Institute Of Technology	Monoclonal antibodies that bind human CD161
WO2021092355A1 (en)	2019-11-08	2021-05-14	Amgen Inc.	Engineering charge pair mutations for pairing of hetero-igg molecules
AU2020385683A1 (en)	2019-11-18	2022-06-30	Janssen Biotech, Inc.	Vaccines based on mutant CALR and JAK2 and their uses
MX2022005965A (es)	2019-11-19	2022-08-08	Amgen Inc	Formato de anticuerpos multiespecíficos novedosos.
EP4061406A1 (de)	2019-11-20	2022-09-28	Bavarian Nordic A/S	Rekombinante mva-viren zur intratumoralen und/oder intravenösen verabreichung zur behandlung von krebs
KR20220131895A (ko)	2019-11-21	2022-09-29	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법
GB201917480D0 (en)	2019-11-29	2020-01-15	Univ Oxford Innovation Ltd	Antibodies
EP4077376A2 (de)	2019-12-19	2022-10-26	Quidel Corporation	Monoklonale antikörperfusionen
JP2023507190A (ja)	2019-12-20	2023-02-21	ノバルティスアーゲー	増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
GB201919062D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Antibody
GB201919061D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibody
CA3162246A1 (en)	2019-12-20	2021-06-24	Poseida Therapeutics, Inc.	Anti-muc1 compositions and methods of use
GB201919058D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibodies
TW202138388A (zh)	2019-12-30	2021-10-16	美商西根公司	以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
WO2021138407A2 (en)	2020-01-03	2021-07-08	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to cd33 and uses thereof
IL294330A (en)	2020-01-06	2022-08-01	Vaccinex Inc	Anti-ccr8 antibodies and their uses
JP2023510270A (ja)	2020-01-08	2023-03-13	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	進行性骨化性線維異形成症の治療
BR112022013733A2 (pt)	2020-01-11	2022-11-01	Scholar Rock Inc	Inibidores de tgfbeta e uso dos mesmos
WO2021142448A2 (en)	2020-01-11	2021-07-15	Scholar Rock,Inc.	Tgf-beta inhibitors and use thereof
TW202140553A (zh)	2020-01-13	2021-11-01	美商威特拉公司	C5ar1抗體分子及其用途
KR20220128379A (ko)	2020-01-13	2022-09-20	다케다 파머수티컬 컴패니 리미티드	소아 유전성 혈관부종 발작을 치료하기 위한 혈장 칼리크레인 억제제 및 이의 용도
IL293752A (en)	2020-01-17	2022-08-01	Novartis Ag	A combination containing a tim-3 inhibitor and a substance that causes hypomethylation for use in the treatment of myeloplastic syndrome or chronic myelomonocytic leukemia
US20230067811A1 (en)	2020-01-24	2023-03-02	University Of Virginia Patent Foundation	Modulating lymphatic vessels in neurological disease
KR20220144377A (ko)	2020-01-30	2022-10-26	우모자 바이오파마 인코포레이티드	이중특이적 형질도입 촉진제
IL295387A (en)	2020-02-05	2022-10-01	Larimar Therapeutics Inc	Peptide-binding proteins and their uses
AU2021221277A1 (en)	2020-02-11	2022-08-25	Crispr Therapeutics Ag	Anti-idiotype antibodies targeting anti-CD19 chimeric antigen receptor
EP4103611B1 (de)	2020-02-13	2024-03-27	UCB Biopharma SRL	Bispezifische, an hvem und cd9 bindende antikörper
US20230096030A1 (en)	2020-02-13	2023-03-30	UCB Biopharma SRL	Bispecific antibodies against cd9 and cd7
WO2021160269A1 (en)	2020-02-13	2021-08-19	UCB Biopharma SRL	Anti cd44-ctla4 bispecific antibodies
US20230151109A1 (en)	2020-02-13	2023-05-18	UCB Biopharma SRL	Bispecific antibodies against cd9
EP4103608A1 (de)	2020-02-13	2022-12-21	UCB Biopharma SRL	Bispezifische antikörper gegen cd9 und cd137
TW202144389A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在卵巢癌中表現之新抗原及其用途
US20230220074A1 (en)	2020-02-18	2023-07-13	Alector Llc	Pilra antibodies and methods of use thereof
EP3871689A1 (de)	2020-02-26	2021-09-01	sphingotec GmbH	Anti-adm-antikörper, die an den freien n-terminus binden, für einen beschleunigten übergang von adm-gly zu bio-adm bei patienten mit einem adm-gly/bio-adm-verhältnis über einem schwellenwert und kombination mit vitamin c
CN115244081A (zh)	2020-02-27	2022-10-25	艾德里诺医药公司	用于治疗休克患者的抗肾上腺髓质素(adm)结合剂
IL295728A (en)	2020-02-27	2022-10-01	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm backbone without ig for use in the treatment of cure or prevention of shock
WO2021170838A1 (en)	2020-02-27	2021-09-02	4TEEN4 Pharmaceuticals GmbH	Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
JP2023516724A (ja)	2020-03-06	2023-04-20	オーエヌエーセラピューティクスエセ．エレ．	抗ｃｄ３６抗体及び癌を治療するためのそれらの使用
AU2021232853A1 (en)	2020-03-10	2022-09-22	Massachusetts Institute Of Technology	Compositions and methods for immunotherapy of NPM1c-positive cancer
CN115843255A (zh)	2020-03-11	2023-03-24	约瑟夫卡雷拉斯白血病研究基金会	用于治疗b细胞型急性淋巴细胞白血病（b-all）的cd22靶向部分
WO2021183795A1 (en)	2020-03-11	2021-09-16	Poseida Therapeutics, Inc.	Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
AU2021238591A1 (en)	2020-03-16	2022-11-17	Adrenomed Ag	Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against adrenomedullin
CA3171332A1 (en)	2020-03-16	2021-09-23	Andreas Bergmann	Dpp3 in patients infected with coronavirus
EP3922993A1 (de)	2020-06-12	2021-12-15	4TEEN4 Pharmaceuticals GmbH	Dpp3 bei patienten, die mit coronavirus infiziert sind
WO2021202473A2 (en)	2020-03-30	2021-10-07	Danisco Us Inc	Engineered antibodies
WO2021203024A1 (en)	2020-04-03	2021-10-07	Visterra, Inc.	Antibody molecule-drug conjugates and uses thereof
EP4126219A2 (de)	2020-04-04	2023-02-08	Takeda Pharmaceutical Company Limited	Plasmakallikreinhemmer und verwendungen davon zur behandlung von akutem atemnotsyndrom
WO2021205325A1 (en)	2020-04-08	2021-10-14	Pfizer Inc.	Anti-gucy2c antibodies and uses thereof
CA3175523A1 (en)	2020-04-13	2021-10-21	Antti Virtanen	Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
CN115996747A (zh)	2020-04-14	2023-04-21	波赛达治疗公司	用于治疗癌症的组合物和方法
CA3180321A1 (en)	2020-04-24	2021-10-28	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to t cell related cancer cells and uses thereof
US20210338833A1 (en)	2020-05-01	2021-11-04	Massachusetts Institute Of Technology	Chimeric antigen receptor-targeting ligands and uses thereof
US20230167193A1 (en)	2020-05-01	2023-06-01	Novartis Ag	Immunoglobulin variants
CN116096758A (zh)	2020-05-01	2023-05-09	诺华股份有限公司	工程化免疫球蛋白
US20210340524A1 (en)	2020-05-01	2021-11-04	Massachusetts Institute Of Technology	Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021224850A1 (en)	2020-05-06	2021-11-11	Crispr Therapeutics Ag	Mask peptides and masked anti-ptk7 antibodies comprising such
JP2023525304A (ja)	2020-05-08	2023-06-15	ザブロードインスティテュート，インコーポレーテッド	標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
JP2023525140A (ja)	2020-05-13	2023-06-14	アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル）	Ｏｘ４０活性化特性を有する組換えタンパク質
US20230192867A1 (en)	2020-05-15	2023-06-22	Bristol-Myers Squibb Company	Antibodies to garp
AU2021275361A1 (en)	2020-05-17	2023-01-19	Astrazeneca Uk Limited	SARS-CoV-2 antibodies and methods of selecting and using the same
JP2023504675A (ja)	2020-05-19	2023-02-06	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ガンの処置のための結合分子
WO2021239666A1 (en)	2020-05-26	2021-12-02	Diaccurate	Therapeutic methods
US11820824B2 (en)	2020-06-02	2023-11-21	Arcus Biosciences, Inc.	Antibodies to TIGIT
EP4161653A1 (de)	2020-06-03	2023-04-12	Bionecure Therapeutics, Inc.	Trophoblastzelloberflächenantigen-2 (trop-2)-antikörper
WO2021245603A1 (en)	2020-06-04	2021-12-09	Crispr Therapeutics Ag	Anti-cd70 antibodies and uses thereof
CA3187823A1 (en)	2020-06-24	2021-12-30	Visterra, Inc.	Antibody molecules to april and uses thereof
WO2022010797A2 (en)	2020-07-07	2022-01-13	Bionecure Therapeutics, Inc.	Novel maytansinoids as adc payloads and their use for the treatment of cancer
CR20230009A (es)	2020-07-16	2023-01-25	Novartis Ag	Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
JP2023533793A (ja)	2020-07-17	2023-08-04	ファイザー・インク	治療用抗体およびそれらの使用
AU2021313348A1 (en)	2020-07-20	2023-03-09	Astrazeneca Uk Limited	SARS-CoV-2 proteins, anti-SARS-CoV-2 antibodies, and methods of using the same
WO2022026592A2 (en)	2020-07-28	2022-02-03	Celltas Bio, Inc.	Antibody molecules to coronavirus and uses thereof
WO2022029629A1 (en)	2020-08-04	2022-02-10	Crispr Therapeutics Ag	Anti-idiotype antibodies targeting anti-cd70 chimeric antigen receptor
EP4193149A1 (de)	2020-08-04	2023-06-14	Abbott Laboratories	Verbesserte verfahren und kits zum nachweis von sars-cov-2-protein in einer probe
CN116419747A (zh)	2020-08-07	2023-07-11	福蒂斯治疗公司	靶向cd46的免疫偶联物及其使用方法
EP4200018A1 (de)	2020-08-18	2023-06-28	Cephalon LLC	Anti-par-2-antikörper und verfahren zur verwendung davon
US20230322955A1 (en)	2020-08-20	2023-10-12	Amgen Inc.	Antigen binding proteins with non-canonical disulfide in fab region
US20240009310A1 (en)	2020-08-24	2024-01-11	Charité - Universitätsmedizin Berlin	A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6
US20230321242A1 (en)	2020-08-24	2023-10-12	Charité - Universitätsmedizin Berlin	Chimeric antigen receptor (car)-expressing cells recognizing cea
US20220064335A1 (en)	2020-08-25	2022-03-03	Crispr Therapeutics Ag	Anti-idiotype antibodies targeting anti-bcma chimeric antigen receptor
JP2023539645A (ja)	2020-08-26	2023-09-15	マレンゴ・セラピューティクス，インコーポレーテッド	Ｎｋｐ３０に結合する抗体分子およびその使用
GB2616354A (en)	2020-08-26	2023-09-06	Marengo Therapeutics Inc	Methods of detecting TRBC1 or TRBC2
EP4204450A2 (de)	2020-08-26	2023-07-05	Marengo Therapeutics, Inc.	An calreticulin bindende multifunktionelle moleküle und verwendungen davon
WO2022043558A1 (en)	2020-08-31	2022-03-03	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
EP4204021A1 (de)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Verfahren zur behandlung von psma-exprimierenden krebsarten
EP4210832A1 (de)	2020-09-14	2023-07-19	Vor Biopharma, Inc.	Chimäre antigenrezeptoren zur behandlung von krebs
EP4225786A2 (de)	2020-10-07	2023-08-16	Amgen Inc.	Rationale auswahl von bausteinen zur anordnung multispezifischer antikörper
WO2022081718A1 (en)	2020-10-14	2022-04-21	Five Prime Therapeutics, Inc.	Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
IL301859A (en)	2020-10-15	2023-06-01	UCB Biopharma SRL	Binding molecules for CD45 multimerization
US20230382978A1 (en)	2020-10-15	2023-11-30	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
US20240000969A1 (en)	2020-10-21	2024-01-04	Poseida Therapeutics San Diego	Compositions and methods for delivery of nucleic acids
EP4232474A1 (de)	2020-10-21	2023-08-30	Boehringer Ingelheim International GmbH	Bispezifische anti-vegf- und anti-trkb-bindende moleküle zur behandlung von augenerkrankungen
WO2022087274A1 (en)	2020-10-21	2022-04-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies that neutralize type-i interferon (ifn) activity
EP4240765A2 (de)	2020-11-06	2023-09-13	Novartis AG	Antikörper-fc-varianten
AU2021379598A1 (en)	2020-11-10	2023-06-08	Amgen Inc.	Novel linkers of multispecific antigen binding domains
WO2022115538A1 (en)	2020-11-24	2022-06-02	Bio-Techne Corporation	Anti-severe acute respiratory syndrome coronavirus antibodies
IL303328A (en)	2020-12-01	2023-07-01	Aptevo Res & Development Llc	CD3-binding bispecific and heterodimeric antibodies to PSMA
US20220170948A1 (en)	2020-12-01	2022-06-02	Abbott Laboratories	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en)	2021-11-30	2023-06-08	Abbott Laboratories	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4023218A1 (de)	2020-12-02	2022-07-06	S-Form Pharma	Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe
TW202237171A (zh)	2020-12-04	2022-10-01	美商威特拉公司	使用介白素-2藥劑之方法
US20240052042A1 (en)	2020-12-14	2024-02-15	Novartis Ag	Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
AU2021401316A1 (en)	2020-12-18	2023-07-06	Kiniksa Pharmaceuticals, Ltd.	Protein compositions and methods for producing and using the same
EP4271998A1 (de)	2020-12-30	2023-11-08	Abbott Laboratories	Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
KR20230146522A (ko)	2021-01-13	2023-10-19	메모리얼 슬로안 케터링 캔서 센터	항-dll3 항체-약물 접합체
JP2024503657A (ja)	2021-01-13	2024-01-26	メモリアルスローン－ケタリングキャンサーセンター	抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
AU2022211021A1 (en)	2021-01-20	2023-08-03	Visterra, Inc.	Interleukin-2 mutants and uses thereof
WO2022157094A2 (en)	2021-01-22	2022-07-28	Bayer Aktiengesellschaft	Lrrc15 antibodies and conjugates thereof
WO2022162518A2 (en)	2021-01-28	2022-08-04	Janssen Biotech, Inc.	Psma binding proteins and uses thereof
EP4284510A1 (de)	2021-01-29	2023-12-06	Novartis AG	Dosierungsschemata für anti-cd73- und anti-enpd2-antikörper und verwendungen davon
US20220275090A1 (en)	2021-02-22	2022-09-01	Janssen Biotech, Inc.	Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
WO2022182872A2 (en)	2021-02-24	2022-09-01	Alladapt Immunotherapeutics, Inc.	Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
TW202302645A (zh)	2021-03-03	2023-01-16	法商皮爾法伯製藥公司	抗vsig4抗體或抗原結合片段及其用途
JP2024512305A (ja)	2021-03-03	2024-03-19	ザユナイテッドステイツオブアメリカアズリプリゼンテッドバイザセクレタリー、デパートメントオブヘルスアンドヒューマンサービシーズ	破骨細胞生成の新規制御因子としてのＬａタンパク質
AU2022232007A1 (en)	2021-03-12	2023-10-26	Janssen Biotech, Inc.	Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
CA3212729A1 (en)	2021-03-12	2022-09-15	Janssen Biotech, Inc.	Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
JP2024511373A (ja)	2021-03-18	2024-03-13	ノバルティスアーゲー	がんのためのバイオマーカーおよびその使用
WO2022204581A2 (en)	2021-03-26	2022-09-29	Scholar Rock, Inc.	Tgf-beta inhibitors and use thereof
EP4067381A1 (de)	2021-04-01	2022-10-05	Julius-Maximilians-Universität Würzburg	Neue tnfr2-bindende moleküle
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022216993A2 (en)	2021-04-08	2022-10-13	Marengo Therapeutics, Inc.	Multifuntional molecules binding to tcr and uses thereof
CN117651714A (zh)	2021-04-20	2024-03-05	美国安进公司	多特异性和单价IgG分子组装中链配对的静电转向中的平衡电荷分布
AU2022270170A1 (en)	2021-05-07	2023-09-21	Surface Oncology, LLC	Anti-il-27 antibodies and uses thereof
CA3216320A1 (en)	2021-05-18	2022-11-24	Abbott Laboratories	Methods of evaluating brain injury in a pediatric subject
WO2022251446A1 (en)	2021-05-28	2022-12-01	Alexion Pharmaceuticals, Inc.	Methods for detecting cm-tma biomarkers
EP4348260A2 (de)	2021-06-03	2024-04-10	Scholar Rock, Inc.	Tgf-beta inhibitoren und deren therapeutische verwendung
CA3218590A1 (en)	2021-06-07	2022-12-15	Providence Health & Services - Oregon	Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2022261183A2 (en)	2021-06-08	2022-12-15	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2022266034A1 (en)	2021-06-14	2022-12-22	Abbott Laboratories	Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
IL309349A (en)	2021-06-14	2024-02-01	argenx BV	Antibodies against interleukin 9 and methods of using them
TW202317625A (zh)	2021-06-17	2023-05-01	德商百靈佳殷格翰國際股份有限公司	新穎三特異性結合分子
AU2022292462A1 (en)	2021-06-18	2023-12-07	Nammi Therapeutics, Inc.	FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF
WO2022271867A1 (en)	2021-06-23	2022-12-29	Scholar Rock, Inc.	A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
CA3221281A1 (en)	2021-06-29	2023-01-05	Seagen Inc.	Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
WO2023281462A1 (en)	2021-07-09	2023-01-12	Janssen Biotech, Inc.	Manufacturing methods for producing anti-tnf antibody compositions
KR20240032991A (ko)	2021-07-09	2024-03-12	얀센 바이오테크 인코포레이티드	항-tnf 항체 조성물의 생성을 위한 제조 방법
US20230038355A1 (en)	2021-07-09	2023-02-09	Janssen Biotech, Inc.	Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
WO2023285878A1 (en)	2021-07-13	2023-01-19	Aviation-Ophthalmology	Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
CA3225252A1 (en)	2021-07-14	2023-01-19	Jordan JARJOUR	Engineered t cell receptors fused to binding domains from antibodies
WO2023286854A1 (ja)	2021-07-16	2023-01-19	ブライトパス・バイオ株式会社	抗Ｔｉｍ－３抗原抗体または抗体誘導体およびその用途
WO2023010118A1 (en)	2021-07-29	2023-02-02	Vor Biopharma Inc.	Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
AU2022320051A1 (en)	2021-07-30	2024-01-25	ONA Therapeutics S.L.	Anti-cd36 antibodies and their use to treat cancer
WO2023025927A1 (en)	2021-08-26	2023-03-02	Glycanostics S.R.O	Glycoprotein biomarkers for diagnosing cancer
CA3230038A1 (en)	2021-08-31	2023-03-09	Hongwei Zhang	Methods and systems of diagnosing brain injury
EP4144898A1 (de)	2021-09-07	2023-03-08	New/era/mabs GmbH	Verfahren zur selektion oder screenen von antikörpern aus einer antikörperbibliothek
IL310815A (en)	2021-09-14	2024-04-01	Glycanostics S R O	Glycoprotein biomarkers for breast cancer diagnosis
WO2023044483A2 (en)	2021-09-20	2023-03-23	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
WO2023044094A1 (en)	2021-09-20	2023-03-23	Alnylam Pharmaceuticals, Inc.	Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
AU2022354059A1 (en)	2021-09-30	2024-03-28	Abbott Laboratories	Methods and systems of diagnosing brain injury
WO2023060088A1 (en)	2021-10-04	2023-04-13	Poseida Therapeutics, Inc.	Transposon compositions and methods of use thereof
WO2023073615A1 (en)	2021-10-29	2023-05-04	Janssen Biotech, Inc.	Methods of treating crohn's disease with anti-il23 specific antibody
US20230136301A1 (en)	2021-11-03	2023-05-04	Janssen Biotech, Inc.	Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
EP4177266A1 (de)	2021-11-05	2023-05-10	Katholieke Universiteit Leuven	Neutralisierende humane anti-sars-cov-2-antikörper
US20230151087A1 (en)	2021-11-15	2023-05-18	Janssen Biotech, Inc.	Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2023091968A1 (en)	2021-11-17	2023-05-25	Disc Medicine, Inc.	Methods for treating anemia of kidney disease
WO2023092004A1 (en)	2021-11-17	2023-05-25	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
US20230159633A1 (en)	2021-11-23	2023-05-25	Janssen Biotech, Inc.	Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023097254A1 (en)	2021-11-24	2023-06-01	Visterra, Inc.	Engineered antibody molecules to cd138 and uses thereof
WO2023097119A2 (en)	2021-11-29	2023-06-01	Dana-Farber Cancer Institute, Inc.	Methods and compositions to modulate riok2
TW202333772A (zh)	2021-12-01	2023-09-01	美商威特拉公司	使用介白素-2藥劑之方法
WO2023100153A1 (en)	2021-12-03	2023-06-08	Crispr Therapeutics Ag	Use of anti-cd70 antibodies for identifying subjects susceptible for treatment with nk cell-based anti-cd70 therapy
WO2023114978A1 (en)	2021-12-17	2023-06-22	Abbott Laboratories	Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023118508A1 (en)	2021-12-23	2023-06-29	Bavarian Nordic A/S	Recombinant mva viruses for intraperitoneal administration for treating cancer
US20230213536A1 (en)	2021-12-28	2023-07-06	Abbott Laboratories	Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023141576A1 (en)	2022-01-21	2023-07-27	Poseida Therapeutics, Inc.	Compositions and methods for delivery of nucleic acids
US20230295348A1 (en)	2022-01-24	2023-09-21	Novimmune Sa	Composition and methods for the selective activation of cytokine signaling pathways
WO2023144303A1 (en)	2022-01-31	2023-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023150652A1 (en)	2022-02-04	2023-08-10	Abbott Laboratories	Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
US20230383010A1 (en)	2022-02-07	2023-11-30	Visterra, Inc.	Anti-idiotype antibody molecules and uses thereof
WO2023154305A2 (en)	2022-02-10	2023-08-17	Amgen Inc.	Antibody protein product expression constructs for high throughput sequencing
US20240002544A1 (en)	2022-03-07	2024-01-04	Novimmune Sa	Cd28 bispecific antibodies for targeted t cell activation
GB202203588D0 (en)	2022-03-15	2022-04-27	Argonaut Therapeutics Ltd	Cancer diagnostic
WO2023175035A1 (en)	2022-03-15	2023-09-21	Adrenomed Ag	Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
WO2023187707A1 (en)	2022-03-30	2023-10-05	Janssen Biotech, Inc.	Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023192436A1 (en)	2022-03-31	2023-10-05	Alexion Pharmaceuticals, Inc.	Singleplex or multiplexed assay for complement markers in fresh biological samples
GB202205200D0 (en)	2022-04-08	2022-05-25	Ucb Biopharma Sprl	Combination with chemotherapy
GB202205203D0 (en)	2022-04-08	2022-05-25	UCB Biopharma SRL	Combination with inhibitor
TW202400637A (zh)	2022-04-25	2024-01-01	美商威特拉公司	April之抗體分子及其用途
TW202400658A (zh)	2022-04-26	2024-01-01	瑞士商諾華公司	靶向ｉｌ—１３和ｉｌ—１８的多特異性抗體
WO2023209177A1 (en)	2022-04-29	2023-11-02	Astrazeneca Uk Limited	Sars-cov-2 antibodies and methods of using the same
WO2023220695A2 (en)	2022-05-13	2023-11-16	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
WO2023223265A1 (en)	2022-05-18	2023-11-23	Janssen Biotech, Inc.	Method for evaluating and treating psoriatic arthritis with il23 antibody
WO2023240124A1 (en)	2022-06-07	2023-12-14	Regeneron Pharmaceuticals, Inc.	Pseudotyped viral particles for targeting tcr-expressing cells
EP4296279A1 (de)	2022-06-23	2023-12-27	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
WO2024006876A1 (en)	2022-06-29	2024-01-04	Abbott Laboratories	Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024006961A1 (en)	2022-07-01	2024-01-04	Neoleukin Therapeutics, Inc.	Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells
WO2024013315A1 (en)	2022-07-15	2024-01-18	Boehringer Ingelheim International Gmbh	Binding molecules for the treatment of cancer
WO2024013727A1 (en)	2022-07-15	2024-01-18	Janssen Biotech, Inc.	Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024015953A1 (en)	2022-07-15	2024-01-18	Danisco Us Inc.	Methods for producing monoclonal antibodies
WO2024023368A1 (en)	2022-07-29	2024-02-01	4TEEN4 Pharmaceuticals GmbH	Prediction of an increase of dpp3 in a patient with septic shock
WO2024023369A1 (en)	2022-07-29	2024-02-01	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
WO2024030976A2 (en)	2022-08-03	2024-02-08	Voyager Therapeutics, Inc.	Compositions and methods for crossing the blood brain barrier
WO2024050354A1 (en)	2022-08-31	2024-03-07	Washington University	Alphavirus antigen binding antibodies and uses thereof
WO2024050524A1 (en)	2022-09-01	2024-03-07	University Of Georgia Research Foundation, Inc.	Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024054436A1 (en)	2022-09-06	2024-03-14	Alexion Pharmaceuticals, Inc.	Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
WO2024059708A1 (en)	2022-09-15	2024-03-21	Abbott Laboratories	Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024062072A2 (en)	2022-09-21	2024-03-28	Domain Therapeutics	Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062076A1 (en)	2022-09-21	2024-03-28	Domain Therapeutics	Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062082A1 (en)	2022-09-21	2024-03-28	Domain Therapeutics	Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062038A1 (en)	2022-09-21	2024-03-28	Elthera Ag	Novel binding molecules binding to l1cam
EP4345109A1 (de)	2022-09-30	2024-04-03	AdrenoMed AG	Anti-adrenomedullin (adm)-bindemittel zur verwendung bei der behandlung von pädiatrischen patienten mit angeborener herzerkrankung

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4593002A (en) *	1982-01-11	1986-06-03	Salk Institute Biotechnology/Industrial Associates, Inc.	Viruses with recombinant surface proteins
JPS58212781A (ja) *	1982-06-02	1983-12-10	Noda Sangyo Kagaku Kenkyusho	新種バクテリオフア−ジ及びその育種法
CH0229046H1 (de) *	1985-03-30	1998-07-15	Stuart Alan Kauffman	Method for obtaining dna, rna, peptides, polypeptinique. des or proteins by means of a dna recombinant tech
DE3851770T2 (de) *	1987-01-12	1995-02-16	Stratagene Inc	DNS-Klonierungsvektor mit in vivo ausschneidbaren Plasmiden.
DE3703825A1 (de) *	1987-02-07	1988-08-18	Didier Eng	Verfahren und vorrichtung zum herstellen von kohlenstoff-fasern
ATE114723T1 (de) *	1987-03-02	1994-12-15	Enzon Lab Inc	Organismus als träger für ''single chain antibody domain (scad)''.
WO1989006694A1 (en) *	1988-01-15	1989-07-27	Trustees Of The University Of Pennsylvania	Process for selection of proteinaceous substances which mimic growth-inducing molecules
US5223409A (en) *	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
AU4308689A (en) *	1988-09-02	1990-04-02	Protein Engineering Corporation	Generation and selection of recombinant varied binding proteins
JP2919890B2 (ja) *	1988-11-11	1999-07-19	メディカルリサーチカウンスル	単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
CA2016842A1 (en) *	1989-05-16	1990-11-16	Richard A. Lerner	Method for tapping the immunological repertoire
CA2057923A1 (en) *	1989-05-16	1990-11-17	William D. Huse	Co-expression of heteromeric receptors
CA2016841C (en) *	1989-05-16	1999-09-21	William D. Huse	A method for producing polymers having a preselected activity
WO1991010737A1 (en) *	1990-01-11	1991-07-25	Molecular Affinities Corporation	Production of antibodies using gene libraries
US5427908A (en) *	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
EP0600866B1 (de) *	1990-06-01	1997-12-03	Chiron Corporation	Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
GB9015198D0 (en) *	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
EP0469897A3 (en) *	1990-07-31	1992-11-19	The Wistar Institute	Engineered antibodies
IL99552A0 (en) *	1990-09-28	1992-08-18	Ixsys Inc	Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
GB9022190D0 (en) *	1990-10-12	1990-11-28	Perham Richard N	Immunogenic material
WO1992015702A1 (en) *	1991-03-07	1992-09-17	Andrew Raymon Morton Bradbury	The biological selection of useful molecules
DK1471142T3 (da) *	1991-04-10	2009-03-09	Scripps Research Inst	Heterodimere receptor-biblioteker under anvendelse af fagemider

1990
- 1990-05-01 US US07/517,659 patent/US5427908A/en not_active Expired - Lifetime
1991
- 1991-05-01 ES ES91908963T patent/ES2124224T3/es not_active Expired - Lifetime
- 1991-05-01 DE DE69130563T patent/DE69130563T2/de not_active Revoked
- 1991-05-01 EP EP05075052A patent/EP1555328A3/de not_active Withdrawn
- 1991-05-01 JP JP50889691A patent/JP3344584B2/ja not_active Expired - Fee Related
- 1991-05-01 AT AT91908963T patent/ATE174067T1/de not_active IP Right Cessation
- 1991-05-01 EP EP91908963A patent/EP0527839B1/de not_active Revoked
- 1991-05-01 ES ES98200770T patent/ES2235284T3/es not_active Expired - Lifetime
- 1991-05-01 DK DK91908963T patent/DK0527839T3/da active
- 1991-05-01 AU AU77939/91A patent/AU7793991A/en not_active Abandoned
- 1991-05-01 EP EP98200770A patent/EP0866136B1/de not_active Revoked
- 1991-05-01 WO PCT/US1991/002989 patent/WO1991017271A1/en active IP Right Grant
- 1991-05-01 DE DE69133437T patent/DE69133437T2/de not_active Revoked
- 1991-05-01 DK DK98200770T patent/DK0866136T3/da active
- 1991-05-01 DE DE98200770T patent/DE98200770T1/de active Pending
- 1991-05-01 AT AT98200770T patent/ATE286985T1/de not_active IP Right Cessation
1995
- 1995-01-20 US US08/376,326 patent/US5580717A/en not_active Expired - Lifetime
1999
- 1999-02-17 GR GR990400504T patent/GR3029421T3/el unknown

Also Published As

Publication number	Publication date
JPH05506782A (ja)	1993-10-07
WO1991017271A1 (en)	1991-11-14
EP0527839A1 (de)	1993-02-24
ATE286985T1 (de)	2005-01-15
ES2124224T3 (es)	1999-02-01
ES2235284T3 (es)	2005-07-01
EP0866136B1 (de)	2005-01-12
ATE174067T1 (de)	1998-12-15
EP0866136A1 (de)	1998-09-23
DK0527839T3 (da)	1999-08-16
DE69133437T2 (de)	2006-01-05
EP1555328A2 (de)	2005-07-20
EP0527839A4 (en)	1993-06-09
DE98200770T1 (de)	2004-09-30
DE69130563D1 (de)	1999-01-14
JP3344584B2 (ja)	2002-11-11
US5580717A (en)	1996-12-03
EP1555328A3 (de)	2009-05-06
EP0527839B1 (de)	1998-12-02
DE69133437D1 (de)	2005-02-17
DK0866136T3 (da)	2005-05-17
GR3029421T3 (en)	1999-05-28
AU7793991A (en)	1991-11-27
US5427908A (en)	1995-06-27

Legal Events

Date	Code	Title	Description
1999-04-22	8327	Change in the person/name/address of the patent owner	Owner name: BIOSITE DIAGNOSTICS INC., SAN DIEGO, CALIF., US
1999-12-09	8363	Opposition against the patent
2004-02-26	8327	Change in the person/name/address of the patent owner	Owner name: BIOSITE INCORPORATED (N.D.GES.D.STAATES DELAWARE),
2007-03-15	8339	Ceased/non-payment of the annual fee
2010-04-15	8331	Complete revocation
2010-04-22	8380	Miscellaneous part iii	Free format text: DIE ZURUECKNAHME VOM 15.03.2007 WURDE GELOESCHT.

Publication	Publication Date	Title
DE69130563T2 (de)	1999-06-24	Screening-verfahren für genbanken (recombinant libraries)
IL131435A0 (en)	2001-01-28	In vitro peptide or protein expression library
DE69940964D1 (de)	2009-07-16	Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
DE60039596D1 (de)	2008-09-04	Verfahren zur herstellung von monoklonalen antikörpern
DE69323765D1 (de)	1999-04-08	Säugetier-rezeptoren für interleukin 10 (il-10)
GR3019849T3 (en)	1996-08-31	Acute pancreatitis associated protein and means for the diagnosis of acute pancreatitis
GR3023593T3 (en)	1997-08-29	Protein structure of the plant toxin gelonin
FI104495B (fi)	2000-02-15	Soluvastetta tyypin I interferonille mukauttavan proteiinin kloonaus ja ilmeneminen
Dower et al.	1996	Recombinant library screening methods
WO1991015582A3 (en)	1991-12-12	Purified rap gaps, rap gap sequences, and uses thereof
CN106905435A (zh)	2017-06-30	一种制备基于蛋白a突变体的结合蛋白的方法
KR100515858B1 (en)	2005-09-21	PRO617 Polypeptides
DE69637484D1 (de)	2008-05-15	Vektoren/DNA-Sequenzen aus humanen kombinatorischen Antikörper-Bibliotheken
UA35624C2 (uk)	2001-04-16	МОЛЕКУЛА ДНК, ЩО КОДУЄ ПРОТЕЇН TGF-<font face="Symbol">b</font>-РОДИНИ, ВЕКТОР, L-КЛІТИНА, ПРОТЕЇН TGF-<font face="Symbol">b</font>-РОДИНИ, СПОСІБ ЙОГО ОТРИМАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, МОНОКЛОНАЛЬНЕ АНТИТІЛО
KR100515855B1 (en)	2005-09-21	PRO351 Polypeptides
Fairbairn	1989	INVESTIGATIONS ON ERYTHROCYTE MEMBRANE PROTEINS USING MOLECULAR CLONING TECHNIQUES.
KR100515857B1 (en)	2005-09-21	PRO792 Polypeptides
DE69827532D1 (de)	2004-12-16	Polypeptide und dafür kodierende Nukleinsäure
DK1191101T3 (da)	2004-10-11	PRO241 polypeptider og nucleinsyre kodende herfor
ATE405590T1 (de)	2008-09-15	Menschliches hcar-ähnliches protein und dafür kodierende nukleinsäure